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At the commencement of this work there was evidence to suggest that a bacterial ototoxin, 
pneumolysin, was at least partly responsible for meningitis-induced hearing losses caused by 
Streptococcus pneumoniae type II; preliminary evidence existed for an ototoxin produced by 
Haemophilus influenzae type b (Hib).
There was also evidence to suggest that:
(i) excitatory amino acids (EAAs), nitric oxide (NO) and reactive oxygen species (ROSs) may also 
be involved in hearing losses induced by meningitis;
(ii) N-methyl-D-aspartic acid (NMDA) and non-NMDA receptors are involved in excitatory 
damage produced by EAAs in the cochlea, with non-NMDA receptors playing a predominant role;
(iii) NO and ROSs mediated the ototoxic effects which ensue from activation of NMDA receptors 
in the cochlea.
There were no reports concerning the possible involvement of NO and ROSs in the ototoxic 
effects which ensue from activation of non-NMDA receptors.
Summary of this work
All bacterial extracts and other chemicals were perfused into the cochlea of anaesthetised guinea 
pigs and the level of ototoxicity of each extract/chemical was determined by recording auditory 
evoked potentials.
1. Attempts were made to demonstrate/identify ototoxins in cytoplasmic contents of -S'. 
pneumoniae type ITT, Hib and Neisseria meningitidis.
Ototoxic activity was demonstrated in extracts of Hib, N. meningitidis and wild type S. 
pneumoniae type III. Tentative evidence was adduced to demonstrate the presence of a 
‘pneumolysin-like’ protein in extracts of Hib and N. meningitidis. The amounts of this protein 
present, estimated by inspection of SDS gel analyses of comparable gel loadings, reflected the 
ototoxic potency of these meningitogenic bacteria: S. pneumoniae > Hib> N. meningitidis (trace). 
In addition, extracts from a pneumolysin-deficient mutant of £ pneumoniae type III were ototoxic 
as were preparations of wild type extracts immunopurified with anti-pneumolysin 
immunosorbents; this suggests the possibility of another ototoxin in S. pneumoniae.
2. Evidence points to the possibility that excitotoxicity in the cochlea during meningitis contributes 
to some (particularly transient) hearing losses probably involving activation of non-NMDA, as 
well as NMDA receptors. If the non-NMDA receptors were definitively shown to be involved in 
the induction of deafness, it is unlikely that such effects would be mediated by NO, and ROSs, for 
the following reasons. NO synthase inhibitors (L-nitro arginine methyl ester (L-NAME) and L- 
methyl arginine (L-MA)) and ROS scavengers (Superoxide dismutase (SOD) and deferoxamine 
(DEF)) afforded no protection on cochleae from the excitotoxic actions of kainate and quisqualate 
- known agonists of non-NMDA receptors - as judged by electrophysiological and morphological 
criteria.
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Meningitis is an infection of the meninges which can be caused by both viral and bacterial 
pathogens. There are approximately 3000 reported cases of bacterial meningitis each year in the 
UK (National meningitis trust 1992). Despite the development of antibiotics, the rapid time 
course of the infection and poor immunity within the cerebrospinal fluid (CSF) leads to a high 
incidence of mortality and neurological sequelae in survivors. Hearing loss is one of the most 
common sequelae of bacterial meningitis.
The initial symptoms of bacterial meningitis may progress over one or two days, but can develop 
very rapidly, sometimes in a matter of hours. Therefore prompt diagnosis and antibiotic treatment 
is essential in order to facilitate a full recovery. Initial diagnosis of bacterial meningitis is often 
difficult because there are a number of different symptoms, and many of these are also symptoms 
of flu. They include headache, fever, vomiting, neck stiffness, drowsiness, dislike of bright lights 
and a purpuric rash. In addition, babies may have high pitched/moaning cry, pale or blotchy skin, 
refuse feeds, and can be fretful or difficult to wake. If seizures or coma develop the prognosis is 
poor. Clinically, the diagnosis is confirmed by sampling of the CSF. Bacteria can be identified by 
CSF culture or antigen detection. Classically, the CSF is turbid due to leukocytosis (white blood 
cells in the CSF), the CSF protein concentration is high, and the ratio of CSF/plasma glucose 
concentration is low. Since CSF abnormalities are not always apparent, definitive diagnosis rests 
with identification of bacteria in the CSF. Upon diagnosis, patients should receive anti-microbial 
therapy immediately which is commonly a combination of penicillin and chloramphenicol. In the 
case of multi-resistant bacterial strains, third generation cephalosporins are the frequent choice. 
Chemoprophylaxis is recommended for close contacts in order to eliminate carriers, and 
Rifampicin is usually used.
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There are three main pathogens which cause bacterial meningitis: Streptococcus pneumoniae 
(pneumococcus), Haemophilus influenzae type b (Hib), and Neisseria meningitidis 
(meningococcus). Pneumococci are gram positive dipplcocci (l|im diameter) which are often 
arranged in chains. They are facultative anaerobes and are readily lysed by surface active agents 
such as bile salts. There are at least 84 capsular types (Brooks, Butel and Omston 1995) 
serotyped according to immunologically distinct capsular polysaccharides. Haemophilus 
influenzae are gram negative short pleomorphic coccobacilli (lxl.5x0.3 gm) which are 
fastidious facultative anaerobes (Brooks et al. 1995). There are 6 types of capsulated 
Haemophilus influenzae subtyped a-f. The six subtypes can be serologically typed according to 
capsular polysaccharides with specific antiserum by agglutination or Quellung reaction. H. 
influenzae type b is responsible for 95% invasive diseases caused by H. influenzae. 
Meningococci are gram negative oval dipplococci (0.8pm diameter) and are exacting in their 
growth requirements (Brooks et al. 1995); some are facultative anaerobes. There are more than 8 
serotypes of meningococci which can be serotyped according to their polysaccharide capsular 
antigens. The most important serotypes in causing disease are types A, B, C, Y and W135. Group 
B N. meningitidis is currently the prevalent meningeal pathogen within the UK and is associated 
with both local outbreaks of the disease as well as epidemics.
S. pneumoniae, H. influenzae and N. meningitidis were responsible for 13, 48 and 20 % of 
reported bacterial meningitis cases in the United States between 1978 and 1981 (Schlech, Ward, 
Band et al. 1985). Of the remaining (19%) cases, 6% were caused by unknown pathogens. 
Neonatal bacterial meningitis was most commonly evoked by Streptococcus agalactia, and S. 
pneumoniae was the main pathogen responsible for meningitis in patients more than 60 years old. 
H. influenzae, N. meningitidis and S. pneumoniae were responsible for the majority of cases 
between these ages (Schlech et al. 1985). These data demonstrate that the predominant etiologic 
agent of bacterial meningitis varies with the age of the host. The incidence of H. itfluenzae type 
b meningitis is now falling dramatically due to the success of widespread vaccination with 
conjugate H. influenzae type b vaccines (Greenwood, Slack and Peutherer 1997), described later 
in this Chapter. Therefore S. pneumoniae and N. meningitidis are likely to be the leading cause of 
bacterial meningitis in future reports. This is supported by a recent report of 124 bacterial 
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meningitis cases in children aged between 4 weeks and 16 years in the UK. Only 1 case was 
caused by H. influenzae type b whereas N. meningitidis and S. pneumoniae were responsible for 
92 and 18 cases respectively (Richardson, Reid, Tarlow et al. 1997). This is in direct contrast to 
the pre-//. influenzae type b vaccine reports in which H. influenzae type b was the predominant 
causative agent of bacterial meningitis in children of this age (Schlech et al. 1985).
1.1.1. Experimental Study of the Pathogenesis of Bacterial 
Meningitis
Several animal models have been developed in order to study the pathological events that occur 
during bacterial meningitis. The two most common models are the infant rat and the adult rabbit 
models of meningitis (Tauber and Zwahlen 1994). The infant rat model of meningitis most 
closely resembles meningitis in humans and is of particular use for studying the early 
pathological events (reviewed in Tauber and Zwahlen 1994). In this model, bacterial meningitis 
frequently develops following intranasal inoculation of bacteria, and the whole course of the 
infection from the initial nasopharyngeal colonisation can be studied. Unfortunately, unless 
primates are used, frequent sampling of the CSF is not possible in infant animals, and larger adult 
animals rarely develop meningitis following intranasal inoculation. Therefore an adult model of 
meningitis has been developed in which bacteria are inoculated directly into the blood or CSF. 
This bypasses the initial stages of colonisation and invasion into the blood stream which can be 
age dependent, and allows the frequent sampling of CSF. Although this is an artificial route of 
infection, it produces a consistent infection with a reproducible time course (Bhatt, Halpin, Hsu 
et al. 1991). In addition, meningitis can be induced by bacterial products and inflammatory 
mediators allowing investigation of the role of specific individual factors in the pathogenesis of 
bacterial meningitis (Tuomanen, Lui, Hengstler et al. 1985). The pathogenicity of H. influenzae 
has been most commonly studied in the infant rat model of meningitis (Moxon, Smith, Averill et 
al. 1974; Kaplan, Hawkins, Kline et al. 1989; Wiederman, Hawkins, Johnson et al. 1986), but has 
been also studied in mice (Schneerson, Rodriguez, Parke et al. 1971), rabbits (Osborne, Comis, 
Tarlow et al. 1995: Tuomanen, Saukkonen, Sande et al. 1989) and primates (Daum, Sheifele, 
Syriopoulou et al. 1978). Experimental pneumococcal meningitis has been induced in rats
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(Strake, Mitten, Ewing et al. 1996), guinea pigs (Winter, Comis, Osborne et al. 1997), dogs 
(Scheid, Park, Dacey et al. 1979) and cats (Hochwald, Nakamura, Chase et al. 1984), but has 
been most commonly induced in adult rabbits (Bhatt et al. 1991; Tuomanen et al. 1989). 
Experimental meningococcal meningitis has been induced in adult rabbits (Tuomanen et al. 
1989), infant rats (Saukkonen 1988), and most commonly in mice (Salit and Tomalty 1986). 
Animal models of meningococcal infections have proved difficult because of the relative 
avirulence of this pathogen in hosts other than humans. Mice have been the most common choice 
because there are well characterised lines of inbred mice which are immunologically and 
genetically susceptible to meningococcal infection. In addition, gastric mucin has been used to 
enhance infections by providing more available iron for bacterial growth (Arko 1989).
In vitro studies using cultured human cells, and organ cultures have also been used to study the 
pathogenesis of Hib, pneumococcus and meningococcus (Ring, Weiser and Tuomanen 1998; 
Stephens 1989; Stephens and Farley 1991; St Geme and Cutter 1995).
1.1.2. Pathogenesis of Bacterial Meningitis
Bacteria enter the body at the nasopharynx. There is an initial colonisation of the nasopharynx 
which most commonly results in an asymptomatic carrier state, but occasionally results in 
invasion into the submucosa and bloodstream. Use of isogenic mutants of H. influenzae type b 
demonstrate that organisms which gain access to the blood and central nervous system (CNS) are 
the progeny of a small fraction of the original challenge inoculum, probably a single bacterium 
(Moxon and Murphy 1978). Virulent bacteria have evolved divergent mechanisms for 
colonisation and invasion, some of which are common to S. pneumoniae, H. influenzae type b, 
and N. meningitidis. These include, attachment to mucus and to nonciliated epithelial cells, 
ciliostasis, cytotoxicity, multiplication, and invasion of the nasopharyngeal mucosal surfaces. 
Invasion of the nasopharynx by H. influenzae type b is intercellular involving breakdown of 
epithelial cell tight junctions between epithelial cells, whereas meningococci invade the 
nasopharynx by endocytic internalisation (Stephens and Farley 1991). The mechanism by which 
pneumococci gain access to the blood stream is not clear (Boulnois 1992).
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Once meningitogenic bacteria reach the blood stream, the course of the disease depends on the 
ability of host defences to clear the bacteria. If host defences are insufficient bacteria multiply 
and then proceed to invade the CNS. Since other bacterial species produce continuous 
bacteraemia without inducing meningitis, there must be virulence factors involved in invasion of 
the meninges which are unique to meningitogenic bacteria. Current evidence suggests that 
bacteria enter the CSF in the lateral ventricles, presumably through the choroid plexi (Daum et al. 
1978). The mechanism by which bacteria gain access to the CSF is not clear, but several theories 
have been put forward. The Trojan horse theory suggests that bacteria gain access to the CSF in 
association with monocytes migrating along their normal pathways. Transmission electron 
microscopic studies indicate that H. influenzae type b cross the endothelial barrier by direct 
invasion of the endothelial cells similar to that reported for endothelial cells of the human 
umbilical vein (Virji, Kayhty, Ferguson et al. 1991). Recent studies have shown that 
pneumococcal invasion of rat and human brain microvascular endothelial cells is intracellular and 
is likely to be mediated by the interaction of platelet activating factor (PAF) receptors in the 
expressed by the endothelial cells with choline binding proteins in the pneumococcal cell wall 
(Ringe/ al. 1998).
Since host defences within the CSF are inadequate, bacteria in the CSF are able to multiply 
rapidly. Leukocytosis follows bacterial invasion of the CSF. Current opinion is that leukocytes 
invade the CSF by a 3 step process (Springer 1994). Initially leukocytes roll along the endothelial 
cells of the blood-brain barrier (BBB), they then adhere firmly to the endothelial cells and later 
traverse the BBB (transmigration). The first step is achieved by the presence of selectins on the 
endothelial lining of the BBB and counter carbohydrate receptors on the leukocytes. The second 
and third steps are achieved by i) the interaction of chemoattractors (displayed or released on the 
endothelium of blood vessels) with specific leukocyte membrane receptors, and ii) binding of 
integrins (on leukocyte membranes) with immunoglobulin (Ig) superfamily members on the 
endothelium (Springer 1994) (Figure 1.1.2.), Selectins are dramatically mobilised or synthesised 
in response to cytokines, and leukocytes are only adhesive to the BBB when activated by external 
stimuli. Therefore it is thought that bacterial invasion into the CSF causes a local release of 














Step 1 Step 2 Step 3
Figure 1.1.2. Diagrams to illustrate the 3 
step process of leukocytosis.
1. Selectin molecules that bind on carbohydrate 
ligands, often displayed on mucin-like molecules, 
are responsible for the inital tethering of a 
flowing leukocyte to the vessel wall and for 
labile, rolling adhesions. Tethering brings 
leukocytes into proximity with chemoattractants 
that are displayed on or released from the 
endothelial lining of the vessel wall.
2. Chemoattractants bind to receptors that span 
the membrane seven times on the surface of 
leukocytes. These couple to G proteins, which 
transduce signals that activate integrin 
adhesiveness. The integrins can then bind to Ig 
superfamily members on the endothelium, 
increasing adhesiveness and resulting in arrest 
of the rolling leukocyte.
3. Following directional cues from 
chemoattractants and using integrins for traction, 
leukocytes then cross the endothelial lining of 
the blood vessel and enter the tissue.
(Taken from Springer 1994)
display/release of chemoattractors. These factors enable leukocytes with the appropriate counter 
receptors and integrins to extravásate into the sub arachnoid space (SAS).
A break down in the BBB also follows bacterial invasion into the CSF and is characterised by 
an accumulation of proteins within the CSF. The BBB is located at the cerebral microvascular 
endothelial cells and exhibits functional and morphological differences to other endothelial cells. 
Cerebral endothelial cells possess narrow intercellular tight junctions which hinder paracellular 
transport of hydrophilic compounds, and pinocytotic vesicular transport is virtually absent which 
implies that fluid phase uptake is limited (De Vries, Kuiper, De Boer et al. 1997). During 
experimental H. influenzae type b meningitis in rats a separation of the tight junctions and an 
increase in the number of pinocytotic vesicles, correlated with penetration of albumin into the 
CSF has been observed (Quagliarello, Long and Scheid 1986). The mechanism by which this 
damage to the BBB occurs is not clear.
Bacterial invasion of the CSF results in cerebral oedema of multiple origin which is responsible 
for the increase in intracranial pressure associated with meningeal infections. Vasogenic 
oedema results from increased leakage of fluid from cerebral capillaries due to breakdown of the 
BBB. Cytotoxic oedema results from swelling of cellular elements due to electrolyte changes 
caused by leukocytes and/or bacterial toxic factors. Increased CSF levels of antidiuretic hormone 
can also contribute to cytotoxic oedema by diluting the extracellular fluid and increasing the 
permeability of the brain to water. In addition interstitial oedema results from obstruction of the 
drainage of CSF into the blood due to dysfunction of arachnoid villi by entrapment of leukocytes.
Secondary bacteraemia may result from local CNS suppurative processes allowing bacteria to 
continuously enter and leave the CSF. This is often seen in experimental meningitis in which 
bacteraemia is produced following intracistemal inoculation (Winter 1997). When the blood 
vessels of the brain become infected with bacteria (vasculitis), narrowing of the vessels or 
thrombus formation can occur, leading to ischaemia or infarction of the brain. Vasospasm can 
also occur via humoral factors. If large arteries in the base of the brain are involved severe 
neurological complications can arise (Igrashi, Gilmartin, Gerald et al. 1984). Impeded blood 
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flow to the brain results in an increased concentration of lactate and decreased concentration of 
glucose in the blood which is important in diagnosis of clinical bacterial meningitis.
Eventually, one or more of the physiological alterations evoked by meningeal invasion results in 
neuronal injury and irreversible focal or diffuse brain damage.
1.1.3. Cytokines and Inflammation
During meningitis there is a compartmentalised local release of inflammatory mediators within 
the CSF in response to bacteria and bacterial products. The ensuing response is produced by a 
complex cascade involving hosts cells and many inflammatory mediators including 
polymorphonucleocytes (PMNs), proinflammatory mediators (cytokines and PAF), excitatory 
amino acids (EAAs) and reactive oxygen species (ROSs).
The two main cytokines which initiate the inflammatory response are Interleukin 1 (IL-1) and 
Tumour Necrosis Factor a (TNFa) (reviewed in Saez-Llorenz, Ramillo, Mustafa et al. 1990). 
These are found in the CSF of most patients with bacterial meningitis, but not in the CSF of 
control or viral meningitis patients (Mustafa, Lebel, Ramillo et al. 1989a). IL-1 is produced and 
released by mononuclear phagocytes activated by bacterial products such as cell wall components 
and toxins (Riesenfeld-Om, Wolpe, Garcia-Bustos et al. 1989). Other cells including microglia, 
astrocytes and cerebral endothelial cells are also capable of producing IL-1 (De Vries et al. 
1997). The presence of IL-1 in the CSF correlates with presence of TNFa, and adverse outcome. 
High levels of IL-1 have been correlated with neurological sequelae (Mustafa et al. 1989a). 
Intracistemal injection of EL-1 alone is capable of inducing inflammation similar to that seen in 
bacterial meningitis including leukocytosis and an increase in permeability of the BBB 
(Quagliarello, Wispelway, Long et al. 1991). TNFa is produced and released primarily by 
monocytes and macrophages, although other cells including astrocytes, microglial cells and 
cerebral endothelial cells are capable of TNFa production (De Vries et al. 1997). It is produced in 
response to multiple stimuli including microbial or immunological insults, particularly endotoxin 
(Mustafa, Ramilo, Olsen et al. 1989b). In physiological concentrations, TNFa is believed to 
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benefit the host by aiding the hosts immune system and assisting tissue repair. However, at 
greater concentrations, TNFa can lead to fatal toxic reactions similar to that seen by 
administration of endotoxin or infection with gram negative bacteria. Intracisternal injection of 
TNFa induces leukocytosis and alterations in the BBB (Kim, Wass, Cross et al. 1992), and in 
combination with IL-1 is synergisitic in inducing meningeal inflammation (Quagliarello et al. 
1991). In experimental models of meningitis, administration of anti-TNFa monoclonal antibody 
attenuates the inflammatory response to Hib endotoxin (Mustafa et al. 1989b).
Phospholipase A2 is responsible for the production of two main inflammatory pathways: one 
which results in the production of PAF and a second (the arachidonic acid pathway) which 
results in the production of prostaglandins, thromboxanes and leukotrienes (eicosanoids). In 
outline, leukotrienes cause PMN chemotaxis which results in leukocytosis, and, PAF and 
thromboxanes promote thrombosis in the microcirculation which ultimately results in regional 
cell death. Phospholipase A2 is activated on membrane phospholipids of many cells including 
neutrophils, platelets and vascular endothelial cells in response to bacterial (and other) antigens. 
Since IL-1 and TNFa appear to induce phospholipase A2 activity, some of the effects of these 
cytokines are likely to be mediated by the production of PAF and eicosanoids (Saez-Llorenz et 
al. 1990).
Polymorphonucleocytes enter the CSF during meningitis in response to cytokines. Although 
PMNs are essential in eradicating bacteria from the blood, experimental studies indicate that the 
action of PMNs in the CSF is more detrimental than beneficial. This is clearly seen in 
experimental meningitis in rabbits induced by live S. pneumoniae, N. meningitidis, H. influenzae, 
pneumococcal cell wall or lipopolysaccharide (LPS) in which inhibition of leukocytosis by 
administration of monoclonal antibodies to the CS18/11 adhesion promoting receptors 
significantly reduced the alteration of permeability of the BBB, delayed secondary bacteraemia, 
and prevented mortality and cerebral oedema (Tuomanen et al. 1989). Since PMNs rely on 
antibodies and cytokines to select targets for their action, the lack of opsonins and complement in 
the CSF means that the action of PMNs is less well targeted and results in damage of host tissues. 
Toxic agents released by PMNs include ROSs, nitric oxide (NO), proteases and glutamate.
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There is now accumulating evidence that nitric oxide or a secondary oxidant derived from nitric 
oxide is involved in the pathophysiological events during meningitis. Several clinical studies 
have reported increased levels in CSF of nitrite and nitrate (products derived from NO) in 
patients with bacterial meningitis (Komelisse, Hoekman, Visser et al. 1996a; Van Furth, 
Seijmmonbergen, Groeneveld et al. 1996). Moreover, Komelisse et al. (1996a) reported that 
elevated nitrite and nitrate levels in CSF correlate with TNFa and glucose levels, and a decrease 
in the level of 1-arginine (precursor of NO). Increased levels of nitrates in the CSF have also been 
reported during experimental meningitis and were correlated with increased permeability of the 
BBB (Buster, Weintrob, Townsend et al. 1995).
Several studies have been carried out using various nitric oxide synthase (NOS) inhibitors to 
determine whether NO is involved in the inflammatory response during experimental meningitis 
(reviewed in Pfister and Scheid 1997): NOS inhibitors attenuate the inflammatory response in the 
early phase of meningitis (Buster et al. 1995; Boje 1995; Boje 1996; Koedel, Bematowicz, Paul 
et al. 1995). However, the effects of such inhibitors on the more advanced stages of meningitis is 
less clear. For example, NOS inhibitors considerably worsened neuronal injury in vivo (Leib, 
Kim, Black et al. 1996), whereas NOS inhibitors attenuated toxicity in astrocytes and microglia 
produced by gram positive cell walls in vitro (Kim and Tauber 1996).
The source of NO production during meningitis is not known. Bacterial production of NO/nitrate 
is unlikely since nitrite and nitrate levels are raised in meningococcal meningitis patients and 
meningococci do not form NO (Vanfurth, Despland, Lutschg et al. 1996), and, increased nitrite 
levels are seen in experimental models of meningitis using endotoxin alone (Buster et al 1995; 
Korytko and Boje 1996) or heat killed pneumococci (Koedel et al. 1995). A number of host cells 
are capable of producing NO by NOS, including endothelial cells, astrocytes, microglia, 
cerebellar neurones, and white blood cells (Korytko and Boje 1996). There are two types of 
constitutively produced NOS, endothelial (type ID) and neuronal (type I) NOS, which produce 
small amounts of NO in response to an increase in intracellular Ca . A third inducible NOS (type 
II NOS) is expressed in response to a specific combination of cytokines (including IL-1 and
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TNFa) by a number of cells including smooth muscle cells, macrophages and glial cells. 
Inducible NOS (iNOS) synthesises large amounts of nitric oxide until it is inactivated by another 
specific combination of cytokines (including interleukins 4, 8, and 10, TNFP, and platelet derived 
factors) (Mayer and Hemmens 1997). Therefore inducible NOS would seem to be a likely 
candidate as a tissue-damaging determinant in meningitis. The time course and effect of NOS 
inhibitors on NO production during experimental meningitis supports the concept that iNOS is 
responsible (Korytko and Boje 1996; Boje 1996). However, dexamethasone is an inhibitor of 
inducible NOS, and its administration was not associated with reduced levels of nitrite in the CSF 
of patients with bacterial meningitis (Komelisse et al. 1996a). Therefore neuronal and endothelial 
NOS may also be involved in the increased production of NO during meningitis.
In conclusion, NO appears to play an important role in the pathogenesis of early events 
associated with bacterial meningitis However, further investigations are necessary in order to 
elucidate the exact source and site of action of NO produced during bacterial meningitis. Since 
previous studies have used non-selective NOS inhibitors, more selective inhibitors of nitric oxide 
should help to clarify the situation.
Reactive oxygen species (ROSs) are by-products of aerobic metabolism which have the potential 
to disrupt cellular function and structure. A number of different anti-oxidants have been shown to 
produce beneficial effects on the inflammation associated with bacterial meningitis (reviewed in 
Pfister and Scheid 1997). Scavengers of hydrogen peroxide, superoxide, and hydroxyl radicals 
have all been shown to attenuate the early inflammatory response in experimental meningitis. For 
example, Koedel et al. (1995) demonstrated that superoxide dismutase (scavenger of superoxide) 
produced attenuation of brain water content, intracranial pressure and CSF white blood cell count 
similar to that seen by inhibition of NOS. Therefore ROSs appear to play an important role in the 
early pathogenic events of bacterial meningitis.
CSF concentrations of excitatory amino acids are elevated in human clinical and in rabbit 
experimental bacterial meningitis (Guerra-Romero, Tureen, Fournier et al. 1993), and are 
10
correlated with the severity of the disease (Spranger, Schwab, Krempien et al. 1996). Moreover, 
in experimental meningitis models, a non-specific glutamate receptor antagonist attenuated 
neuronal injury (Leib, Kim, Ferriero et al. 1996), and a non-competitive NMDA receptor 
antagonist attenuated oedema and BBB injury (Bass, Engelhard, Trembovler et al. 1996). In 
addition, toxicity of cerebellar neurones produced by macrophages in vitro was blocked by 
NMDA receptor antagonists, but not by catalase or SOD (Piani, Spranger, Frei et al. 1992). 
Therefore EAAs also appear to play a role in the pathogenesis of bacterial meningitis. The source 
of excitatory amino acids during meningitis is unclear. Since re-uptake of amino acids is energy 
dependent at the synapse, ischaemia could lead to accumulation of the amino acids. In addition, 
increased permeability of the BBB to excitatory amino acids, release of amino acids from PMNs 
or cells in the CNS, decreased clearance of amino acids from the CSF, and increased binding of 
amino acids to brain tissue could all contribute to the deleterious effects seen in meningitis 
(Pfister, Fontana, Tauber et al. 1994).
In conclusion, many different mediators are involved in the inflammatory response produced 
during bacterial meningitis. The precise interaction of each of these factors is not clear. Despite 
some bacterial killing by the inflammatory response, clinical and experimental data clearly 
indicate that the majority of the deleterious consequences of bacterial meningitis are a direct 
consequence of this inflammatory response by the host (Townsend and Scheid 1996). Antibiotics 
ultimately reduce inflammation by eliminating the bacteria, however, initially they can worsen 
the inflammation by releasing bacterial products which stimulate the release of inflammatory 
mediators. For example, the fraction of free endotoxin in CSF increases 10-fold during bacterial 
death induced by antibiotics which act on the bacterial cell wall (Arditi, Ables and Yogev 1989; 
Tauber, Shibl, Hackbarth et al. 1987). It is during this critical stage at which antibiotics are 
administered that control of the inflammatory response would be most beneficial.
1.1.4. Control of the Inflammatory response
There is now evidence of an increase in naturally occurring anti-inflammatory mediators during 
meningitis. Interleukin 10 (IL-10) is an endogenous interleukin which suppresses the synthesis 
of pro-inflammatory cytokines. It is produced by monocytes/macrophages, and lymphocytes and 
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its concentration in the CSF and CSF/blood ratio is elevated in children with bacterial meningitis 
(Komelisse, Savelkoul, Mulder et al. 1996). Systemically administered IL-10 attenuated the 
increase in regional cerebral blood flow, brain water content, intracranial pressure and CSF white 
blood cell count in experimental pneumococcal meningitis (Koedel, Bematowicz, Frei et al. 
1996). In addition, systemic and intrathecal administration of IL-10 reduced the TNFa and 
lactate levels in CSF in experimental meningitis induced by H. influenzae type b or Listeria 
monocytogenes (Paris, Hickey, Trujillo et al. 1997). There are also naturally occurring TNFa 
antagonists. These are soluble extracellular domains of the 55 and 75 kDa membrane bound 
TNF receptors (sTNFR-55 and sTNFR-75) which neutralise the activity of TNFa. sTNFR-55 
and sTNFR-75 are shed from the surface of PMN cells and monocytes in response to many of 
the same inflammatoiy stimuli which are known to induce TNFa release, and IL-10 stimulates 
their release from monocytes in vitro. In clinical meningitis the levels of sTNFR-55 and sTNFR- 
75 are significantly raised (Komelisse et al. 1996b). Therefore it is likely that both IL-10 and the 
sTNFRs are released by the host during meningitis in an attempt to control the inflammatory 
response.
Several types of anti-inflammatory drugs have been shown to be advantageous in the treatment of 
experimental bacterial meningitis; these include corticosteroids, anti-cytokine antibodies, PAF 
antagonists, free radical scavengers, NOS inhibitors, and antagonists of leukocyte-endothelial cell 
adhesions (reviewed in Pfister and Scheid 1997). However, many of these studies did not include 
antibiotic treatment in addition to the anti-inflammatory therapy. Clinically, only corticosteroids 
have been tested as adjunctive therapy in bacterial meningitis. The current evidence on the use of 
dexamethasone as adjunctive therapy in the treatment of bacterial meningitis is reviewed by 
Townsend and Scheid (1996). There is a wide variation in the effects of dexamethasone on 
inflammatory indices and outcome. Nevertheless, meta-analysis (combined analysis of data from 
different studies) of data from four well designed double-blinded placebo-controlled studies 
supports the contention that neurological sequelae (particularly severe bilateral sensorineural 
hearing loss) are reduced by concomitant therapy with dexamethasone. Since the large majority 
of data is from children, the effects of dexamethasone therapy on adults is not clear. In these four 
studies, gastrointestinal bleeding in two patients was the only reported adverse effect. However, 
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since anti-inflammatories may attenuate the increased permeability of the BBB during bacterial 
meningitis, several groups have investigated the effect of dexamethasone treatment on antibiotic 
penetration of the CSF in experimental meningitis. Despite some reductions in the concentrations 
of antibiotics in the CSF, there appears to be no reduction in sterilisation of the CSF by most of 
the commonly used antibiotics (Rodriguez, Kaplan, Hawkins et al. 1991a; Scheid and Brodeur 
1983). However, bacterial killing by vancomycin in the CSF was significantly reduced by 
concomitant therapy with dexamethasone (Paris, Hickley, Uscher et al. 1994). Therefore, the 
current evidence supports the use of dexamethasone therapy in the treatment of bacterial 
meningitis in children, but not if the choice of antibiotics includes vancomycin (i.e. for multi­
resistant strains). In the case of bacterial meningitis in adults, the use of dexamethasone is 
advisable if the prognosis is poor, or there are already many bacteria in the CSF upon admission 
(Townsend and Scheid 1996). In all patients for whom dexamethasone is used as adjunctive 
therapy, monitoring for adverse effects (e.g. gastrointestinal bleeding) should be carried out 
(Townsend and Scheid 1996). In addition, it may be wise to carry out a second lumbar puncture 
in the treatment of multiple resistant strains to document the action of the antibiotic when 
adjunctive dexamethasone therapy is used.
1.1.5. Bacterial Virulence Factors
Virulence factors are those microbial elements which enhance ability to cause infection and 
disease. In addition to counteracting host defences, they are responsible for many of the 
complications of bacterial meningitis by their potent activation of the inflammatory response.
Surface encapsulation is an important virulence attribute in evading host defences. All the 
common meningitogenic bacteria are encapsulated. Moreover, bacterial meningitis is most 
commonly caused by a small proportion of the numerous capsular types associated with each 
meningeal pathogen. Since unencapsulated strains are often more adherent and invasive than 
encapsulated strains in vitro (St Geme and Falkow 1992), it would seem that the capsule does not 
facilitate translocation across cellular barriers. The prevalence of encapsulated strains is more 
likely due to the ability of the capsule to enhance survival in the blood and CSF by inhibiting 
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neutrophil phagocytosis and resisting classical complement-mediated bactericidal activity. The 
fact that virulence of meningitogenic bacteria is determined mainly by the capsule is 
demonstrated by the highly protective action of specific anti-capsular antibodies in human and 
experimental meningitis caused by H. influenzae type b, N. meningitidis and S. pneumoniae 
(Greenwood, Slack and Peutherer 1997).
Cell wall components are considered to be the most important bacterial factors in evoking an 
inflammatory response. The cell wall of gram positive bacteria is comprised mostly of 
peptidoglycan and lipoteichoic acid (LTA), whereas the cell wall of gram negative bacteria 
contains only a single layer of peptidoglycan, but also contains endotoxin (Lipopolysaccharide); 
(Fig. 1.1.5.),
Lipopolysaccharide (LPS) is found embedded in the outside layer of the outer membrane of all 
gram negative bacteria. It is the one of the most significant virulence structures in gram negative 
bacteria. LPS is excreted by bacterial cells in small amounts, but can produce toxicity while still 
attached to the bacterial cell wall (Mustafa, Ramillo, Syrogiannopoulos et al. 1989c). Since 
toxicity evoked by LPS can be blocked by neutralising the lipid component (Lipid A) 
(Burroughs, Cabellos, Prasad et al 1992; Tauber, Shibl, Hackbarth et al. 1987), it follows that 
this is the toxiphore in this complex molecule. The polysaccharide component has a variable 
terminal segment exposed on the outer surface of the bacteria which is a major surface antigen. 
The LPS of H. influenzae type b and N. meningitidis has very short polysaccharides and hence is 
conventionally called lipooligosaccharide (LOS). Hib and meningococcal LOS show 
heterogeneity both within and between strains (Roche and Moxon 1995; Smith, Parsons and Cole 
1995). They each can be modified in vivo and become capable of resistance to LOS directed 
antibodies. In the case of H. influenzae type b, this modification is serum dependent but the 
mechanism is unknown (Inzana and Anderson 1985). In the case of N. meningitidis this is due to 
sialylation of terminal sugar residues which leads to the generation of an epitope that mimics one 
present on host cells. N. meningitidis can sialylate its LOS endogenously, or exogenously from 
substrates in in vivo secretions, serum and host cells (Smith et al. 1995). Some strains of H. 
influenzae type b have endogenously sialylated LOS components (Mandrell, McLaughlin, Aba
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Figure.1.1.5. a) Comparison of the cell envelope structures of gram-positive and 
gram-negative bacteria.
b) Molecular structure of the gram-negative cell envelope.
Taken from Medical Microbiology, Murray, Drew, Kobayashi and Thompson.
The C.V. Mosby Company 1990.
Kwiak et al. 1992), but their involvement in the pathogenesis of H. influenzae type b is not 
known. H. influenzae type b LOS has been shown to be involved in a number of the pathological 
events that occur during meningitis and alone has been shown to evoke responses identical to the 
events evoked by living bacteria (Burroughs et al. 1992). H. influenzae type b LOS inhibits 
ciliary activity of human respiratory epithelial cells in vitro (Stephens and Farley 1991), and 
facilitates dissemination of H. influenzae from the nasopharynx to the blood in vivo (Weiser, 
Williams and Moxon 1990). In addition, H. influenzae type b LOS causes a dose-dependent and 
time-dependent increase in permeability of the BBB with a greater effect than live H. influenzae 
type b despite identical LPS concentrations in vivo. Since meningeal inflammation produced by 
LPS is significantly reduced by inhibition of leukocytosis (Tuomanen et al. 1989) it is thought 
that the majority of the BBB damage produced by LOS in vivo is mediated by the leukocytosis 
evoked by LPS. However, Hib LOS evokes breakdown of an in vitro BBB model (monolayers of 
cultured bovine brain endothelial cells) via a serum-dependent cytotoxic pathway (Patrick, Betts, 
Frey et al. 1992). Therefore, Hib LOS appears to be capable of some cytotoxic effects which are 
not secondary to leukocytosis in vitro. Neutralisation of meningococcal LOS in experimental 
sepsis enhanced survival slightly (Bannatayne, Harnett and Cheung 1977), but the role of 
meningococcal LOS in meningitis has not been studied. Meningococcal LOS was toxic in 
fallopian tube organ culture, but did not affect ciliary function in nasopharyngeal organ cultures 
(Stephens and Farley 1991). However, since meningococcal LOS can be modified by sialylation 
exogenously as well as endogenously, in vitro effects may not fully represent in vivo effects.
Pneumococcal cell walls which contain considerable amounts of peptidoglycan and cell wall 
polysaccharides including teichoic acid (TA), are also capable of inducing an inflammatory 
response which is very similar to that produced by live pneumococci. In the rabbit model of 
bacterial meningitis, pneumococcal teichoic acid and peptidoglycan, (but not capsular material) 
at physiologically relevant concentrations evoked meningeal inflammation (measured by CSF 
white blood cell (WBC) count) similar to that seen after infection with whole pneumococci 
(Tuomanen et al. 1985). Since purified pneumococcal cell wall material is a powerful stimulus 
for the production of IL-1 by human monocytes (Riesenfeld-Om et al. 1989), this cytokine most 
likely mediates many of the inflammatory effects produced by pneumococcal cell wall. Like
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LPS, peptidoglycan is released in a cell-free form during growth and particularly following death 
induced by cytokines (Burroughs, Prasad, Cabellos et al. 1993). Purified peptidoglycan from H. 
influenzae induced meningeal inflammation in a rabbit model of meningitis (Burroughs et al. 
1993). Thus it would appear that in this context peptidoglycan is involved in both gram negative 
and gram positive bacterial virulence. There is some evidence that antibodies directed towards 
cell wall polysaccharides are protective in animal models of pneumococcal meningitis (Briles, 
Forman, Horowitz et al. 1989). However, these antibodies do not appear to stimulate 
phagocytosis, and are much less protective than anti-capsular antibodies. In addition, the levels of 
anti-cell wall polysaccharide antibodies were not significantly different in healthy subjects of 
different ages, or between healthy subjects and patients with pneumococcal disease (Musher, 
Watson and Baughn 1990). Therefore the relative contribution made by antibodies to 
pneumococcal cell wall components to overall host defence mechanisms is not clear.
Many meningitogenic bacteria produce IgAl proteases which may facilitate colonisation of 
mucosal surfaces by reducing opsonisation by secretory IgAl. H. influenzae type b, N. 
meningitidis and 5. pneumoniae all produce IgAl specific proteases (Komfeld and Plaut 1981). 
However, no direct evidence for their role in pathogenicity exists because they are highly specific 
and do not cleave IgA from any of the animals used in experimental meningitis.
Pili are filamentous protein structures composed of repeating identical subunits (pilins). H. 
influenzae type b and N. meningitidis express pili, and are capable of pili phase variation, which 
is environmentally regulated (Stull, Mendelman, Schoenbom et al. 1984; Pinner, Spellman and 
Stephens 1991). To my knowledge, there is no evidence that pili are involved in the pathogenesis 
of pneumococcal infections. Hib pili may enhance adherence to human epithelial cells in culture 
(St Geme and Cutter 1995), but were not essential for adherence to human epithelial cells in 
organ culture (Stephens and Farley 1991). Moreover, non piliated Hib were more invasive in 
organ culture (Stephens and Farley 1991). Therefore Hib pili may be advantageous for 
colonisation, but are not essential for invasion. Since the majority of Hib isolates from the blood 
and CSF of patients with meningitis lack detectable pili (Stull et al. 1984), it appears that 
following colonisation and invasion of the nasopharynx, pili are not needed by Hib.
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In contrast, pili are important virulence factors in meningococcal infections. Expression of 
assembled pili appears to be the major determinant of meningococcal attachment to 
nasopharyngeal epithelial cells (Stephens and Farley 1991). In addition, meningococcal isolates 
from the blood and CSF are very often piliated (De Voe and Gilchrist 1975), therefore pili may 
play a role in meningococcal virulence beyond initial colonisation and invasion (Stephens and 
Farley 1991). Meningococcal pili appear to mediate interactions with endothelial cells, epithelial 
cells and erythrocytes (reviewed in Nassif and So 1995). Therefore pili could be involved in 
adhesion to cerebrovascular epithelial cells in order to facilitate invasion of the CSF (as seen by 
E.coli) (Parkkinen, Korhonen and Pere 1988). In addition, since pili-deficient mutants of 
meningococci are not able to haemagglutinate erythrocytes (Nassif and So 1995), pili may 
facilitate haemagglutination and therefore promote thrombosis.
Exotoxins are protein toxins secreted from bacterial cells during growth, or released upon lysis, 
which can promote damaging effects in parts of the body remote from the site of infection. Some 
of the exotoxins which may play a role in virulence of S. pneumoniae, H. influenzae type b and 
N. meningitidis are discussed below.
Autolysin is a major cell-wall hydrolase which enhances virulence of pneumococci by producing 
autolysis. Autolysin is thought to be bound to lipoteichoic acid in the pneumococcal cell 
envelope (Diaz, Garcia, Acaso et al. 1989). If pneumococcal cell wall biosynthesis ceases (e.g. 
due to nutrient starvation or antibiotic treatment) autolysin is activated and causes the cell to lyse. 
Studies using autolysin-deficient pneumococcal mutants have provided conflicting evidence 
concerning the contribution of autolysin to pneumococcal virulence (reviewed in Paton, Andrew, 
Boulnois and Mitchell 1993). However, immunisation with autolysin was only effective against 
bacteria which are capable of expressing pneumolysin, and the degree of protection was similar 
to that produced by immunisation with pneumolysin (Lock, Hansman and Paton 1992). Therefore 
autolysin appears to mediate its virulence predominantly by release of pneumolysin.
Pneumolysin is a thiol-activated cytolysin released upon lysis of pneumococci. It is produced by 
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virtually all clinical isolates of^S. pneumoniae (Kanclerski and Mollby 1987) and appears to be 
highly conserved amongst pneumococcal serotypes (Mitchell, Mendez, Paton et al. 1990). 
Significant titres of antibodies directed against pneumolysin are found in patients with 
pneumococcal disease, and are low in healthy subjects within the highest risk ages groups 
(Kanclerski, Blomquist, Granstrom et al. 1988). At high concentrations, pneumolysin oligomers 
form transmembrane pores in mammalian cells which leads to cell lysis. At lower (sublytic) 
concentrations, pneumolysin is toxic to virtually every type of cell in the lung (Cundell, Masure 
and Tuomanen. 1995), stimulates the production of many inflammatory cytokines (Houldsworth, 
Andrew and Mitchell 1994), inhibits the respiratory burst, bactericidal activity and migration of 
human PMNs (Paton and Ferrante 1983), inhibits antibody synthesis (Ferrante, Rowan-Kelly and 
Paton 1984), and activates the classical complement pathway in the absence of anti-toxin 
antibody (Paton, Rowan-Kelly and Ferrrante 1984). The role which pneumolysin plays in the 
pathogenesis of pneumococcal infections has been clearly demonstrated by reduced virulence in 
pneumolysin deficient mutants (Berry, Yother, Briles et al. 1989; Berry, Paton and Hansman 
1992). In addition immunisation with pneumolysin significantly improved survival of mice to 
subsequent pneumococcal challenge infections (Paton, Lock and Hansman. 1983).
A second haemolysin produced by S. pnuemoniae has recently been demonstrated. Haemolytic 
activity previously attributed to pneumolysin has now been demonstrated with pneumolysin 
deficient mutants and with wild type S. pneumoniae treated with anti-pneumolysin antisera 
(Canvin, Paton, Boulnois et al. 1997). The role that this second haemolysin plays in pathogenesis 
has not yet been determined.
Neuraminidase is an enzyme produced by all clinical isolates of S. pneumoniae (O’Toole, 
Goode and Howe 1971) which cleaves sialic acid from host glycolipids, glycoproteins and 
oligosaccharides on cell surfaces or in body fluids. The incidence of coma and bacteraemia is 
significantly greater in patients with elevated CSF levels of neuraminidase (O’Toole et al. 1971). 
Immunisation of mice with neuraminidase slightly enhanced their survival times in subsequent 
pneumococcal challenge infections (Lock, Paton and Hansman 1988). Preliminary data from 
studies using neuraminidase-deficient mutant pneumococci did not provide any evidence of a role 
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for neuraminidase in the virulence of pneumococci, however further investigations are necessary 
(Winter 1997). Neuraminidase is capable of causing considerable damage and may also aid 
adhesion to epithelial and endothelial cells by exposing cell surface receptors (Paton et al. 1993).
Hyaluronidase cleaves hyaluronic acid and is produced by virtually all clinical isolates of S. 
pneumoniae (Brooks et al. 1995). Preliminary findings using hyaluronidase-deficient mutant 
pneumococci suggest that hyaluronidase may play a role in the virulence of pneumococci, 
however further investigations are necessary (Winter 1997). Since hyaluronic acid is found in 
connective tissue and extracellular matrices it could be proposed that hyaluronidase aids bacterial 
colonisation and dissemination.
Haemocin is a bactericidal protein produced by 95% H. influenzae type b strains which has been 
strongly associated with encapsulated H. influenzae type b strains (Tunkel and Scheid 1993) and 
may play a role in the pathogenesis of invasive H. influenzae type b infections, particularly in the 
initial colonisation of the nasopharynx (LiPuma, Sharetzsky, Edlind and Stull 1992).
Two iron-regulated proteins related to the RTX (repeats in toxin) family of toxins have 
recently been described in meningococci (Thompson, Wang, West et al. 1993). Proteins 
belonging to the RTX family have a common gene sequence of amino acid repeats arranged in 
tandem and are usually related to target specific cytolytic exotoxins produced by gram negative 
bacteria. The function of the RTX related proteins in N. meningitidis is not yet known, although 
they appear to be non-haemolytic and non-leukotoxic (Thompson et al. 1993).
1.1.6. Host defences
In order to counteract invading organisms, the mammalian host has developed a number of 
defence mechanisms.
IgA antibodies are present in nasopharyngeal secretions and serum. Many meningitogenic 
bacteria including H. influenzae type b, N. meningitidis and X pneumoniae produce IgA specific 
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proteases which cleave serum and secretory IgA antibodies (Komfeld and Plaut 1981). However, 
some of the IgA antibodies (e.g. IgA2 subclass) are resistant to hydrolysis by bacterial proteases 
and so may play a role in preventing colonisation (Gilbert, Plaut, Longmaid et al. 1983).
Within the host, bacteria are phagocytosed by leukocytes facilitated by antibodies and the 
complement system. Complement and antibody activity in the CSF is raised only slightly (if at 
all) during meningitis, and is insufficient for bacterial lysis or opsonisation (Simberkoff, 
Moldover and Rahal 1980) therefore blood borne phagocytosis is the site of most bacterial 
killing. In the non-immune host opsonisation for phagocytosis can only be achieved by 
complement activity. In the immune host the combination of antibody and complement activity 
can be used for opsonisation. Some antibodies (e.g. against H. influenzae type b capsule) can act 
as opsonins independent of complement activity, but full opsonic potential is only achieved when 
the classical complement pathway is activated. Therefore complement activity is essential for 
opsonisation of encapsulated meningitogenic bacteria such as H. influenzae type b, N. 
meningitidis and S. pneumoniae in both immune and non immune patients. This has been 
illustrated clinically, because a greater incidence of bacterial meningitis is seen in individuals 
with compromised complement systems (Ross and Densen 1984). However, different 
components of the complement system appear to be important in the elimination of individual 
pathogens. For example, opsonisation by C3b appears to be particularly important in H. 
influenzae type b infections (Noel, Bauer, and Edelson 1992) whereas C5-C8 bactericidal activity 
is particularly important in meningococcal disease (Densen 1989). An outline of the complement 
cascades can be seen in Figure 1.16.
Of all types of antibodies, those directed towards capsular polysaccharides are the most 
protective against meningitogenic bacteria including H. influenzae type b, S. pneumoniae and 
several serotypes of N. meningitidis. However, most capsular polysaccharides elicit T-cell 
independent responses, i.e. there is no induction of memory, the response is oligoclonal, 
dependent on age, lacks affinity maturation and has poor antibody class switching. Therefore, in 
addition to capsular polysaccharides, vaccines against meningitogenic bacteria incorporate other 
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Figure 1.16. Overview of the main components and effector actions of 
complement (Taken from Janeway and Travers 1994).
The early events of both the classical or antibody-initiated pathway and the alternative 
pathway involve a series of cleavage reactions culminating in the formation of an enzymatic 
activity called a C3/C5 convertase, since it cleaves complement components C3 and C5. This is 
the point at which the two pathways converge and the effector functions of complement are 
generated. The larger cleavage fragment of C3 (C3b) binds to the membrane and opsonizes 
bacteria, allowing phagocytes to internalise them. The small fragments of C5 and C3 called C5a 
and C3a, are peptide mediators of local inflammation. C4a, generated by cleavage of C4 during 
the early events of the classical pathway (* and not by the action of C3/C5 convertase) is also a 
peptide mediator of inflammation, but its effects are relatively weak. Similarly, the large 
cleavage fragment of C4, C4b is a weak opsonin (not shown). Finally, C3b binds C5, allowing 
generation of C5b that associates with the bacterial membrane and triggers the late events, in 
which the terminal components of complement assemble into a membrane-attack complex that 
damages the membrane of the pathogen.
response which is independent of age and induces anamnestic responses. Anti-Hib capsular and 
anti-pneumococcal capsular antibodies develop in most children by the age of 3-4, however anti 
pneumococcal capsular antibodies decline past the age of 50-60. Therefore those most at risk 
from H. influenzae type b and pneumococcal disease are those aged <3-4 and >50 (pneumococcal 
disease only)
H. influenzae type b vaccines have been introduced world wide and have resulted in a dramatic 
fall in the incidence of H. influenzae type b disease. There are several conjugate vaccines 
available which consist of the polyribosylribitolphosphate (PRP) polysaccharide from type b 
capsule covalently linked to a protein (e.g. diphtheria and tetanus toxoids) which enhances the 
immunogenicity of PRP.
Currently a 23-valent polysaccharide pneumococcal vaccine is available which contains capsular 
polysaccharides from types 1, 2, 3, 6B, 9N, 9V, 10A, 11A, 12F, 14, 15b, 17F, 18C , 19F, 19A, 
20, 22F, 23F and 33F. However, there are two problems with this vaccine. Firstly the vaccine is 
not protective against all isolates (90%), and secondly, the vaccine is poorly immunogenic in 
those most at risk (e.g. immunocompromised patients, elderly people and young children 
(Greenwood et al. 1997; Musher 1992). Therefore the vaccine is most commonly given to 
patients with predisposing factors such as those with sickle cell anaemia or those who have 
undergone splenectomy (Greenwood et al. 1997).
Meningococcal vaccines containing the polysaccharides of groups A, C, Y and W135 are 
available and are currently used in selective populations (e.g. military and civilian epidemics). 
However, the vaccine provides only short-lasting protection and the group C polysaccharide is 
not immunogenic in infants less than 2 years old (Lepow, Gold Schneider, Gold et al. 1977; 
Ceesay, Allen, Menon et al. 1993). There is as yet no vaccine for N. meningitidis type B: the 
group В polysaccharide is poorly immunogenic in humans of all ages.
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1.2. Hearing loss in Bacterial Meningitis.
It is thought that bacterial meningitis is responsible for 90% of profound hearing impairments 
acquired postnatally in children under 3 (Fortnum 1992). Fortnum (1992) reported that between 
1977-1990 the incidence of sensorineural deafness in bacterial meningitis was between 3.5 and 
37.2% with a mean incidence of 9.6%. The incidence of hearing loss varies according to the 
bacterial pathogen. Pneumococcal meningitis is associated with the greatest incidence of hearing 
loss followed by Hib and meningococcal infections respectively. Fortnum (1992) reported that 
between 21.4 and 50% (mean of 31.8%) patients with pneumococcal meningitis develop 
sensorineural hearing losses compared with 5.9-18.1% (mean of 11.4%) of patients with Hib 
meningitis and 5-10.5% (mean of 7.5%) with meningococcal meningitis.
Several methods have been adopted to detect hearing loss during human and experimental 
meningitis. Before describing these methods an outline of the anatomy and physiology of the 
cochlea is given.
1.2.1. Anatomy of the Cochlea
The inner ear contains the vestibular and auditory sense organs. The cochlea (auditory apparatus) 
is a coiled bony channel within the petrous part of the temporal bone. It is 35mm long with 2’/4 
turns in man. The cochlea contains the auditory receptor cells and is divided longitudinally into 
three chambers (Figl.2.1.1,). The inner most central chamber is called scala media. Scala media 
does not communicate with the other scalae and contains the sensory organ of Corti. It is filled 
with endolymph which is very similar to intracellular fluid (high [K+] and low [Na+]). Scala 
media is separated from an upper compartment called scala vestibuli by Reissner’s membrane, 
and a lower compartment called scala tympani by the basilar membrane. At the base of the 
cochlea scala tympani and scala vestibuli are bordered by membranes designated round and 
oval windows respectively. At the apex of the cochlea these two scalae meet at a small opening 
called helicotrema. These peripheral chambers are filled with perilymph which resembles an ultra 
















Figure I.2.I.I. A section through one of the turns of the cochlea. 
(Taken from Guyton 1991 Textbook of Medical Physiology 8th Edition)
Round Window
Endolymphatic Space 




Figure I.2.I.2. A cross section through the temporal bone to illustrate 
the connection of the CSF with the perilymph of the cochlea via the 
cochlear aqueduct. (Taken from Bhatt etal. 1993)
in the wall of scala tympani which leads into the cochlear aqueduct which connects the CSF in 
the sub arachnoid space with the perilymph of the cochlea (Figure 1.2.1.2.), The central axis of 
the cochlea is the bony modiolus which contains the vascular and neural elements which serve 
the cochlea. Lining the outer wall of scala media a three-cell-layered structure is found which is 
called stria vascularis. Stria vascularis contains an intra-epithelial capillary plexus and secretory 
cells. Stria vascularis which is the major blood supply of the cochlea and is also responsible for 
the maintenance of the large positive endocochlear potential within scala media (+80mV) by 
actively pumping ions in and out of the endolymph.
The organ of Corti is a specialised structure containing the sensory hair cells which rests on the 
basilar membrane (Fig.1.2.1.3.), It consists of one row of inner hair cells and three rows of outer 
hair cells. The inner hair cells and outer hair cells are separated by a triangular Tunnel of Corti 
formed from pillars/rods of Corti which give rigidity to the structure. The inner hair cell and 
outer hair cell populations lie medial and lateral to the Tunnel of Corti respectively. Supporting 
cells surround the rods and hair cells. The supporting cells and rods of Corti hold the organ of 
Corti firmly on top of the basilar membrane. Cuticular thickenings at the apex of hair cells 
{cuticular plates), tight junctions between the hair cells and supporting cells, and phalangeal 
processes from supporting cells form a reticular lamina which precludes the perilymph and 
endolymph from mixing. This produces an electrochemical gradient across the hair cells because 
the surface of the cells are surrounded by endolymph whereas the rest of the cell is bathed in 
perilymph. Lying above the hair cells is the tectorial membrane. The tectorial membrane is a 
gelatinous and fibrous flap fixed to the Organ of Corti only on its inner radial edge.
Hair cells are sensory cells adapted to transduce mechanical stimuli to electrical signals. The 
mechanosensitive organelle, the hair bundle, is found at the apical surface of the hair cells 
inserted into the cuticular plate. The hair bundle contains 3-4 rows of 30-300 specialised 
processes named stereocilia. The hair bundle is hexagonally packed and stereocilia are arranged 
in ranks of increasing height. Stereocilia are rigid structures whose cytoskeleton is composed of 
hexagonally packed bundles of longitudinal actin filaments, which are extensively cross-linked 
(Tilney, Derosier and Mulroy 1980). The stereocilia taper a few pm above the basal insertion into
23



















Figure I.2.I.3. A cross section through the organ of Corti as it appears in 
the basal turn. BV: Blood Vessel; DC : Deiters’ cells; HC : Hensen’s cells; IPC : Inner 
phalangeal cell. Taken From Pickles 1982.
Figure I.2.I.4. Representative diagram of a cross section through a 
mammalian hair cell to illustrate the organisation of the stereocilia and 
links connecting them. Adapted from Pickles and Corey 1992.
the cuticular plate to form a rootlet at which point the stereocilia pivot and slide along one 
another's shafts (Tilney et al. 1980). Lateral links run parallel to the apical surface of the hair cell 
joining adjacent stereocilia in all directions (Osborne and Comis and Pickles 1984). They 
interconnect stereocilia to allow them to pivot most easily along an axis which is 90° to mirror 
symmetry. There are also specialised links called tip links at the tips of the stereocilia which join 
the top of each stereocilia to the side wall of adjacent taller stereocilia (Fig. I.2.I.4.), Tip links 
have a fine central filament likely to be proteinaceous (Osborne and Comis 1990) surrounded by 
a glycocalyx (Osborne, Comis and Pickles 1988). The ability of tip links to stretch by greater 
than 100%, their diameter of 6nm, and, the fact that they disappear after treatment with elastase 
all point to an elastin-like component of tip links (Preyer, Hemmert, Zenner, and Gummer 1995; 
Osborne and Comis 1990).
Outer hair cells are cylindrical shaped cells with a W or V shaped arrangement of stereocilia 
whereas inner hair cells are flask shaped cells with a line arrangement of stereocilia. The tips of 
the tallest stereocilia of the outer hair cells but not the inner hair cells are firmly embedded within 
the tectorial membrane (Lim 1980).
1.2.2. Mechanism of hearing
Sound waves are directed into the middle ear by the external ear and cause the tympanic 
membrane to vibrate. This auditory signal at the tympanic membrane is transferred via the 
ossicles to the oval window of the cochlea. The sound energy forces the oval window in and out 
of scala vestibuli producing pressure waves within the perilymph. The wave of pressure passes 
from the base to the apex of the cochlea in scala vestibuli, and then passes out of the cochlea 
along the basilar membrane and scala tympani. It is the displacement of the basilar membrane 
that stimulates the organ of Corti where the mechanical energy is transduced into an electrical 
signal (Fig. I.2.2.I.), The tectorial membrane and basilar membrane are hinged on different axes 
and the travelling wave motion of the fluids and structures within the cochlea causes a shearing 
force between the basilar membrane and the tectorial membrane. This shearing force directly 
deflects the hair bundles of the outer hair cells as the stereocilia are embedded within the tectorial
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Figure 1.2.2.1. Longitudinal section through the cochlea and middle ear 
to illustrate the passage of sound energy. Taken From Berne and Levy 1996.
Figure I.2.2.2. Cross section through the organ of Corti to show the 
shearing force between the tectorial membrane and basilar membrane 
during sound stimulation. This shearing force directly deflects the hair bundles of the 
outer hair cells as the stereocilia are embedded within the tectorial membrane, and indirectly 
deflects the hair bundles of the inner hair cells by the subsequent flow of sub-tectorial fluid.
Taken From Berne and Levy 1996.
membrane, and indirectly deflects the hair bundles of the inner hair cells by the subsequent flow 
of sub-tectorial fluid (Fig I.2.2.2.). Hence inner hair cells are velocity sensitive and outer hair 
cells are displacement sensitive.
Deflection of the hair bundle in a positive direction (towards its taller edge) causes depolarisation 
of the hair cell {receptor potential). If the receptor potential increases, the rate of 
neurotransmitter release at the basal surface is increased. Displacement of the hair bundle in a 
negative direction (towards the shorter stereocilia) hyperpolarises the hair cell, reducing the 
receptor potential and hence reducing the rate of release of neurotransmitter. Oblique deflection 
of the hair bundle evokes a response dependent on the vector component of the stimulus in the 
positive direction. The receptor potential is dependent on both direction and magnitude of the 
stimulus. The relationship between displacement and the receptor potential is sigmoidal hence the 
response saturates at a certain point (Fig. I.2.2.3.), The relationship is very steep such that 90% 
response is evoked by deflection of the stereocilia by only 50-120nm at the tip. The 
depolarisation and hyperpolarisation are achieved by the opening and closing of ionic 
transduction channels respectively. In the unstimulated cell 15% transduction channels are open 
hence the number of channels open can be increased or decreased. The resting potential of the 
cell is approximately -60mV which is the result of the inward flow of cations through the 15% 
transduction channels open (reviewed in Hudspeth 1989).
The transduction channels are relatively non selective to alkali cations (Li+, Na+, K+, Rb+ & Cs+ 
are roughly equally permeant: Corey and Hudspeth 1979a). Since endolymph is rich in K+, these 
ions carry much of the transducer current. Ca++ is however a necessary cofactor in transduction 
since transduction ceases below about lOpM Ca++ (Corey and Hudspeth 1979a). The increased 
receptor potential evoked by the influx of cations opens voltage gated Ca++ channels in the hair 
cell membrane, and the resultant increase in the influx of Ca++ evokes an increase in the rate of 
release of transmitter into the synaptic cleft. The increase in transmitter binding to receptors on 
the post-synaptic membrane results in an increased depolarisation of the afferent nerve ending. 






Figure I.2.2.3. Graphs to illustrate the range of movements over which the 
hair cell shows greatest a) compliance, and b) receptor potential. Gating 
compliance is a reduction in the hair bundle stiffness (a) measured by applying known forces 
to a bundle with a flexible glass fibre, then calculating from the fibres flexion the stiffness of 
the attached bundle. The fact that the compliance is greatest over the range of hair bundle 
positions where transduction is most sensitive (b) suggests that the compliance results from 
the opening and closing of transduction channels.
(Taken from Hudspeth 1989)
Figure I.2.2.4. Diagrams to illustrate the tip link/gating springs theory of 
transduction proposed by Pickles et al. 1984.
a) The lateral links hold the tips of the shorter stereocilia against the longer stereocilia. When 
the bundle of stereocilia is deflected, a vertical shear is produced between the rows, which is 
detected by the single upwards-pointing tip link (transduction link), running from the tip of 
the shorter stereocilium. It is suggested that the stretch of the this tip link decreases the 
membrane resistance. Taken from Pickles et al. 1984.
b) A simple structural model comes from the suggestion that each tip link is a gating spring. 
Displacing the bundle towards the tallest stereocilia (a positive stimulus) stretches the tip links 
to increase tension. The channels (somewhere in the distal ends of the stereocilia) are shown 
in this figure to be at the lower end of each tip link, but equally well could be at the upper end, 
or, indeed both. Taken from Pickles and Corey 1992.
sent along the auditory nerve to the cochlear nucleus. Movement in the negative direction closes 
these transduction channels, decreasing K+ and Ca++ entry and thus hyperpolarising the cell. This 
leads to a decrease in the excitatory neurotransmitter release and hence a decrease in activity in 
the afferent neurone.
The link between hair bundle deflection and transduction channel opening was the missing link in 
the mechanotransduction theory. The short latency of the response (approximately 13ps at 37°C 
in bullfrog sacculus hair cells) and temperature dependence (Corey and Hudspeth 1979b) led 
these investigators to believe that a simple direct coupling system was most likely. Therefore 
they proposed a biophysical model in which the transduction channels were directly gated by an 
elastic element (Corey and Hudspeth 1983). Deflection of stereocilia in a positive direction puts 
tension on an elastic element (which had not yet been identified) which directly opens 
transduction channels allowing cation flow and hence depolarising the cell. Movement in the 
opposite direction reduces the tension on the elastic element directly closing transduction 
channels and hyperpolarising the cell by reducing cation flow into the cell. This model was 
supported by measurements of hair bundle compliance which were greatest over the range of 
bundle displacements at which transduction channels open and close (Howard and Hudspeth 
1988). This had been predicted by the gating spring model due to the shortening of the elastic 
gating elements when the channels are moved from their closed to open state. The identification 
of tip links by Osborne, Comis and Pickles 1984 then lead to the tip link theory of transduction 
(Pickles, Comis and Osborne 1984) which has become widely accepted (other possible 
explanations are reviewed by Hackney and Furness 1995 and Pickles and Corey 1992). It is based 
on a gating spring hypothesis in which the elastic element is the tip link (Figs. I.2.2.4. and 
1.2.2.5.) The main lines of evidence are:
• The tip link is the only known structural element which can explain the directional specificity 
of the sensitivity of the hair cells.
• Tip links appear to be present in all vertebrate hair cells capable of mechanotransduction 
(reviewed in Pickles and Corey 1992).
• Most evidence suggests that transduction channels are located at the tips of stereocilia which 
is consistent with the location of tip links (reviewed in Denk, Holt, Shepherd et al. 1995 and
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Figure I.2.2.5. Gating spring model of transduction and adaptation.
A depicts a positive (left) and negative (right) deflection of a hair bundle (direction indicated in C) B indicates 
the resultant transduction current (top line is zero). A positive stimulus increases the inward transduction 
current (left), as adaptation proceeds, the current declines toward a plateau. During negative stimulation, the 
transduction current (right) initially declines then rebounds as adaptation occurs. C depicts the proposed tip 
link theory of transduction and adaptation. Positive stimulation (left) elongates the tip link stretched between 
the stereocilia and thus pulls open a transduction channel· The entry of Ça** into the cytoplasm provokes 
slipping of the myosin molecules at the insertional plaque, so that the tip link shortens and the channel 
recloses. When a negative stimulus is presented (right) molecules pull the tip link’s insertion up the 
stereocilium, restoring tension and reopening the channel. D indicates the displacement-response relations. 
When a bundle sits at its resting position, transduction channels carry about 15% of their maximal current 
(point I at left). The responses that occur during rapid deflections of the bundle to other positions (for example, 
point II) define a sigmoidal relation between bundle displacement and the channels’ open probability. As 
adaptation takes place this sigmoidal relationship is shifted along the displacement axis. Adapted from 
Hudspeth and Gillespie 1994
CLOSED
ADAPTED OPEN
Figure I.2.2.6. Summary diagram representing the tip link theory of 
adaptation. When stimulated, opening of transduction channels allows Ca entry into the stereociha at 
the tip link This causes passive slipping of the tip link down an actin-myosin motor closing the transduction 
channel· If moved in the opposite direction adaptation occurs by active tensioning of the tip link by moving up 
the actin/myosin motor. Taken from Hamill and McBride 1994.
Hackney and Furness 1995).
• Elimination of extracellular Ca++ which inhibits transduction is also associated with a positive 
displacement of the hair bundle (the stereocilia appear to relax forward) and the tip links 
appear to vanish (Assad et al. 1991).
• Estimates of the number of transduction channels per cell have been derived from several 
physiological measurements and are equal to 1 or two per stereocilia which is consistent with 
transduction channels at one or both ends of the tip link (Hackney and Furness 1995).
• The tip link theory of transduction provides an explanation for adaptation (see next section).
In order to respond to small stimuli despite background inputs there is a need for resetting of 
responsiveness by the hair cells (adaptation). Steady displacement of a hair cell bundle causes 
the displacement/voltage curve to move along the displacement axis to match the new position of 
the bundle without any appreciable change in shape of the curve (Howard and Hudspeth 1988). It 
is an active mechanism performed by the hair cells which reduces the response to saturating 
displacements and repositions the maximum sensitivity of the steady bundle position. Adaptation 
is best explained by the tip link theory for mechanotransduction. The most recent theory of 
adaptation is that a molecular motor at the upper end of the tip links regulates tension in the tip 
links by sliding up and down the actin core of the stereocilium (Fig. I.2.2.6.), The rate of slipping 
down or climbing up is regulated by Ca++ concentration which is determined in part by Ca++ 
influx through transduction channels (reviewed in Hudspeth and Gillespie 1994). The motor is 
thought to be a cluster of approximately 50 myosin molecules, most evidence suggests myosin I 
or a related myosin isozyme. Calmodulin appears to be important in binding to and controlling 
activity of the hair bundle myosin I (Walker and Hudspeth 1996).
The cochlea is capable of fine frequency tuning. Each site along the cochlea is maximally 
sensitive to a particular frequency, and each site projects fibres to a specific site in the cochlear 
nucleus (tonotopic organisation). The base of the cochlea responds to high frequency auditory 
stimuli, whereas the apex of the cochlea responds to low frequency stimuli. A number of passive 
and active mechanisms are involved. I shall briefly outline these mechanisms.
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Passive tuning is achieved by the varied structure of the cochlea from the base to the apex. The 
resonant frequency of any object is determined by its mass and its flexibility. The shape and 
composition of the basilar membrane is not homogeneous along its length, hair cells are shorter at 
the base than at the apex. The stereocilial bundles of the hair cells also vary along the length of 
the cochlea, stereocilia being longer and less stiff at the apical end of the cochlea and shorter and 
stiffer at the basal end of the cochlea. This gradient in the structure of the organ of Corti along the 
cochlea results in maximum displacement of the basilar membrane and hair bundles at a specific 
site along the cochlea according to the frequency of the stimulus. Although passive tuning is 
responsible for some of the frequency tuning ability of the cochlea, it cannot fully explain the 
sharp tuning characteristics of the cochlea. Therefore additional active tuning mechanisms are 
involved in vivo. Mathematical models suggest that there could be some source of mechanical 
power which simultaneously overcomes the viscous damping and provides the filtering and 
sensitivity seen in the cochlea (reviewed in Yates, Johnstone, Patuzzi et al. 1992). Outer hair 
cells are capable of mechanomotility, that is they can perform mechanotransduction in reverse, to 
convert electrical activity into movement of the hair cell (Brownell, Bader, Bertrand et al. 1985). 
In addition, outer hair cell activity is essential for maximal frequency tuning responses in the 
cochlea (reviewed in Pickles 1985). Therefore it is thought that outer hair cells are responsible for 
the active tuning of the cochlea through a motile response which produces a mechanical input 
into basilar membrane movement. Hair bundle deflection of outer hair cells produces a receptor 
potential which then in turn leads to a change in shape of the outer hair cell. This change in shape 
of the outer hair cells is thought to amplify actively the movement of the basilar membrane at this 
particular site. In this way the outer hair cells counter the damping effects of the cochlear fluids 
and increase the signal-to-noise ratio by selectively amplifying the response to a relevant 
frequency. The precise motile response involved in active tuning is not yet clear. An excellent 
review of the several different motile responses by outer hair cells which have been reported in 
response to both mechanical deflection and electrical stimulation is given by Yates et al. (1992).
1.2.3. Innervation of the cochlea
Afferent and efferent innervation of the cochlea may be divided into 2 distinct groups according 
to which hair cell type is innervated (Fig. 1.2.3.),
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Figure 1.2.3. Schematic drawing of the neural organisation of the mammalian cochlea.
For clarifity, inner hair cell circuitry has been completed on only the left, and outer hair cell circuitry on the right. 
TB: trapezoid body; MSO: medial superior olivary complex; LSO: lateral superior olivary complex;
CN: Cochlear nucleus; IV: Fourth ventricle.
Adapted from Eybalin
Afferent innervation is made up of neurones whose cell bodies are found in the spiral ganglion. 
Type I afferents receive input from inner hair cells, they make up 90-95% afferent innervation of 
the cochlea and each inner hair cell receives up to 30 afferent synapses. Type II afferents receive 
input from outer hair cells, they make up only 5-10% afferent input from the cochlea, and each 
collateral receives input from 6-100 outer hair cells. The type I neurotransmitter has been studied 
extensively. It is likely that more than one neurotransmitter is involved, but most evidence points 
towards glutamate as the principal neurotransmitter. The neurotransmitter of type II afferents has 
been less well studied due to the difficulty in isolating purely type II synapses. However the little 
data there is points towards glutamate or a parent substance operative at this synapse too 
(reviewed in Eybalin 1993).
There are several types of glutamate receptors named according to their most potent agonists 
There are 3 main ionotropic receptors, (linked directly to ion channels) these are N-methy-D- 
aspartic acid (NMDA), a-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) and 
kainic acid (kainate). There is also a metabotropic receptor which is linked to the second 
messenger inositol trisphosphate. The metabotropic receptor is agonised by quisqualate, as is the 
AMPA receptor. There is strong evidence for the presence of the three ionotropic receptors in the 
cochlea (Eybalin 1993). Recently it has been shown that quisqualate evokes an increase in 
inositol trisphosphate in the rat cochlea. This suggests that metabotropic receptors may also be 
present in the cochlea (Pujol, Eybalin and Puel 1995).
Efferent innervation of the cochlea originates in the superior olivary complex. Medial efferents 
synapse directly onto the base of outer hair cells. Each fibre innervates several outer hair cells 
often from different rows, but with most innervation on the internal row. The function of the 
medial efferents has been well studied and the current theory is that medial efferents contribute to 
the mechanical tuning which the outer hair cells provide through their motility (reviewed in 
Eybalin 1993). Lateral efferents are unmyelinated fibres which synapse onto type I afferent 
dendrites on their postsynaptic terminals at the base of the inner hair cells. The function of lateral 
efferents is less well understood. It is thought that lateral efferents may be responsible for
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establishing and/or maintaining the spontaneous activity of type I fibres. There is now 
considerable evidence that both medial and lateral efferents utilise acetylcholine (Ach) as a 
neurotransmitter. However, Ach is not the only neurotransmitter involved since opioid 
neurotransmitters are involved (Sahley and Nodar 1994), and GABA may also be utilised (Felix 
and Ehrenberger 1992).
1.2.4. Methods of assessing hearing loss
Several methods have been employed to detect meningitis-induced hearing losses in human 
clinical cases and experimental animals. In all cases, conductive deafness associated with otitis 
media should be precluded by examination of the tympanic membrane and tympanometry.
Conventional pure tone audiometry is used clinically in patients who have recovered, and are 
old enough (usually children >3-4 years old) to produce reliable subjective measurements. In 
neonates and younger children or during acute illness in older subjects and in experimental 
meningitis hearing is most commonly assessed by auditory brain stem evoked responses 
(ABERs). By coupling electrodes to the skin at the vertex of the skull and to the mastoid on both 
sides, brain stem electrical potentials can be recorded. The response to several 100s or 1000s of 
transient auditory stimuli is averaged which eliminates random activity and sums activity 
produced in response to the auditory stimuli. The resultant waveform (ABER) typically has 4 or 5 
major peaks. Experiments in cats have shown that the WAVE I arises from the auditory nerve, 
WAVE II from the cochlear nucleus, WAVE III from the superior olivary complex, and WAVES 
IV and V from the region of the lateral lemniscus or inferior colliculus (Buchwald and Huang 
1975). Analysis of these waves to various intensities of sound can give an indication of the 
hearing ability of the individual and an indication as to whether the hearing loss is of central 
(cochlear nucleus) or peripheral (i.e. cranial nerve or cochlear) origin. Recently, otoacoustic 
emissions (OAEs) have been measured in addition to ABERs in order to give an indication of the 
cochlear function, in patients with meningitis (Richardson et al. 1997). OAEs are minute sounds 
produced by the cochlea that can be recorded from nearly all normal ears. They are thought to 
represent outer hair cell activity and so can give an indication of the function of the organ of 
Corti. OAEs are abolished by lesions of the cochlea, but remain intact in retrocochlear deafness
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(Probst, Lonsbury-Martin and Martin 1991).
In experimental models of meningitis, the ABER method has been the commonest method of 
hearing assessment. However, more recently auditory evoked cochlear potentials have been 
recorded from the round window membrane during experimental meningitis in the guinea pig 
(Winter et al. 1997). An electrode lying on the round window membrane (or inserted into scala 
tympani) can pick up electrical potentials produced by the cochlea in response to sound stimuli. 
The compound action potential (CAP) is the most frequently recorded cochlear potential because 
it is a very reliable and informative response. It arises from the synchronous discharge of a large 
number of afferent fibres in the auditory nerve. It is a postsynaptic response produced by the 
afferent nerve fibres innervating the region of the cochlea most sensitive to a particular stimulus 
frequency (Figure 1.2.4.), The CAP is best elicited by stimuli that have a short rise time (<lms) 
such as an acoustic click or tone. Since travelling waves travel most rapidly over the basal part of 
the cochlea, only fibres from the high frequency basal region of the cochlea are activated in 
synchrony. Therefore cochlear fibres responding to 4kHz and above are the main contributors to 
the gross CAP (Pickles 1982). By recording CAP responses to different frequencies a 
measurement of the ability of the cochlea to respond to sounds of different frequencies can be 
compared before, during and after experimental meningitis. The size of the CAP is affected by all 
the events that lead to afferent neurone activity, that is conduction of sound to the inner ear, 
transduction by the hair cells and synaptic transmission. The CAP can also be affected by efferent 
activity.
Another commonly recorded cochlear potential which can be obtained from the round window 
membrane (or from within scala tympani) is the cochlear microphonic (CM). The CM is the 
alternating electrical response (receptor potential) produced by hair cells during an acoustic 
stimulus which exactly mirrors the stimulus in terms of frequency and phase. The CM is elicited 
by pure tones of moderate intensity. Therefore the CM is a good indicator of hair cell function. 
Since outer hair cells comprise approximately 3/4 of the hair cell population, they are the main 
contributors to the CM. The CM is affected by all events that lead to production of a receptor 
potential in the hair cells, that is conduction of the sound to the inner hair cells and
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Figure 1.2.4. Example of a Compound Action Potential (CAP) 
elicited with a 10kHz tone pip (amplified 20,000x).
The peaks and troughs of the wave form (positive and negative deflections) 
are denoted by a P and N respectively, and numbered in sequence.
mechanotransduction by the hair cells.
1.2.5. Site of damage responsible for hearing loss in Meningitis
Sensorineural hearing loss associated with meningitis could be a result of damage to one or more 
sites: central auditory nuclei and fibres, peripheral auditory neurones (i.e. eighth cranial nerve), 
or the inner ear itself. However, several lines of evidence indicate that the majority of meningitis- 
induced hearing losses result from damage to the cochlea itself. The first clinical evidence for this 
was from post mortem examinations of temporal bones from patients who had died from bacterial 
meningitis. These examinations revealed labyrinthitis, i.e. inflammation of the inner ear (Igrashi, 
Saito, Alford et al. 1974; Eavey, Gao, Schuknecht et al. 1985). This was first confirmed in 
experimental meningitis by Moxon et al. (1974). Intranasal inoculation of H. influenzae type b 
into infant rats produced labyrinthitis (as judged by post mortem histological examinations) in 
several animals. Labyrinthitis has now been demonstrated following experimental meningitis in 
several species and induced by several bacteria, including Hib in infant rats (Moxon et al. 1974 ; 
Kaplan etal. 1989), adult rats (Wiederman et al. 1986) and adult rabbits (Osborne etal. 1995), S. 
pneumoniae in infant rats (Rodriguez, Kaplan, Hawkins et al. 1991b), adult guinea pigs (Blank, 
Davis, VanDeWater et al. 1994; Winter et al. 1997) and adult rabbits (Bhatt et al. 1991; Bhatt, 
lauretano, Cabellos et al. 1993), Streptococcus suis in adult guinea pigs (Kay 1991), and 
Escherichia coli in adult rabbits (Osborne et al. 1995). However, cochlear histology has not been 
reported in meningitis induced by N. meningitidis.
Clinically, the next major step in identifying the lesion responsible for meningitis-induced 
deafness was the development of the ABERs which allowed assessment of the hearing ability in 
patients with acute meningitis. This technique has revealed that meningitis-induced hearing 
losses are early in onset (<24 h admission to hospital), and late onset hearing losses do not occur 
(Vienny, Despland, Lutschg et al. 1984). In addition, the hearing losses are likely to have 
peripheral origin in many cases since they can develop in the absence of apparent brain damage 
(Ozdamar, Kraus and Stein 1983). Transient hearing losses have also been reported in patients 
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with bacterial meningitis (Vienny et al. 1984). The first experimental model of meningitis to 
incorporate hearing assessment was carried out by Kay (1991). Measurement of ABERs in 
response to click stimuli in guinea pigs inoculated with S.suis produced hearing losses in some 
animals which were associated with labyrinthitis. This was also seen in an adult rabbit model of 
pneumococcal meningitis (Bhatt et al. 1991); hearing loss developed in all animals, and began at 
approximately 12 h post inoculation which confirmed the early onset of meningitis-induced 
hearing losses. In addition, Bhatt et al. 1991 used tone evoked ABERs and found that hearing 
losses progressed from high to low frequencies, consistent with a basal to apical spread of 
inflammation. Morphological examinations by electron microscopy of cochleae following similar 
experiments but induced by E.coli revealed specific lesions to the organ of Corti associated with 
meningitis-induced hearing losses (Winter, Marwick, Osborne et al. 1996). Finally, Winter (et al. 
1997 or more detailed in Winter 1997) developed an adult guinea pig model of pneumococcal 
meningitis which allowed the recording of cochlear potentials from the round window membrane 
of the cochlea. This model confirmed that the cochlea was the site of meningitis-induced 
deafness since pneumococcal meningitis consistently produced CAP losses equivalent to more 
than 20dB at 6 h post intracranial inoculation, which as judged by EM examinations were 
associated with specific lesions to the organ of Corti.
All the histological studies of the cochlea following human and experimental meningitis 
discussed here were concerned with inflammation predominantly in the perilymph of cochleae; 
there were little of no inflammatory cells in the endolymph (Igrashi et al. 1974; Eavey et al. 
1985; Moxon et al. 1974; Wiederman et al. 1986; Kaplan et al. 1989; Rodriguez et al. 1991b; 
Kay 1991; Bhatt et al. 1991; Bhatt et al. 1993; Blank et al. 1994; Osborne et al. 1995; Winter et 
al. 1997). Since the perilymphatic chambers of the cochlea are directly connected to the CSF by 
the cochlear aqueduct, it would seem most likely that bacteria gain access to the cochlea through 
this route. In fact, inflammation and bacteria were often found in the cochlear aqueduct following 
human and experimental meningitis (Igrashi et al. 1974; Eavey et al. 1985; Moxon et al. 1974; 
Wiederman et al. 1986; Bhatt et al. 1991; Bhatt et al. 1993; Blank et al. 1994). The basal-apical 
progression of both hearing losses and inflammation described by Bhatt et al. 1993 is consistent 
with a cochlear aqueduct route of entry. The cochlear aqueduct contains a meshwork of reticular 
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cells and connective fibres among which are occasional macrophages. Almost all human cochlea 
aqueducts (96-100%) are patent and large enough for the passage of both bacteria and 
inflammatory cells (Paiva 1970; Rask-Anderson, Stahle and Wilbrand 1977). Therefore this is an 
obvious route by which bacteria could enter the cochlea. The other alternatives are a 
hematogenous spread or a modiolar route of entry for which there is little evidence following 
experimental meningitis. However, a recent temporal bone study from patients with acute 
meningitis revealed that in addition to the cochlear aqueduct, the modiolus is likely to be a 
common and important pathway in humans by its perineural and perivascular channels (Merchant 
and Gopen 1996). Merchant and Gopen (1996) concluded that the modiolus may be a more 
common route of infection in humans than in rabbits, possibly due to the anatomical differences 
of these structures between the two species.
1.2.6. Mechanism of cochlear damage during bacterial meningitis.
The mechanism by which cochlear damage occurs during meningitis is not clear. In order to 
assess whether bacterial factors or inflammatory mediators are ototoxic, two main methods have 
been employed. In both cases, test substances are administered into scala tympani at the base of 
the cochlea whence it diffuses across the basilar membrane into the organ of Corti. This 
administration site is close to the cochlear aqueduct and so closely resembles entry of 
bacterial/inflammatory factors during meningitis. The test substance is either perfused directly 
into scala tympani by making a small hole in the outer bone of the cochlea, or applied to the 
window through which it diffuses into scala tympani. Hearing can then be assessed by either 
ABERs, OAEs, or by recording cochlear potentials such as the CAP and CM (described in 
section 1.2.4.). Additional measurements include the endocochlear potential (described in section 
1.2.1) which is essential for mechanoelectrical transduction, leading to electrical activity of single 
fibres of the auditory nerve. Employing the round window and cochlear perfusion methods, some 
bacterial factors have been shown to produce ototoxicity in the cochlea.
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1.2.6.1. Bacterial Ototoxins (toxins which cause ototoxicity)
S. pneumoniae
Comis, Osborne, Stephen et al. 1993 showed that perfusion of either 1 or 10pg pneumolysin into 
scala tympani of guinea pig cochleae produced large CAP and CM losses (equivalent to >40dB) 
which were associated with specific lesions to the hair cells and supporting cells. More recently. 
Winter et al. (1997) found that pneumolysin-deficient mutant pneumococci produced 
considerably attenuated hearing losses (as judged by CAP recordings from the round window 
membrane) in a guinea pig model of meningitis in comparison to wild type pneumococci; much 
smaller hearing losses were associated with the mutant. Therefore pneumolysin is a potent 
ototoxin which is likely to be responsible for the majority of the hearing losses associated with 
this pathogen.
H. influenzae type b Ototoxins
Apart from endotoxin (see later section), no ototoxins have been isolated from H. influenzae type 
b. Preliminary unpublished data from this laboratory suggested the existence of an ototoxic 
protein factor in a crude cytoplasmic extract of H. influenzae type b. To date this is the only 
evidence of which I am aware of the existence of a “protein” Hib ototoxin..
Meningococcal Ototoxins
Apart from endotoxin (see next section) there is at present no evidence of an ototoxin produced 
by N. meningitidis.
In conclusion, despite the fact that an identified ototoxin (pneumolysin) plays a major role in the 
evolution of meningitis-induced deafness in experimental pneumococcal meningitis, very little 
work has been carried out to determine whether other potent ototoxins are responsible for the 
meningitis-induced hearing losses associated with other meningitogenic bacteria.
I.2.6.2. Cell wall components
Perfusion of purified endotoxin (LPS) (from E.coli, or Salmonella typhimurium·, at 100 and 25pg 
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doses respectively) directly into scala tympani of guinea pig cochleae produced small losses 
(equivalent to <20dB) in the CAP and ABERs respectively (Comis, Osborne and Tarlow 1991; 
Darrow, Keithley and Harris 1992). The hearing losses were associated with a small degree of 
morphological damage to the surface of the organ of Corti. Maximal hearing losses produced by 
E.coli LPS were reached over a period of 4 hours, showed considerable inter animal variation, 
and were attenuated by prior dexamethasone treatment (Comis et al. 1991). The hearing losses 
produced by Salmonella typhimurium LPS were transient, peak losses were seen at days 2 and 4, 
but had returned to almost baseline within 7 days (Darrow et al. 1992). There have also been 
several reports of hearing losses and morphological damage to the cochlea following round 
window application of endotoxin purified from several different pathogens including H. 
influenzae type b (Lin 1990, Kim and Kim 1995, Watanabe and Hakuhisa 1996). Hearing losses 
began at around 3h, peaked at around 24-48h and persisted up to between 5 days and 2 weeks 
post application. Morphological examinations revealed inflammation predominantly within the 
perilymphatic chambers, and some hair cell damage which involved reversible vacuolation 
(Watanabe and Hakuhisa. 1996). Therefore, since the in vivo ototoxicity produced by LPS is slow 
in onset (several hours) and can be attenuated by prior administration of dexamethasone (Comis 
et al. 1991) it appears to be mediated by the resultant inflammatory response. However, 
endotoxin is directly ototoxic to outer hair cells in vitro (Dulon, Huang and Schacht 1990). A 
similar discrepancy between the in vivo and in vitro toxicity of LPS was described earlier in this 
chapter (section 1.1.5.) in data from experiments investigating the toxicity of LPS on the BBB. 
This inconsistency could be due to several reasons including in vivo modification of LPS, 
different bacterial sources of LPS, or different bioactive concentrations used.
Perfusion oflOpg lipoteichoic acid (from Streptococcus pyrogenes ) into scala tympani of guinea 
pig cochleae produced a small (20-3 OdB) loss in the CAP at 3 h post perfusion (Unpublished data 
Macmillan-Browse and Comis 1994), similar to that seen by perfusion of LPS (Comis et al. 
1991). In addition, experimental meningitis induced by pneumococcal cell wall extracts produced 
some small hearing losses (Winter 1997). Further investigations are clearly necessary to establish 
the role (if any) of these bacterial fractions in causing hearing loss.
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In conclusion, release of cell wall components by autolysis and antibiotic killing during 
meningitis may produce a sufficient concentration of cell wall components in the CSF and/or the 
cochlea to be ototoxic, most likely via the resultant inflammatory response. However, such 
hearing losses associated with cell wall components are likely to be small and may be reversible 
and are therefore unlikely to be responsible for those meningitis-induced hearing losses which are 
profound and permanent.
I.2.6.3. Nitric Oxide, Excitatory Amino Acids and Reactive Oxygen Species
During the course of bacterial meningitis, several toxic agents are released by bacteria, 
leukocytes and other host cells (discussed earlier in this chapter). Amongst these products of 
bacterial invasion are three strong candidate mediators of ototoxicity. Excitatory amino acids, 
nitric oxide, and reactive oxygen species have all been reported to be elevated in the CSF during 
bacterial meningitis, and are all potentially capable of producing ototoxicity:
Several groups have now reported that perfusion of a nitric oxide (NO) donor (Sodium 
Nitroprusside (SNP)) into scala tympani of guinea pig cochleae produced a fall in the size of the 
auditory evoked potentials (Amaee, Comis, and Osborne 1995; Chen, Nenov, Skellett et al. 1995; 
Dean-Dais, Prazma, Ball et al. 1996; Kong, Ren and Nuttal 1996), including the CAP, CM, and 
endocochlear potential. This ototoxicity produced by SNP occurred despite an increase in 
cochlear blood flow (Kong et al. 1996) which was probably due to the potent vasodilatory action 
of NO. The electrophysiological losses were associated with swelling of the afferent neurones 
mainly on the basal side (Kong et al. 1996), and were mediated in part by cGMP because they 
were attenuated by methylene blue (Dean-Dais et al. 1996). The ototoxic effects of SNP were 
likely to have been due to its breakdown product of NO rather than cyanide, since comparable 
concentrations of ferrocyanide produced no ototoxicity, and preliminary data suggest that afferent 
swelling is also produced by pure NO donors which do not release cyanide (Kong et al. 1996). 
There are no data concerning the in vitro toxicity of NO in the cochlea.
Perfusion of Reactive Oxygen Species (ROSs) generating systems which produce H2O2, OH’or
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O2 into scala tympani of guinea pig cochleae produced some CAP losses. Since this ototoxicity 
was inhibited by co-perfusion with selective scavengers for each ROS (catalase, deferoxamine 
and superoxide dismutase respectively) the action of the generating systems was specific to ROS 
production (Clerici and Yang 1996). In these studies morphological examinations were not 
carried out. In addition, ROSs are toxic to isolated outer hair cells in vitro (Dulon et al. 1990; and 
Clerici, Dimartino and Prasad 1995).
Excitatory amino acids (EAAs) can produce ototoxicity in guinea pig cochleae by excessive 
stimulation of glutamate receptors. This has been demonstrated by both excessive release of the 
afferent neurotransmitter during acoustic trauma, or by perfusion with glutamate (for reviews see 
Eybalin 1993; Pujol, Puel, D’Aldin et al. 1993). The ototoxicity is selective to the afferent 
neurones of the inner hair cells and can be demonstrated electrophysiologically and 
morphologically. It is specific to the action of glutamate at the post synaptic glutamate receptors 
because it can be mimicked by perfusion of selective glutamate agonists. Since greatest 
protection on the cochlea from noise-induced and ischaemic induced excitotoxic damage was 
provided by inhibition of the non NMDA receptors, it can be argued that the non NMDA 
receptors are the predominant mediators of excitotoxicity. However, NMDA receptors are also 
involved because full protection also required inhibition of the NMDA receptors (Pujol, Puel and 
Eybalin 1992 and Pujol et al. 1993).
Although there have been no direct investigations into the role of NO, ROSs and glutamate in 
meningitis-induced deafness, a role in mediating the ototoxicity produced by pneumolysin has 
been implicated. Prior treatment of the cochlea with either a NOS inhibitor, or NMDA receptor 
antagonists protected the cochlea from the action of pneumolysin (Amaee et al. 1995). In 
addition, NMDA-evoked CAP and CM losses were blocked by inhibition of NO or the 
superoxide scavenger superoxide dismutase (Amaee, Comis, Osborne et al. 1997), and 
morphological damage evoked by NMDA was similar to that produced by the NO donor SNP 
(Amaee et al. 1997). In summary, ototoxicity produced by pneumolysin appears to have been 
mediated by NMDA receptors by production of NO and an involvement of superoxide. Since 
morphological examinations revealed perturbation of the reticular lamina barrier following 
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perfusion with pneumolysin (Amaee 1995), Amaee proposed the following scheme. Pneumolysin 
formed pores in the reticular lamina which resulted in mixing of the endolymph and perilymph. 
The raised [K+] in the perilymph resulted in excessive release of the excitatory neurotransmitter 
glutamate. Excessive stimulation of NMDA receptors by glutamate leads to an increase in the 
concentration of intracellular Ca^ which activated NOS to produce NO. Peroxynitrite is formed 
by the reaction of NO with superoxide anions and decomposes to form the highly damaging 
cytotoxic oxidants, hydroxyl radical and nitrogen dioxide.
Since the ototoxicity produced by the excessive release of glutamate is thought to be 
predominantly mediated by non-NMDA receptors (discussed earlier in this section), non-NMDA 
receptors could also be involved in the ototoxicity produced by pneumolysin via a common 
pathway. This is supported by the fact that although NMDA antagonists were capable of fully 
blocking all electrophysiological losses produced by pneumolysin, they were not able to 
completely block the morphological damage produced by pneumolysin (Amaee et al. 1995). 
There is no evidence that non-NMDA receptors mediate ototoxicity in the cochlea by NO or ROS 
production. However, since toxicity produced by non-NMDA receptors can be attenuated by 
NOS inhibitors and ROS scavengers in some brain cells (Dutrait, Culcasi, Cazevieille et al. 1995; 
Schulz, Henshaw and Siwek 1995), it is plausible. A schematic representation of the pathway by 
which NO and ROSs could contribute to the excitotoxicity evoked by Non-NMDA and NMDA 







POST SYNPATIC ArriX AFFERENT ^Calcu,ml ■
DENDRITE
Peroxynitrite
^[Reactive Oxygen Species] ¡ <- - - - - - - - - - - -
Nitric Oxide 
Synthase





Figure 1.2.6.3. Schematic representation of the routes by which Nitric Oxide and Reactive Oxygen Species may contribute to the 
excititoxicity caused by Non-NMDA and NMDA receptor activation. Activation of calcium permeable Non-NMDA receptors, and activation of 
NMDA receptors evokes an increase in the concentration of Ca+I inside the post synaptic afferent dendrite. The increase in Ca' * could evoke cell damage in a number of 
ways including activation of NOS to produce NO, and release of ROSs (e g. by inhibition of various mitochondrial enzymes). NO and ROSs alone can cause some 
cellular damage and if NO were to react with superoxide, peroxynitrite is produced which decomposes to form the highly damaging cytotoxic oxidants, hydroxyl radical 
and nitrogen dioxide. If the activation of the Non-NMDA receptors is sufficiently excessive the influx of Na’ ’ (though the receptors) and Cl· (passive influx) may evoke 
damage to the cell by osmotic swelling. [ ]i denotes intracellular concentration, and a large arrow next to this indicates in increase in intracellular concentration.
1.2.7. Hearing loss in Bacterial Meningitis : Conclusions
• The majority of meningitis-induced hearing losses originate in the cochlea, rather than the 
CNS.
• Bacteria and inflammatory cells gain access to the cochlea directly from the CSF and not 
through the blood. The most likely route of access is the cochlear aqueduct.
• Permanent meningitis-induced deafness occurs early in the course of meningitis (<12h)
• It is possible/probable that potent bacterial ototoxins are responsible for the majority of the 
profound meningitis-induced hearing losses.
• Less potent ototoxic factors such as cell wall components may contribute to the meningitis- 
induced deafness, but alone they are more likely to be the cause of small or transient hearing 
losses.
• Other toxic agents released during meningitis may also be involved e.g. excitatory amino 
acids nitric oxide and reactive oxygen species. A link between these three ototoxic agents has 
been proposed. However the involvement of non-NMDA receptors has not been investigated.
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1.3. Aims and Objectives
1. Despite evidence that specific bacterial ototoxins are likely to be responsible for the profound 
permanent meningitis-induced hearing losses, there has only been one identified ototoxin 
isolated from the three major meningitogenic bacteria i.e. pneumolysin. Therefore the major 
part of this thesis is dedicated to identifying the presence of ototoxic factors in the three main 
meningitogenic bacteria.
2. Since NO, ROSs and excitatory acids may be involved in meningitis-induced deafness. The 
final part of the work described in this thesis was carried out to establish whether the action 
of NO and ROSs and excitotoxicity in the cochlea occurs through one common pathway. This 
had been demonstrated in the case of NMD A receptors, therefore this study was carried out to 




2.1 Assessment of Ototoxicity
An in vivo method of investigation was adopted because this most closely resembles the 
interaction of bacterial components and other chemicals with the cochlea during infections. The 
cochlear perfusion model was used as this allows us to determine whether bacterial extracts and 
chemicals are directly ototoxic, whereas hearing losses produced during a meningitis model may 
involve other routes of ototoxicity. This method mimics the route of entry during meningitis, and 
there is little or no barrier to diffusion of substances between scala tympani and the organ of Corti 
(Tonndorf, Duvall and Reneau 1962). Since samples contained proteins with high molecular 
weights application via the round window was not plausible as this is permeable to substances 
<500-1000 Da only (Juhn, Hamaguchi and Goycoolea 1989).
2.2. The Cochlear Perfusion Model
The cochlear perfusion method was used to assess the ototoxicity of all samples (method 
discussed in Nuttal, LaRouere and Lawrence, 1982). The method described here includes a 
number of modifications on the original method (Comis and Leng, 1979). Firstly, to reduce the 
increased longitudinal flow of cochlear fluid (> 600-fold) resulting from perforation of the cochlea 
(Ohyama, Salt and Thalmann et al, 1988), the atlanto-occipital membrane covering cistema 
magna was punctured. This enabled a study of the cochlear response to perfusates over a 
considerable period of time, whereas the entire perilymph would have been replaced in under 8 
min if puncture of the atlanto-occipital membrane was not carried out (Ohyama et al. 1988). 
Secondly, since bacterial extracts and fractions are not produced in large quantities the method of 
perfusion of samples into the cochlea was modified in order to enable perfusion of small samples. 
Previously a microinfusion pump was used which requires a minimum volume of 1ml of test 
samples due to the large volume of dead space. Successful perfusions were achieved with volumes 
of test substances approaching 200|fl using a 250yl fixed volume micropipette controlled using a 
hand perfusion kit.
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2.2.1. Animal Selection and Exclusions
The animals used in the present study were pigmented adult guinea pigs weighing between 500 
and 750g. Hearing was assessed superficially by selecting only animals with a positive bilateral 
Preyers reflex. Statistical and summary data were excluded from animals with initial Compound 
Action Potentials (CAP) ‘thresholds’ (defined in next section) above a defined level as these 
animals are likely to have had pre-existing hearing loss. The defined levels were >50 dB SPL at 10 
and 5 kHz, and 65dB SPL at 3kHz.
Anaesthesia was induced with an intra-peritoneal injection of 25% urethane (5.5ml/kg). Intra­
peritoneal injections of 0.5 ml 25% urethane were administered to top up the anaesthesia if 
necessary. The animals were tracheotomised and the trachea was cleaned using tissue wicks at a 
minimum of half hourly intervals in order to maintain a patent airway throughout the experiment. 
The left auditory bulla was exposed via a ventrolateral approach involving removal of the 
posterior process of the inferior margin of the left mandible. A midline incision was made over the 
anteroposterior region of the skull and the temporalis and occipitalis muscles were reflected. The 
outer cartilaginous segments of the external auditory meati were carefully cut close to the skull to 
expose the meati without interrupting its patency (e.g. with leaked blood or flaps of cartilage). 
Puncture of the atlanto-occipital membrane covering cistema magna was carried out to reduce 
longitudinal flow of the cochlea fluids (as discussed earlier in this chapter). The head of the animal 
was fixed within a stereotaxic frame using a jaw bar and 2 ear bars inserted into the external 
auditory meati. The temperature of the animal was monitored by an anal probe and maintained at 
38°C using a thermostatically regulated heating table.
Once securely fixed within the stereotaxic frame the lateral aspect of the left bulla was fully 
exposed beneath the styloid and digrastic muscles using blunt dissection and retraction. The 
styloid process was removed to allow access for the micropipette (used for perfusions and 
recordings). The lower margin of the bulla was opened in order to expose the cochlea whilst 
maintaining the integrity of the tympanic membrane and the middle ear. A round hole of 
approximately 50|im diameter was bored into scala tympani at the basal turn of the cochlea 
(approximately 2mm from the round window) using a hand-held drill. A second, slightly larger 
hole was drilled at the apex of the cochlea to allow efflux of the perfusate. Any fluid that 
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accumulated around the cochlea as a result of cochlear fluid leakage or efflux during perfusion 
was mopped up using tissue wicks prior to all electrophysiological recordings. Auditory 
stimulation was provided by a piezoelectric transducer coupled to a hollow left ear bar. The 
auditory evoked potentials were measured before perfusion of test substances (control values), 
and then at 1 min, 5 min, 10 min and at 10 min intervals until 90 min post perfusion.
A summary diagram of the experimental set up can be seen in Fig. 2.
2.2.2 Perfusion of Samples into Scala Tympani
Test substances were administered using a glass micropipette connected via polythene tubing to a 
fixed volume Gilson pipette (250pl Micro/Pettor) connected to a hand perfusion kit. A stainless 
steel wire electrode was sealed within the micropipette for recordings of sound evoked potentials. 
The tip of the pipette (just less than 50 pm diameter) was inserted into the basal hole with a 
Bonetti micromanipulator to create a tight fluid seal. The test substance was perfused at a rate of 
approximately 10pl/min for one minute. Test substances were kept at room temperature 
(approximately 20°C). It is well established that the sound evoked potentials of the guinea pig 
cochlea are highly dependent on temperature (Inamura, Kusakari and Takasaka 1987). However, 
because exposure of the cochlea results in a significant drop in the temperature of the cochlea (to 
around 32°C) (Nuttall and LaRouere 1980), perfusion of the samples at room temperature reduces 
the temperature of the cochlea by only 1 or 2°C, and therefore produces little or no effect on the 
auditory potentials (Nuttall et al. 1982). The cochlea is capable of stable performance at this 
temperature (Nuttall et al. 1982), and any losses which are produced by a temperature drop are 
transient and thus distinguishable from sustained ototoxic events.
Where more than one substance was to be perfused into the cochlea, the following protocol was 
followed. After perfusion of the first substance and the completion of the required 
electrophysiological measurements, the micropipette was withdrawn from the cochlea, emptied 
and refilled with the second substance. The micropipette was then replaced and a series of control 
readings taken prior to the second perfusion. The time between perfusions varied according to the 
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Figure 2. Labelled photograph to show the set up of the animal 
and equipment during recordings.
The Guinea pig is held in a head holder on top of a thermostatically regulated heated plate. 
The left bulla is opened to expose the cochlea into which a dual purpose micropipette/electrode 
is inserted. The pippete/electrode is connected to both the recording apparatus, and a Micro/Pettor 
containing the test substance. Sound stimuli are provided by a piezoelectric transducer which 
directs sound into the left ear via a hollow ear bar.
recording were stable (i.e. 2 or more recordings in which there was no more than 5dB difference 
in CAP recordings).
2.2.3 Fixation of Cochlear Tissue
Immediately after the final electrophysiological measurements, the left (treated) cochlea was fixed 
by intravital microperfusion of lOOpl fixative (4°C) (2.5% glutaraldehyde in 0.05M BES ((2 
hydroxyethyl)-2 amino-ethane sulphonic acid) buffer and 0.05M sucrose, see appendix I). 
Animals were then killed by transection of the brainstem, and both bullae were removed. The right 
(untreated) cochlea was exposed and fixed by removal of the very apical end of the cochlea and 
perfusion of the same fixative through the round window using the hand perfusion kit. Both 
treated and untreated cochleae were immersed in fixative and stored at 4°C for at least 24 hours.
2.2.4. Electrophysiological Recordings
The auditory evoked potentials measured during this study were the compound action potential 
(CAP) and cochlear microphonics (CMs).
Tone pips were generated by a gated oscillator (Farnell type LFM4). The opening time of the gate 
was phase locked to the incoming signal so that all tone pips started at point zero of the wave 
form. After attenuation the signal was used to drive the piezoelectric speaker. The intensity of the 
tone pips was calibrated using a B&K amplifier (type 2606) and microphone (type 4134). OdB 
attenuation corresponded to 95,90 and 105 dB SPL at 10, 5 and 3 kHz respectively. The cochlear 
responses were amplified (x 20k), filtered (300Hz-15kHz) and displayed on a MacLab.
CAPs were elicited by stimulation with a 10ms duration tone pip. The attenuation necessary to 
evoke a CAP of Nl-Pl amplitude of 100|iV (2V post amplification) was determined and defined 
as the threshold CAP for this study. The threshold was determined by averaging the responses to 8 
tone pips (performed by MacLab) and alteration of the stimulus intensity until an average Nl-Pl 
amplitude of 100pV was produced. A fall in the CAP was calculated as the increased intensity in 
sound (dB) required to restore the amplitude to 100pV. CAP thresholds were measured at 10, 5 
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and either 1 or 3 kHz (1kHz was measured in initial experiments, but 3kHz was adopted in later 
experiments due low sound pressure level produced by the equipment at this frequency).
CMs were elicited using tone pips of 10ms duration at 5kHz. The peak to peak amplitude of the 
CM traces produced in response to four pips were recorded and averaged (by a Gould (DSO) 
1602 digital oscilloscope) over a range of stimulus intensities (-60 to 0 dB SPL in 10 dB 
increments).
2.2.5. Morphological examinations
It was not possible to cany out morphological examinations on all treated cochleae due to both 
financial and time constraints. Cochleae could be examined by either Scanning Electron 
Microscopy (SEM) or Transmission Electron Microscopy (TEM), but not both because specimen 
preparations were different for each. Specimen preparations were far simpler (and therefore 
cheaper and quicker) for SEM than TEM, and SEM allowed examination of the whole organ of 
Corti compared with small sections of the organ of Corti examined when carrying out TEM 
examinations. Therefore SEM examination was carried out on at least one cochlea from each 
treatment group which produced ototoxicity as judged by CAP and CM losses, whereas TEM 
examinations were carried out only when there were sufficient specimens and time available.
SEM
24hrs to 7 days post fixation modioli of both fixed treated and untreated cochleae were dissected 
out and the height of the cochlea reduced by removal of some of the apical end (to allow mounting 
into the electron microscopy specimen holders). 7-14 days post fixation modioli were serially 
dehydrated in acetone (Ih in 50%, 70%, 80%, 90%, 95%, 100 %, and 100% acetone), and dried 
by the critical point drying method using liquid carbon dioxide. The modioli were then mounted on 
copper SEM holders using Araldite, and sputter coated with platinum (EMsope 5C500 low 
voltage sputter coater) to a depth of 12-15 nm as judged by the thickness monitor. Preparations 
were examined under a JEOL 120 CXII transmission electron microscope fitted with a 
TEMSCAN scanning attachment. The images were viewed by a secondary electron detector with 
an acceleration voltage of 40 kV.
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TEM
12-48hrs post fixation modioli of treated cochleae (and some but not all untreated cochleae) were 
dissected out, and then treated with osmium tetraoxide for 30 min (l%(w/v) see appendix I). 
Modioli were then immersed in 70% ethanol and one or two large pieces (~ half a turn) of organ 
of Corti dissected free. A basal portion of the organ of Corti was always removed, and an 
additional middle piece was taken from some cochleae (3 and 2 turns from the apex respectively). 
The samples were serially dehydrated in ethanol (15min each in 70%, 90%, 100%, 100%), 
transferred into propylene oxide (2x 15 min), and then into a 1:1 (v/v) solution of resin/propylene 
oxide for Ih. The samples were then embedded in degassed resin (a modification of Epon 812 see 
appendix I), and polymerisation was carried out over 24-48h at 60°C. An LKB Ultracut E 
ultramicrotome was fitted with a glass knife for cutting semithin sections, and with a diamond 
knife for cutting ultrathin sections. Semithin sections were stained with 1% toluidine blue and 
examined using a light microscope. Ultrathin sections were picked up on Formvar coated copper 
grids, stained with aqueous uranyl acetate and lead citrate in a Reichert Ultrostainer and examined 
using a JEOL 120CXII TEM with an acceleration voltage of 80 kV.
2.3. Perfusates
2.3.1. Dissolution and Dialysis
Prior to perfusion, all samples were either dissolved in or dialysed into artificial perilymph (APL) 
(see appendix I). Samples were dialysed at 4°C in a volume of APL equal to 1000 fold the sample 
size with at least two changes after a minimum of 3h each. Bacterial extracts were stored frozen in 
aliquots at -20°C and thawed just prior to perfusion. Dissolution of drugs and final dilutions of 




Unless stated otherwise, all chemicals were purchased from Sigma Chemicals Co. Ltd. Chemicals 
used for Part II of this study (Chapter 10) were Quisqualate (QA), Kainate (KA), Nitro-L-arginine 
methyl ester (L-NAME), Methyl-L-arginine (L-MA), Superoxide Dismutase (SOD), and 
Deferoxamine mesylate (DEF). All chemicals were of the highest purity commercially available.
2.3.3. Acquisition of Bacterial Extracts
All culture, harvesting and disruption of bacteria were carried out off site. The pneumococcal 
extracts were a generous gift from Prof. T Mitchell at Leicester (now Glasgow) University. 
Bacterial extracts were from the genetically mapped wild type isolate S. pneumoniae type 3 
GB050Z, and the pneumolysin deficient mutant S. pneumoniae type 3 GB050Z which was 
constructed by insertion-duplication mutagenesis (see appendix Π). Bacterial cells were harvested 
from the cultures in which they had grown by centrifugation (20 min, 8000 rpm, Sorvall GSA 
rotor), and resuspended in 60 ml phosphate-buffered saline. The bacterial cells were disrupted by 
sonication (Braun sonicator setting 70 for 6 x 30sec with 1 min cooling between bursts). The 
disruptates were clarified by centrifugation (30 min, 20,000rpm Sorvall SS34 rotor), filter 
sterilised (0.45mm acrodisc) and stored at -20°C until used. Hib and meningococcal extracts 
were purchased from Centre for Applied Microbiology and Research (CAMR) at Porton Down, 
Wiltshire. Hib and meningococcal extracts were from clinically isolated strains (a group В 
meningococcal isolate received from Prof. John Heckels at Southampton Univeristy, and Hib St 
Chauhan strain). The Hib bacterial extract was prepared as follows. Bacterial plates were grown 
at 37°C in 5% CO2, liquid cultures at 37°C, shaken at 150rpm, and fermented at for 41h. Bacterial 
cells were separated from the culture in which they had been grown by filtration. The cells were 
then disrupted chemically and physically. Chemically the cells were lysed by mixture with EDTA 
(70ml of lOmM EDTA at pH 7.0), and physically the cells were disrupted by two passes through a 
French pressure cell (compression force of 20,000 psi). The resultant cell disruptate was 
centrifuged at 16,000 rpm for 20 minutes at 4°C. The supernatant was removed and freeze dried 
in 10ml aliquots. The meningococcal bacterial extract was prepared using the following method. 
Bacteria were grown on brain heart infusion (ВШ) slopes (+ NAD and haemin) at 37°C for 48h. 
The culture was washed from each of fours slopes (using 2ml medium) and used to innoculate 
20ml ВШ (+ supplements) at 37°C for 24h (250 rpm). This 20ml was then used to innoculate
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200ml BHI (+ supplements) at 37°C for 16h (200 rpm).This 200ml was then used to innoculate a 
5 litre fermenter at 37 for 6h (2.5 litre/min 500rpm stirring). Bacterial cells were harvested from a 
5 litre fermentation by filtration (0.45u-0.2u) and resuspended in PBS (83ml). After storage at — 
20 C, cells were disrupted by two passages through a French pressure cell (compression force of 
13 000 psi). The disrupted material was then centrifuged (20 000 rpm, 90 min), the top layer of 
the supernatant was removed (15ml) and the remaining supernatant was made up to 1 litre with 
PBS, filtered, and freeze dried in 50 ml amounts.
2.3.4. Treatments of Bacterial Extracts
Part I of this study was carried out in collaboration with Dr Lynn Dover who was responsible for 
all treatments of bacterial extracts which were carried out at the University of Birmingham.
2.3.4.I. Reconstitution of bacterial extracts
To each freeze dried aliquot of Hib bacterial disruptate 8ml of endotoxin free water was added and 
the material was allowed to dissolve on ice for 20 minutes. The volume of the solution was 
measured and adjusted to 10ml with endotoxin free water. Large particles of insoluble material 
were removed by centrifugation at 3300xg at 4°C for 10 min. The supernatant fluid was 
withdrawn and sterilised by filtration through Minisart filter (pore diameter = 0.22pm; Sartorius) 
into a sterile universal bottle. In this state the extract was known as a crude extract. The crude 
extract was then dispensed into 1ml aliquots and stored at -20°C until used for bioassay or further 
fractionation.
2.3.4.2. Sterility testing
Upon arrival at Birmingham University, all bacterial extracts were tested for sterility prior to any 
perfusions. In addition, all samples were filter sterilised through a 0.22pm filter following 
reconstitution.
2.3.4.3. Concentration of bacterial extracts
Bacterial extracts were concentrated by two methods. Initially extracts were concentrated using 
Sephadex G-10 which absorbs molecules of molecular mass below the exclusion limit of the 
Sephadex (1500 Da for globular proteins), i.e. large solutes are concentrated without simultaneous 
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concentration of buffer components. Sephadex was added to bacterial extracts, and the swollen 
sephadex was removed by centrifugation. Later in the study, Centriplus 10 filters (Amicon; 
Nominal molecular weight cut off of + lOkDa) were used instead of Sephadex G-10 to reduce any 
loss of extract proteins which may have occurred by adsorption to the concentrating medium.
2.3.4.4. Thiol activation of bacterial extracts and bovine serum albumin (BSA)
The reducing agent Dithriothreitol (DTT) was added to each extract to a concentration of ImM 
and the extracts were then held on ice for 3 hours followed by dialysis in degassed APL in full 
sealed bottles to remove the reducing agent and limit the re-oxidation of the sample. The 
bicarbonate component of APL was added after degassing to prevent pH alterations caused by 
CO2 removal. In order to assess the non specific effects of thiol activation on the cochlea, DTT 
treated bovine serum albumin (BSA) was tested for ototoxicity. BSA was chosen as it contains 
numerous disulphide bonds (Swissprot). 2mg/ml BSA (equal concentration to bacterial extracts) 
was DTT treated exactly as described for bacterial extracts.
2.3.4.5. Ultracentrifugation of bacterial extracts
Extracts were centrifuged at 500,000 x g at 4°C for 16 h initially, and for 30min in all further 
ultracentrifugations. The supernatant fluid was carefully withdrawn and stored in aliquots at - 
20°C. The deposited material was gently resuspended to the original volume in APL using a glass 
rod. After transfer to Eppendorf tubes the material was sonicated for 30 min in a cup horn 
sonicator containing iced-water. In some experiments, this pellet material was then centrifuged 
again to remove any contaminating cytoplasmic components before re-suspension in APL by 
sonication. This material was termed “washed pellet”.
2.3.4.6. Fractionation of the supernatant by Anion exchange chromatography
All fractions were carried out using Fast flow - diethylaminoethyl (DEAE) sepharose. Small 
columns were poured (Bed volume = 1.5ml) and equilibrated by washing with 50ml 50mM 
Tris.HCl, pH7.5 overnight. Samples containing 15mg protein (volume @ 1ml) were loaded onto 
the columns and non-adsorbed proteins were eluted using 20ml 50mM Tris.HCl pH7.5. Adsorbed 
proteins were eluted using various concentrations of sodium chloride in the above buffer. Step 
elution schemes were carried out using eluents in 10ml aliquots. Eluates were all collected and re­
concentrated to <lml and were then dialysed overnight. Eluates were diluted with enough sterile
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APL to return the samples to their original volumes.
In order to establish the elution characteristics of the extracts from the DEAE-seahorse, an 
elution profile was produced by using the fractionation procedure as described above, except that 
the Tris eluted sample was collected in 9 fractions (600-1200^1 each) and the IM NaCl eluted 
sample was collected in 6 small fractions (600-1300jil each). Protein determinations were carried 
out for all fractions.
2.3.4.7. Bulking of bacterial extract fractions with Bovine Serum Albumin (BSA)
Fractions of bacterial extracts were bulked with BSA to reduce any digestion of ototoxins by co­
purification with protease/s. Two schemes were used, fractions were either supplemented with 
BSA to 10 mg.mT1 immediately after elution or were eluted with eluents containing 10 mg.mT1 
BSA.
2.3.4.8. Adsorption Of Pneumolysin From Wild Type Cell Extracts
Immunopurification of wild type pneumococcal extract was carried out by Prof Mitchell at 
Leicester University. An immuno-affinity chromatography column was made by coupling rabbit 
anti-pneumolysin immunoglobulin G to a Hi-Trap NHS activated column following the 
manufacturers’ instructions. The haemolytic titre of the wild type extract was determined by 
dilutions in PBS followed by the addition of 2% sheep erythrocytes. The endpoint was taken as 
the well in which 50% of the cells had lysed after 30 min at 37°C. 5ml extract from the wild type 
pneumococcus GB050Z was applied slowly to the anti-pneumolysin affinity column followed by 
5ml PBS. The column eluate was passed through the column a further three times. This adsorbed 
extract was found to have no detectable haemolytic activity and was thus considered to be free of 
pneumolysin. The sample was stored at -20°C until used.
2.3.5. Protein analysis of Bacterial Extracts
All protein analysis was carried out by Dr Lynn Dover.
2.3.5.1. Protein Content Determinations
The Biorad protein assay reagent was used to determine protein concentration in bacterial 
extracts. Slight modifications to the manufacturers’ protocol were used. Samples of bacterial
extracts of an appropriate volume were taken and diluted with water to a final volume of 100ml. 
Each sample was then mixed with 150ml 0.2M NaOH in a disposable cuvette before the addition 
of 3ml Protein Assay reagent (Na OH was added to disrupt any protein-bearing membrane 
vesicles). After 2 minutes’ incubation at room temperature the protein content of each sample was 
quantified by measuring A595nm. Bovine serum albumin was used as a standard for all protein 
determinations.
2.3.5.2. Polyacrylamide gel electrophoresis of bacterial extracts (PAGE)
Sodium dodecyl sulphate (SDS)-PAGE
Standard protocols were used for the separation of proteins by SDS-PAGE. Homogeneous 
resolving gels (160 x 120 x 1mm) were cast at 12%T (w/v total monomers), 2.67%C(w/w cross 
linker, bis-acrylamide). Samples were prepared for electrophoresis by mixing with an equal loading 
buffer (62.5mM Tris.HCl, pH6.8, 0.02% (w/v) SDS, 5% (v/v) P-mercaptoethanol, 20 % (v/v) 
glycerol, 0.025% (w/v) bromophenol blue) and were held at 100°C for 3 min. Electrophoresis was 
carried out at a constant current of 35mA for 2h at 4°C. Protein bands were visualised by staining 
with Coomassie Brilliant Blue G-250.
Native-PAGE
The electrophoretic conditions were the same as used for SDS-PAGE other than SDS was 
omitted from all buffers, resolving gels were cast at 5%T, 2.67%C and samples were prepared for 
electrophoresis by mixing with an equal volume of sample loading buffer which contained no 0- 
mercaptoethanol and SDS. Samples were not heat denatured prior to electrophoresis. Protein 
bands were visualised by staining with Coomassie Brilliant Blue G-250.
2.3.5.3. Staining of gels with Coomassie Brilliant Blue
Gels were stained for 3h in a solution comprising 0.05% (w/v) Coomassie Brilliant Blue G-250 in 
glacial acetic acid/methanol/water (1:5:5 by vol) and were then destained overnight using 10% 
methanol (v/v), 7.5% (v/v) acetic acid in distilled water. Stained gels were dried and recorded by 
optical scanning with an Epson GT9000 scanner. The brightness and contrast of the scanned 
images were adjusted to achieve an accurate representation of the stained gel using Adobe 
Photoshop 3.0.
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2.3.5.4. Detection of pneumolysin in bacterial extracts by Western Blot
After electrophoresis of bacterial extracts on either SDS- or native-PAGE, proteins were 
transferred to nitro-cellulose filters (BioTrace NT, Gelman Sciences Inc., 0.45mm pore size) 
overnight at a constant current of 0.1mA at 4°C in 0.3% Tris, 1.44% glycine, 0.1% SDS. All 
washes and incubations of filters were carried out at 25°C in hybridisation tubes within a Hybaid 
hybridisation oven. The nitro-cellulose filters were saturated with protein to reduce non-specific 
antibody binding by incubating with 50ml 2% blocking solution (Boehringer Mannheim) for 2h. A 
le° antibody solution was prepared as a 1:1000 dilution of MAb7 stock (anti-pneumolysin 
monoclonal antibody) in phosphate buffered saline (PBS). The blocking solution was removed and 
filters were incubated with 10ml of primary monoclonal antibody solution at 25°C for 2h. In order 
to remove excess Mab7, filters were then washed three times with 30ml PBST (0.0005% Tween 
20/PBS) for lOmin each. The filters were incubated with a detection conjugate (1:500 dilution 
Goat, anti-mouse IgG alkaline phosphatase conjugate in PBST) (Sigma Immunochemicals) for 2h. 
Excess detection conjugate was then removed by washing three times with 30ml PBST for lOmin 
each. Conjugate-labelled immune complexes were visualised by incubation with the precipitating 
substrate system for alkaline phosphatase. BCIP/NBT (0.56mM 5-bromo-4-chloro-3-indolyl 
phosphate, 0.48mM nitro blue tetrazolium, 59.3mM MgCh in lOmM Tris, pH 9.2) (Sigma 
Chemicals) for 20 min at room temperature in a plastic dish. The reaction was stopped by washing 
the filter in de-ionised water and the results recorded by optical scanning with an Epson GT9000 
scanner. The brightness and contrast of the scanned images were adjusted to achieve an accurate 
representation of the stained gel using Adobe Photoshop 3.0.
CHAPTER 3
Results Introduction
3.1 Interpretation of Electrophysiological Data
Before describing the experiments in this section, it is important to restate the principles used to 
govern the interpretation of the data. Experimental data produced by the cochlear perfusion model 
shows a moderate degree of variability. The degree of variability is dependent on the ototoxic 
potency of the test substance, and also on the physiological condition of the animal which can 
deteriorate. In addition, the guinea pigs used were not inbred and showed some inter-animal 
variability in their susceptibility to ototoxic factors. However, if interpreted with caution this 
model is a good one to detect ototoxicity.
Control experiments were carried out involving the perfusion of artificial perilymph (APL) into 
scala tympani and the assessment of degree of hearing loss. Typically, control perfusions produced 
a loss in the CAP of between 0 and 8 dB and loss in the CM between 0 and 25% at 90 min post 
perfusion; however in some cases the CAP and CM did decline to 15dB and 30% losses 
respectively. Data from within experimental programmes can also act as sufficient, if not superior 
controls to those of APL perfusions, and also reduce the number of animals used. Based on 
evidence from APL controls, and data from within experimental programmes, I have defined CAP 
and CM losses as ‘positive’ if they are >20dB or >40% respectively. These are arbitrary cut off 
levels, above which I am confident that losses indicate a genuine ototoxic effect. Losses below 
these levels may be indicative of ototoxicity - particularly losses in CAPs of 15-20dB, and losses in 
CMs of 30-40%. However, losses in this range will be interpreted individually in the light of other 
pertinent data when attempting to assign biological significance. I have also defined ototoxicity as 
potent and moderate if CAP losses observed were >40dB and between 20 and 40dB respectively.
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Sometimes, an increase in all auditory potentials was seen immediately following perfusion. This 
may have been due to poor initial coupling of the fluid bathing the recording electrode with the 
perilymph of the cochlea prior to perfusion. In such cases, hearing losses were recalculated by 
taking the Imin recordings as the control values.
The initial auditory thresholds of all data presented in this thesis can be seen in Fig. 3. The 
thresholds varied according to frequency and showed a considerable range which was a result of 
both animal variability, and positioning of the basal hole. Within this study I have defined a 
threshold value (50dB SPL at 10 or 5kHz, and 65dB SPL at 3kHz), above which animals are 
likely to have had pre-existing cochlear damage. Within each chapter, I have also identified any 
animals which were clearly presenting auditory thresholds which were well outside the normal 
distribution of that group. Data will be presented from animals which displayed initial CAP 
thresholds above the defined level, or well above the normal distribution of the group, however 
the data has been excluded from statistical analysis and summary charts. From my experience with 
this model, animals which present high initial auditory thresholds often demonstrate a reduced 
sensitivity to ototoxic stimuli in comparison to animals with lower initial thresholds, however in 
the majority of cases, these animals will still display some sensitivity to potent ototoxic agents (as 
judged by agents which produce >40dB CAP loss in animals with initial thresholds within the 
normal distribution). Therefore I believe that data from these animals can contribute valuable 
information if interpreted with caution.
The CAP could be accurately determined to within ±ldB in the majority of cases. Occasionally an 
individual animal showed greater variability, but by increasing the number of CAPs averaged, 
measurements of the CAP were accurate to at least ± 3dB. In early experiments the CAP was 
recorded at 10, 5 and 1kHz. It often proved difficult to elicit a CAP with a 1kHz stimulus 
therefore the 1kHz CAP was replaced with the 3kHz CAP. The synchronicity of action potentials 
in individual fibres reduces as you move from the base to the apex of the cochlea. As substantial 
synchronicity is necessary to achieve a CAP, it becomes increasingly difficult to elicit a CAP with 
stimuli of decreasing frequency. At 3kHz it was sometimes difficult to elicit a CAP due to this
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All data
Figure 3 Threshold CAP values of all animals used in the work 
described in chapters 4-9.
problem; however the 3kHz CAP was considerably more reliable than the 1kHz CAP. It was 
sometimes difficult to measure a 5kHz CAP because of interference by the cochlear microphonic 
which masked the underlying CAP, and could not always be filtered out. For the above reasons 
results of the 5, 3, and 1 kHz CAP are not included in all the data sets.
As previously discussed (Section 2.2.2.), hypothermia of the cochlea produces a fall in auditory 
potentials. In some experiments a transient loss in the CAP was seen immediately post perfusion. 
This was seen most commonly at the 10kHz frequency. Although every attempt was made to 
ensure that each sample was perfused into the cochlea at room temperature, some samples 
(retrieved from the ice box in which they were held before use) may have been insufficiently 
equilibrated to ambient temperature when perfused. Therefore it is likely that perfusion of samples 
below ambient temperature into the cochlea was responsible for at least some of the transient 
losses in the CAP seen immediately post perfusion. The pronounced loss in the CAP at 10kHz 
may have been due to a basal-apical difference in response to cooling as described by (Ohlemiller 
and Siegel 1992), but it may also reflect the timing of the response as the 10kHz CAP was the first 
recording measured after perfusion.
3.2 Presentation Of Experimental Data And Statistical Analysis
A loss in CAPs was measured as the increase in stimulus intensity necessary to restore the Nl-Pl 
amplitude to its reference value of 100gV. A loss in CM was calculated as the percentage drop in 
the peak CM with respect to the peak control value (i.e. 100-(X/control xlOO)), and rounded to 
the nearest whole figure. A decrease in the size of CAP or CM is expressed as a positive loss, and 
an increase is expressed as a negative loss. Positive ototoxicity has been defined as a loss in the 
CAP in excess of 20dB, and a loss in the CM in excess of 40%. Potent ototoxicity has been 
defined as a loss in the CAP in excess of 40dB. Average losses are expressed as the mean ± 
standard deviation. Where standard deviations are not expressed the result is from one animal 
only. The data are presented in two forms. All original data are presented graphically to allow 
rapid assimilation of patterns of change. They are also presented in tabular form from which mean 
losses and standard deviations are calculated in order to compare data between groups. Within 
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each group the number of animals used varied. This was necessary in order to keep the number of 
animals to a minimum.
Statistical analysis was carried out on 10kHz CAP losses at all time points between 1 and 90 min 
post perfusion. The CAP was analysed at 10kHz as this is the most sensitive recording and thus is 
most likely to reveal differences between treatment groups. Repeated measures ANOVA was 
carried out between all treatment groups within each section to determine the statistical 
significance of treatment at all time points, and also to determine the statistical significance of the 
change in the CAP with time.
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CHAPTER 4
Ototoxicity In Haemophilus influenzae Type b (Hib) 
Bacterial Disruptate
It had been previously demonstrated that a potent ototoxic factor exists in the crude cytoplasmic 
extracts of Hib. This potent ototoxic factor is inactivated by mild heating (56°C for 10 min) or by 
treatment with a proteinase (insoluble proteinase K complexed to acrylic beads) and is vastly more 
ototoxic than phenol/water extracts of LOS (Amaee 1995). Thus it appears that there may be a 
protein toxin in the cytoplasm of Hib which is potently ototoxic. In this section an attempt was 
made to purify and characterise the ototoxic factor. To my knowledge this is the first attempt to 
purify and characterise an ototoxic factor in the cytoplasmic contents of Hib.
Four batches of Hib were grown and worked up at CAMR. One batch was used for all the 
experiments described in this section. In total, 40 animals were used in this chapter, and the initial 
auditory thresholds can be seen in Fig. 4. Data from three animals were excluded from statistical 
and summary information as one displayed initial auditory thresholds above the defined level, the 
second animal died during the experiment, and the third was killed at 50 min.
Aims and Objectives
1. To fractionate the bacterial disruptate into a soluble fraction and pellet by ultracentrifugation.
2. To fractionate the soluble fraction by anion exchange chromatography.
3. To perfuse the crude and fractionated bacterial extracts into scala tympani and monitor 
electrophysiological responses.
4. To examine by electron microscopy perfused cochleae if ototoxicity was observed in terms of 
electrophysiological responses.
58
Figure 4. Threshold CAP values of all animals used in the work 
described in this chapter.
Red circles indicate thresholds either above the defined level 
(50dB at 10 and 5kHz and 65dB at 3kHz), 
or well outside the normal distribution of the group.
4.1 Crude Hib Bacterial Disruptate
4.1.1 Undiluted Crude Disruptate
The crude Hib bacterial disruptate was tested for ototoxicity in three animals (Fig. 4.1.1; Table 
4.1.1) and produced positive 10kHz CAPs losses in all animals. At 90 min, 10kHz CAP losses in 
animals 1, 2 and 3 were 45, 25 and 78dB respectively. Animal 3 displayed positive losses in CAPs 
at all frequencies within 5 min of perfusion. Animals 2 and 3 displayed no positive CM loss, 
whereas animal 1 exhibited a positive loss in the CM of 54% at 90 min
Table 4.1.1: Electrophysiological losses evoked by perfusion with crude Hib bacterial 





Animal 1 Animal 2 Animal 3





















Threshold CAPs (dEI) and Peak CM (mV)
30 27 67 0.22 45 40 - 0.26 -5 -10 35 0.26
Loss in CAPs (dB' or CM (% control)
1 7 8 1 -1 9 6 - -12 55 38 19 -12
5 27 26 3 34 13 12 - -5 75 48 21 -5
10 31 18 3 6 19 14 - 21 75 50 25 -3
30 36 - 6 15 19 14 • 2 75 51 28 8
60 40 - 10 36 27 19 - 19 77 55 29 24
90 45 - 13 54 25 17 - . 14 78 54 31 28
4.1.2 Dilution of the Crude Hib Bacterial Disruptate I (1:10 dilution)
For future reference the crude disruptate was diluted and assessed for ototoxicity in order to 
determine minimal concentrations which were active. Initially the sample was diluted to 1:10 and 
tested for ototoxicity in three animals (Fig. 4.1.2; Table 4.1.2), Perfusion of crude Hib disruptate 
diluted 1:10 produced positive losses in CAPs in all animals. At 90 min, 10kHz CAP losses were 
28, 45, and 23 dB in animals 4, 5 and 6 respectively. Positive CM losses were not displayed by any 
animal.
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■ Animal 1 • Animal 2 A Animal 3
Figure 4.1.1. Losses in the CAP and CM in three animals, each treated with 
crude Hib bacterial disruptate.
a-c) Losses in the CAP elicited with 10, 5 and 1 kHz stimuli respectively, 
d) Loss in the CM elicited with a 5kHz stimuli.
■ Animal 4 · Animal 5 ▲ Animal 6
Figure 4.1.2. Losses in the CAP and CM in three animals, each treated with 1:10 
crude Hib bacterial disruptate.
a-c) Losses in the CAP elicited with 10, 5 and 1kHz stimuli respectively, 
d) Loss in the CM elicited with a 5kHz stimuli.
Table 4.1.2 : Electrophysiological losses evoked by perfusion with crude Hib bacterial 





Animal 4 Animal 5 Animal 6





















Threshold CAPs (c B) and Peak CM (mV)
-5 -10 41 0.18 29 -5 41 0.20 32 23 43 0.18
Loss in CAPs (d B) orC VI (% control)
1 26 17 4 2 5 20 2 -35 11 6 7 -6
5 25 27 7 16 13 23 10 -37 12 5 6 -8
10 28 30 8 20 14 28 12 -35 13 7 7 0
30 30 32 7 26 32 48 29 -30 17 7 7 -10
60 29 29 7 14 41 57 32 14 22 14 9 -6
90 28 26 4 -4 45 61 32 23 23 14 10 10
4.1.3 Dilution of the Crude Hib Bacterial Disruptate II (1:20)
As the initial dilution of Hib extract displayed potent ototoxicity, the crude Hib disruptate was 
further diluted to determine the threshold concentration of ototoxic activity. Crude Hib disruptate 
diluted 1:20 was tested for ototoxicity in three animals (Fig. 4.1.3; Table 4.1.3), Positive losses in 
CAPs were seen in animal 7 at 1 min which recovered by 5 min, indicating a temperature effect 
(discussed in section 3.1.). But, at 90 min animal 7 lost 28dB in the 10kHz CAP, and animal 8 lost 
22dB in the 5kHz CAP. No positive loss in the CM was seen in either animal, however animal 7 
displayed increases in the CM in excess of 60% at most time points.
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Figure 4.1.3. Losses in the CAP and CM in two animals, each treated with 1:20 
crude Hib bacterial disruptate.
a-c) Losses in the CAP elicited with 10, 5 and 1kHz stimuli respectively, 
d) Loss in the CM elicited with a 5kHz stimuli.
Table 4.1.3 : Electrophysiological losses evoked by perfusion with 






Animal 7 Animal 8















Threshold CAPs (dB) and Peak CM (mV)
24 13 50 0.14 19 -6 42 0.34
Loss in CAPS (dB) or CM (% control)
1 39 32 9 -73 5 -2 0 2
5 6 7 3 -86 6 -3 0 -1
10 11 13 5 -90 9 -1 1 0
30 29 17 9 -50 13 10 3 1
60 31 18 9 -63 17 22 4 4
90 28 14 8 -63 18 22 6 16
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4.1.4 Dilution of the Crude Hib Bacterial Disruptate III (1:50)
As the 1:20 dilution of the crude Hib bacterial disruptate displayed some ototoxicity, crude Hib 
bacterial disruptate was diluted to 1:50 and assessed for ototoxicity in one animal (Fig. 4.1.4; 
Table 4.1.4), Animal 9 has been excluded from statistical analysis as the animal was killed after 
the 40 min recording. Perfusion of crude Hib bacterial disruptate diluted 1:50 produced no 
positive losses in CAPs or CM at 40 min. Losses did not exceed lOdB and 7% in the CAPs and 
CM respectively.
Table 4.1.4 : Electrophysiological losses evoked by 
perfusion with crude Hib bacterial disruptate diluted 1:50 in 







10 kHz 5 kHz 1 kHz
0 
(control)
Threshold CAPs (c B) Peak CM mV)
11 6 47 0.34
Losses in CAPs (dB) and CM (% control)
1 -1 2 -3 0
5 2 3 -2 3
10 6 7 0 7
30 8 8 0 3
40 7 10 0 7
4.1.5 . Crude Hib Bacterial Disruptate :
Summary and Conclusions
Average 90 min losses in CAPs and CMs produced by crude Hib bacterial disruptate extracts are 
summarised in Table 4.1.5,
Table 4.1.5: Average 90 min losses evoked by perfusion with Crude Hib 




Average losses (± SD) in CAPs (dB) or CM (%) 
at 90 min post perfusion
CAP at 10 kHz CAP at 5 kHz CAP at 1kHz CM
Undiluted (n=3) 49 ±27 35 ±26 22 ±13 32 ±20
Diluted 1:10 (n=3) 32 ±12 34 ±24 15±15 10±13



























Figure 4.1.4. Losses in the CAP and CM in one animal, treated with 1:50 crude 
Hib bacterial disruptate.
a-c) Losses in the CAP elicited with 10, 5 and 1 kHz stimuli respectively.
d) Loss in the CM elicited with a 5kHz stimuli.
Conclusions
• There was evidence for sustained ototoxicity in undiluted, 1:10 and 1:20 crude Hib bacterial 
disruptate. There was no evidence for sustained ototoxicity in 1:50 crude Hib bacterial 
disruptate, however this animal was killed after the 40 min recording.
• There was also some evidence of transient ototoxicity in 1:20 crude Hib bacterial disruptate. 
However this was not consistent between animals and was likely to have been due to 
incomplete equilibration of the sample with ambient temperature.
• Therefore, ototoxicity activity in crude Hib bacterial disruptate is dose dependent, and 
threshold concentration for ototoxic activity (within 90 min) is >1:20 dilution.
4.2. Ultracentrifugation I (16h at 500,000g)
The first step in fractionation of the crude Hib bacterial disruptate was a simple centrifugation step 
(Section 2.3.4.5.) to separate soluble cytoplasmic material from cell wall, membrane and other 
insoluble materials. Initially the ultracentrifugation was carried out at 500,000g, 4°C, 16h and both 
the supernatant and pellet fractions were assessed for ototoxicity.
4.2.1. Supernatant (I) (cytoplasmic contents (I))
The supernatant (I) fraction of crude Hib bacterial disruptate produced no positive losses in CAPs 
or CM in one animal (Fig. 4.2.1; Table 4.2.1). At 90 min, 10kHz CAP loss was 18dB which is 






















Figure 4.2.1. Losses in the CAP and CM in one animal, treated with cytoplasmic 
contents of crude Hib bacterial disruptate.
a-c) Losses in the CAP elicited with 10, 5 and 1kHz stimuli respectively.
d) Loss in the CM elicited with a 5kHz stimuli.
Table 4.2.1 : Electrophysiological losses evoked by perfusion 
with supernatant (I) fraction of Hib crude bacterial disruptate in 







10 kHz 5 kHz 1 kHz
0 
(control)
Threshold CAPs (dB) Peak CM mV)
8 4 45 0.18
Losses in CAPs (dB) and CM (% control)
1 0 1 -2 -4
5 1 5 0 -13
10 0 5 -2 -38
30 7 5 0 10
60 15 5 0 -2
90 18 7 0 19
Conclusions
• There was little or no evidence for ototoxicity in the supernatant fraction (I) of crude Hib 
bacterial disruptate. The pellet fraction (I) was not tested for ototoxic activity as we wished to 
reconsider the ultracentrifugation method before continuing.
4.3 Ultracentrifugation II (30min at 500,0000g)
Previous evidence (Amaee 1995) suggested that the Hib ototoxic factor was present in the soluble 
cytoplasmic contents of crude Hib bacterial disruptate. The initial ultracentrifugation (section 4.2) 
produced a supernatant fraction which displayed some, but considerably reduced ototoxicity (as 
judged by CAP losses) in comparison to the crude extract, indicating perhaps that some of the 
ototoxicity had been sedimented into the pellet fraction. Since we wished to distinguish between 
ototoxic activity that may be produced by LPS and that of any other ototoxic factors we decided 
to modify the ultracentrifugation method in an attempt to eliminate/reduce any sedimentation of 
the ototoxic factor into the pellet (which will contain LPS). In all future fractionations 
ultracentrifugation was earned out at 500,000g for 30 min as apposed to 16 h to retain relatively 
more of the ‘pelleted’ material in the supernatant. Both the supernatant and pellet fractions of the 
crude Hib bacterial disruptate were assessed for ototoxicity.
64
4.3.1 Supernatant (II) (cytoplasmic contents (II))
The supernatant (II) fraction of crude Hib bacterial disruptate was tested for ototoxicity in four 
animals (Fig. 4.3.1; Table 4.3.1) and produced large CAP losses at all frequencies. At 90 min, 
10kHz CAP losses were 61, 75, 68 and 46 dB in animals 11, 12, 13 and 14 respectively. Positive 
CM losses were displayed in animals 12 and 14, but not animals 11 and 13, although animal 11 
displayed a loss in the CM of 37% which is just below the significance level.
Table 4.3.1 : Electrophysiological losses evoked by perfusion 
with Hib cytoplasmic contents in four animals.





Animal 11 Animal 12















Threshold CAPs (dB) and Peak CM (mV)
11 -1 41 0.33 5 -4 45 0.11
Loss in CAPs (dB or CM (% control)
1 9 11 7 9 0 9 0 -6
5 34 49 44 7 55 46 23 3
10 55 74 46 14 70 62 35 22
30 61 91 64 18 70 72 33 0
60 61 91 64 31 75 74 37 19





Animal 13 Animal 14















Threshold CAPs (dB) and Peak CM (mV)
12 10 45 0.28 35 31 57 0.14
Loss in CAPs (dB' or CM (% control)
1 1 -2 -1 3 23 22 21 44
5 21 15 10 -12 36 26 26 54
10 54 52 29 -12 36 26 25 61
30 63 65 30 0 41 32 32 71
60 68 68 38 10 47 37 31 61
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Figure 4.3.1. Losses in the CAP and CM in four animals, each treated with Hib 
cytoplasmic contents (II).
a-c) Losses in the CAP elicited with 10, 5 and1 kHz stimuli respectively.
d) Loss in the CM elicited with a 5kHz stimuli.
4.3.2 Pellet Fraction (II) (cell wall and membrane material (II))
The pellet fraction of the crude Hib bacterial disruptate was tested for ototoxicity in animals 15, 
16 and 17 (Fig. 4.3.2; Table 4.3.2), The data from animal 17 are included in Fig. 4.3.2 and Table 
4.3.2, but are excluded from statistical and summary data as the animal displayed initial auditory 
thresholds outside the defined range. Animals 16 and 17 displayed no positive losses in CAPs 
(losses did not exceed 8dB). In contrast animal 15 displayed positive CAP losses at all frequencies 
and at all time points following perfusion. In all animals there were no positive losses in the CM.
Table 4.3.2: Electrophysiological losses evoked by perfusion with unwashed Hib cell 





Animal 15 Animal 16 Animal 17





















Threshold CAPs (dEI) and Peak CM (mV)
38 12 45 0.32 21 12 46 0.21 61 40 67 0.27
Loss in CAPS (dB or CM (% control)
1 24 37 32 -1 -2 3 0 -4 1 2 0 0
5 28 44 32 -4 1 -2 2 -2 0 2 -2 -2
10 31 47 31 ~4 4 0 -1 -4 2 -2 -4 21
30 30 53 34 2 4 3 0 -4 2 0 -2 -2
60 31 50 35 4 4 3 2 0 5 3 -2 33
90 34 55 36 9 7 8 2 -2 6 5 -1 8
4.3.3 . Washed Pellet Fraction (Cell Wall And Membrane Material)
There was some evidence for ototoxicity in the pellet fraction of the crude Hib bacterial 
disruptate. However the results were not consistent between animals. It is possible that the 
ototoxicity produced by the pellet fraction was due to contamination of the sample with some 
components of the supernatant which is potently ototoxic (as judged by CAP losses >40dB see 
Section 4.3.1). Therefore the pellet sample produced by ultracentrifugation at 500,000g was 
washed twice with APL and reassessed for ototoxicity in animals 18, 19 and 20 (Fig. 4.3.3; Table 
4.3.3), Perfusion of the washed pellet fraction produced no positive CAP losses in animal 18, but 





.A. Animal 15 • Animal 16 eAnimal 17
Figure 4.3.2. Losses in the CAP and CM in four animals, each treated with Hib 
cell wall and memrane material.
a-c) Losses in the CAP elicited with 10, 5 and 1 kHz stimuli respectively.
d) Loss in the CM elicited with a 5kHz stimuli.
■ Animal 18 ▲ Animal 19 •Animal 20
Figure 4.3.3. Losses in the CAP and CM in three animals, each treated with 
washed Hib cell wall and membrane material.
a-c) Losses in the CAP elicited with 10, 5 and 1 kHz stimuli respectively, 
d) Loss in the CM elicited with a 5kHz stimuli.
loss of 26dB in the 10kHz CAP, and animal 20 exhibited a loss of22dB in the 5kHz CAP. In all 
animals there were no positive losses in the CM.
Table 4.3.3: Electrophysiological losses evoked by perfusion with washed Hib cell wall 





Animal 18 Animal 19 Animal 20





















Threshold CAPs (dEI) and Peak CM (mV)
20 10 44 0.23 15 -4 38 0.35 8 -7 40 0.28
Loss in CAPs (dB or CM (% control)
1 0 -6 1 6 8 6 3 8 7 -8 0 -36
5 2 0 1 12 13 9 3 30 12 -3 2 -36
10 3 0 1 6 18 9 5 39 16 2 2 2
30 5 5 3 28 22 13 5 24 9 -2 3 -30
60 9 2 3 28 25 13 5 19 14 12 3 5
90 10 5 4 27 26 14 6 20 17 22 8 7
4.3.4 . Ultracentrifugation II (30 min) : Summary and Conclusions
Average 90 min losses in CAPs and CMs displayed by animals perfused with the fractions 
produced by ultracentrifugation at 500,000g, 30 min, 4°C are summarised in Table 4.3.4.
Table 4.3.4 : Average 90 min losses evoked by perfusion with Crude Hib 
disruptate, and fraction products of ultracentrifugation at 500,000g, 30 min, 4°C.
Positive losses are bold.
Treatment Average losses (± SD) in CAPs (dB) or CM (%) 
at 90 min post perfusion




49 ±27 35 ±26 22 ±13 32 ±20
Supernatant 
(n=4)
62 ±12 68 ±22 45±14 40 ±26
Unwashed
Pellet (n=3)
20 ±19 31 ±33 19 ±24 4±8
Washed
Pellet (n=3)
18±8 14±8 6±2 18 ±10
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Conclusions
• Cytoplasmic contents of the crude Hib bacterial disruptate were potently ototoxic (as judged by 
CAP loss >40dB) in the cochlea. Both unwashed and washed pellet fractions (derived from 
crude Hib bacterial disruptate) produced some low levels of ototoxicity (as judged by CAP loss 
>20dB) in the cochlea, but the results were not consistent between animals.
• Statistical analysis using ANOVA demonstrated a significant difference in the 10kHz CAP 
losses between the supernatant fraction (derived from crude Hib bacterial disruptate) and either 
the washed or unwashed pellet fractions (derived from crude Hib bacterial disruptate) over 
time. The effect of treatment alone was significant (p=0.02 and p=0.03 for the washed and 
unwashed pellet fractions respectively) and the effect of treatment over time was highly 
significant (p=<0.0001 in either case). There was no significant difference in the 10kHz CAP 
losses between the washed and unwashed pellet fractions.
• The results indicated that the majority of the ototoxic activity was associated with the 
cytoplasmic contents of the crude Hib bacterial disruptate (when ultracentrifuged for 30 min at 
500,000g, 4°C) and hence this extract was used for further fractionation.
• The cell wall and membranous material produced some low-level ototoxicity. Since purified E. 
coli LPS produces some ototoxicity in the guinea pig cochlea (Comis et al. 1991) it is possible 
that low level ototoxicity produced by the pellet fraction may have been due to LOS which 
would have been present in considerable amounts within this fraction. This was not further 
examined.
4.4. Anion Exchange Chromatography (I) (Single Step Elution)
This section was carried out in collaboration with Dr Lynn Dover, whose permission I have to 
present the combined data as part of my thesis.
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The next step in fractionation was to use anion exchange chromatography to separate the 
cytoplasmic contents of Hib according to their charge. Initially a small column was set up (bed 
volume approximately 1ml) as described in Methods (Section 2.3.4.6.), 15mg aliquots 
(approximately 1ml) total protein were added to the column. The unadsorbed fraction was 
collected and the bound sample eluted using 10ml IM NaCl. All samples were reconcentrated, 
dialysed in APL, and diluted to a concentration equal to that in the original supernatant material. 
Both the unadsorbed and adsorbed fractions were assessed for ototoxicity.
Elution Profile
An elution profile was carried out to determine at what point the majority of protein was eluted 
from the column during this anion exchange chromatography method (Table 4.4.),
Table 4.4. Elution Profile: Volumes and Protein Content of fractions of crude Hib 
cytoplasmic contents produced by anion exchange chromatography.













1 990 990 0.25 247.5 247.5
2 1200 2190 1.46 1752 1999.5
3 860 3050 0.45 387 2386.5
4 590 3640 0.2 118 2504.5
5 950 4590 0.31 294.5 2799
6 930 5520 0.21 111.6 2910.6
7 815 6335 0.07 57.05 2967.65
8 900 7235 0.18 162 3129.65






10 1160 9415 1.55 1798 4999.05
11 846 10261 8.5 7191 12190.05
12 620 10881 0.54 334.8 12524.85
13 1300 12181 0.02 26 12550.85
14 1200 13381 0.02 24 12574.85
15 890 14271 0.02 62.3 12637.15
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The Tris HC1 eluted fraction (unadsorbed sample) contained 3mg of protein and the IM NaCl 
eluted fraction (adsorbed sample) contained 9mg of protein (12mg in total). No further protein 
was eluted by 4M LiCl. Therefore it was concluded that all of the protein was eluted using 50ml 
IM NaCl, the majority of it having adsorbed to the column and hence this method was used to 
attempt to isolate the ototoxic element in the Hib cytoplasmic contents.
4.4.1. Unadsorbed Fraction
The unadsorbed fraction of the Hib cytoplasmic contents was tested for ototoxicity in animals 21 
and 22 (Fig. 4.4; Table 4.4.1), and produced no positive losses in CAPs or CM. However, in 
animal 21 positive increases in the 5kHz CAP occurred.
Table 4.4.1 : Electrophysiological losses evoked by perfusion with 
unadsorbed fraction of crude Hib cytoplasmic contents in two 





Animal 21 Animal 22















Threshold CAPs (dB) and Peak CM (mV)
17 18 48 0.09 28 40 61 0.21
Loss in CAPS (dB) or CM (% control)
1 8 7 3 -10 2 -24 -9 8
5 9 8 3 8 2 -20 -9 13
10 9 5 4 4 2 -20 -8 1
30 9 6 2 8 2 -21 -10 34
60 10 8 5 -8 4 -20 -10 5
90 12 11 6 4 4 -19 -9 6
4.4.2. IM NaCl Fraction
The adsorbed fraction of the Hib cytoplasmic contents eluted using IM NaCl was tested for 
ototoxicity in animals 23 and 24 (Fig. 4.4; Table 4.4.2), and produced positive losses in the 10 
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and 5kHz CAPs in both animals. Animal 23 displayed a positive CAP loss at all frequencies within 
5 min of perfusion. A positive loss in the CM was seen in animal 23 at 90 min, but not in animal 
24.
Table 4.4.2 : Electrophysiological losses evoked by perfusion 
with 1M NaCI fraction of crude Hib cytoplasmic contents in two 





Animal 23 Animal 24













0 Threshold CAPs (dB) and Peak CM (mV)
(control) 49 34 51 0.14 30 13 51 0.29
Loss in CAPs (dB or CM (% control)
1 12 26 17 27 -1 -1 -1 -5
5 21 34 22 2 13 0 1 8
10 22 35 24 20 13 -1 0 4
30 25 34 25 25 15 7 1 3
60 26 34 26 32 22 15 11 10
90 26 33 26 55 28 22 13 16
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4.4.3. Anion Exchange Chromatography I 
(Single Step Elution): Summary and Conclusions
Average 90 min losses in CAPs and CMs displayed by animals perfused with the fractions 
produced by ‘Anion exchange chromatography Г are summarised in Table 4.4.3.
Table 4.4.3 : Average 90 min losses evoked by perfusion with fractions from 
‘Anion exchange chromatography I’. Positive losses are bold.
Treatment Average losses (± SD) in CAPs (dB) or CM (%) 
at 90 min post perfusion








27 ±1 27±8 19±9 35 ±28
Conclusions
• There was evidence of ototoxicity in the IM NaCl fraction. The unadsorbed fraction produced 
some moderate ototoxicity (as judged by CAP loss), however this was not consistent between 
animals.
• Statistical analysis using ANOVA demonstrated a significant difference between the 10kHz 
CAP losses produced by the unadsorbed and IM NaCl fractions over time. The effect of 
treatment on the CAP at all time points was not significant (p=0.09), but the change in the 
CAP with time was significant (p=0.001).
• The results indicated that the majority of the ototoxic activity was in the IM NaCl fraction of 
the cytoplasmic contents of Hib, and hence this fraction was further fractionated.
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4.5. Anion Exchange Chromatography II (Two-Step Elution )
A column, similar to that described in section 4.4, was loaded in an identical fashion. The column 
was desorbed in a 2 step fashion using 50mM Tris.HCl pH7.5 (10 ml/step) containing 0.2M and 
IM NaCl respectively. Fractions were pooled appropriately and tested for ototoxicity
4.5.1 Unadsorbed Fraction (II)
The unadsorbed fraction (II) of Hib cytoplasmic contents was again tested for ototoxicity in 
animals 25 and 26 (Fig. 4.5 i; Table 4.5.1), and produced no losses in CAPs or CMs. CAP losses 
did not exceed 11 dB.
Table 4.5.1 : Electrophysiological losses evoked by perfusion 
with unadsorbed fraction of crude Hib cytoplasmic contents in two 





Animal 25 Animal 26















Threshold CAPs (dB) and Peak CM (mV)
24 19 48 0.14 6 10 43 0.14
Loss in CAPs (dB) or CM (% control)
1 4 1 -1 -36 9 0 4 -10
5 4 3 3 -36 4 5 0 -10
10 5 5 4 -38 9 7 0 -7
30 10 10 3 -20 7 8 2 -17
60 10 11 6 15 7 7 0 -17
90 8 8 5 -15 10 8 0 -12
4.5.2 0.2M NaCl Fraction
The fraction of the Hib cytoplasmic contents eluted with 0.2M NaCl was tested for ototoxicity in 
animals 27 and 28 (Fig. 4.5 ii; Table 4.5,2). Animal 27 displayed positive CAP losses at 10 and 5 
kHz, whereas CAP losses displayed by animal 28 did not exceed 14dB. CM losses were not 


























■ Animal 25 · Animal 26
Figure 4.5 i. Losses in the CAP and CM in two animals each treated with 
unadsorbed fraction (11) of Hib cell wall cytoplasmic contents .
a-c) Losses in the CAP elicited with 10, 5 and l .kHz stimuli respectively.
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Figure 4.5 ii. Losses in the CAP and CM in five animals, two treated with 0.2M 
NaCI fraction (RED), two treated with 1M NaCI fraction (BLUE) and one treated with 
a mixture of the 0.2M and 1M NaCI fractions (GREEN) of the Hib cytoplasmic 
contents.
a-c) Losses in the CAP elicited with 10, 5 and 1kHz stimuli respectively, 
d) Loss in the CM elicited with a 5kHz stimuli.
Table 4.5.2 : Electrophysiological losses evoked by perfusion 
with 0.2M NaCI fraction of crude Hib cytoplasmic contents in two 





Animal 27 Animal 28















Threshold CAPs (dB) and Peak CM (mV)
27 2 43 0.20 28 30 52 0.15
Loss in CAPs (dB) or CM (% control)
1 5 -1 -1 2 -2 -7 -1 5
5 7 3 0 7 8 3 3 26
10 8 11 2 9 7 12 5 7
30 26 29 9 7 11 13 6 2
60 26 32 9 14 13 13 4 14
90 25 28 6 16 11 14 7 26
4.5.3 IM NaCI Fraction
The IM NaCI fraction of Hib cytoplasmic contents eluted with IM NaCI was tested for 
ototoxicity in animals 29 and 30 (Fig. 4.5 ii; Table 4.5.3), and produced no positive losses in 
CAPs or CMs. CAP losses did not exceed 14dB.
Table 4.5.3: Electrophysiological losses evoked by perfusion with 
1M NaCI fraction of crude Hib cytoplasmic contents in two animals. 





Animal 29 Animal 30













0 Threshold CAPs (dB) and Peak CM (mV)
(control) 2 14 40 0.22 21 9 46 0.22
Loss in CAPs (dB) or CM (% control)
1 5 -2 1 5 0 1 -2 11
5 0 1 1 0 7 0 1 -5
10 -1 0 6 -1 7 6 -1 -5
30 0 2 2 -3 8 7 2 -5
60 11 5 3 4 11 11 4 -5
90 14 9 4 0 13 11 1 5
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4.5.4 Mixture of 0.2M And IM NaCl Eluted Fractions
The 0.2M and IM NaCl fractions were mixed and assessed for ototoxicity to test the hypothesis 
that the ototoxic factor required two or more components which may have been separated during 
this fractionation step. Since the 0.2M NaCl fraction was itself ototoxic, the expectation was for 
an increased ototoxicity in the mixture if two components are necessary. 500pl of each 0.2M and 
IM NaCl fractions were mixed overnight at 4 °C, and then tested for ototoxicity in animal 31 (Fig.
4.5 ii; Table 4.5.4), No positive losses in CAPs or CM were seen. CAP losses did not exceed 
7dB.
Table 4.5.4: Electrophysiological losses evoked by perfusion
with a mixture of the 0.2M and 1M NaCL fractions of crude Hib 
cytoplasmic contents in one animal.







10 kHz 5 kHz 1kHz
0 
(control)
Threshold CAPs (c B) Peak CM mV)
22 14 41 0.19
Losses in CAPs (dB) and CM (% control)
1 -12 0 -1 -19
5 -9 0 -2 -15
10 -7 0 -2 -11
30 -1 -2 -2 -15
60 5 -3 -2 -8
90 7 -2 -2 -8
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4.5.5. Anion Exchange Chromatography II 
(Two-Step Elution): Summary and Conclusions
Average 90 min losses in CAPs and CMs displayed by animals perfused with the fractions 
produced by ‘Anion exchange chromatography II’ are summarised in Table 4.5.5.
Table 4.5.5 : Average 90 min losses evoked by perfusion with produced by ‘Anion 
exchange chromatography II’. Positive losses are bold.
Treatment Average losses (± SD) in the CAPs (dB) or CM (%) 
at 90 min post perfusion
CAP at 10 kHz CAP at 5 kHz CAP at 1kHz CM
0.2M NaCl Fraction(n=2) 18±10 21 ±10 6±1 21 ±7
IM NaCl Fraction(n=2) 13±1 10 ±1 2±2 2±3
0.2 & 1M NaCl Fractions (n=1) 7 -2 -2 -8
Conclusions
• There was evidence for ototoxicity in the 0.2M NaCl fraction, however the results were not 
consistent between animals. The unadsorbed fraction and IM NaCl fraction produced no 
ototoxicity in the guinea pig cochlea. Statistical analysis using ANOVA demonstrated no 
significant difference between the 10kHz CAP losses produced by the unadsorbed, IM NaCl, 
and 0.2M NaCl.
• The mixture of 0.2M and IM NaCl fractions displayed no increase in ototoxicity. Since only 
one animal was used any conclusions must be highly tentative. According to the results it 
would appear there was no ototoxin-enhancing component present in the IM NaCl fraction, or 
the toxin activity in the 0.2M NaCl fraction had been diluted or neutralised.
• The level of ototoxicity (as judged by CAP loss) in fractions produced by anion exchange 
chromatography was considerably lower than seen in crude fractions. Therefore it appeared 
that some activity was being lost during this fractionation step. This loss of activity was not 
due to separation of two or more individual factors required for the ototoxic activity.
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4.6. Anion Exchange Chromatography III (Two-Step Elution)
In order to limit any breakdown of the ototoxic factor potentially due to co-purification with 
proteases, samples were bulked with lOmg bovine serum albumin (BSA) per eluate. In this way if 
there were any protease/s present within the fractions BSA would contribute the majority of the 
available substrate. The column was set up and loaded as in 4.5 (anion exchange chromatography 
II), and all adsorbed fractions were assessed for ototoxicity.
4.6.1 0.2M NaCl Fraction Bulked With BSA.
The adsorbed fraction of the Hib cytoplasmic contents eluted with 0.2M NaCl which was bulked 
with BSA was tested for ototoxicity in animals 32 and 33 (Fig. 4.6; Table 4.6.1), and produced 
positive CAP losses at 10 and 5kHz in both animals. Data from animal 32 are included in Fig. 4.6 
and Table 4.6.1, but are excluded from statistical and summaiy data as the animal died at 50 min. 
Final 10kHz CAP losses were 31 and 35dB in animals 32 and 33 respectively. Neither animal 
displayed positive CM losses.
Table 4.6.1 : Electrophysiological losses evoked by perfusion with 
0.2M fraction of crude Hib cytoplasmic contents bulked with BSA in 





Animal 32 Animal 33















Threshold CAPS (dB) and Peak CM (mV)
25 0 49 0.08 15 0 44 0.15
Loss in CAPS (dB or CM (% control)
1 6 6 2 0 0 -2 0 -39
5 14 16 6 32 5 2 1 -36
10 14 16 9 0 11 8 3 -36
30 23 24 13 14 50 49 26 -33
40 31 33 14 4 42 48 33 -36
60 • • • 51 59 29 -46
90 - • 35 40 15 -46
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• Animal 32 ■ Animal 33 ▲ Animal 34 ♦ Animal 35
Figure 4.6. Losses in the CAP and CM in four animals, two treated with 0.2M 
NaCI fraction (RED) and two treated with 1M NaCI fraction (BLUE) of Hib 
cytoplasmic contents all bulked with BSA.
a-c) Losses in the CAP elicited with 10, 5 and 1kHz stimuli respectively, d) Loss in the
CM elicited with a 5kHz stimuli.
4.6.2 IM NaCl Fraction Bulked with BSA
The adsorbed fraction of the Hib cytoplasmic contents eluted with IM NaCl was tested for 
ototoxicity in animals 34 and 35 (Fig. 4.6; Table 4.6.2), and produced no positive losses in CAPs 
or CMs. However, positive CAP increases and some CM increases were displayed in animal 34, 
which are likely to have been due to poor initial electrical coupling (discussed in section 3.1), 
Nonetheless, recalculation of CAP and CM losses using 1 min recordings as control values, 
reveals no positive losses in CAPs or CM.
Table 4.6.2 : Electrophysiological losses evoked by perfusion with 
1M NaCl fraction of crude Hib cytoplasmic contents bulked with BSA in 





Animal 34 Animal 35















Threshold CAPs (dB) and Peak CM (mV)
42 33 61 0.18 23 12 45 0.16
Loss in CAPs (dB) or CM (% control)
1 -18 -29 -17 -15 2 -2 -2 -11
5 -18 -30 -18 -22 2 -3 0 -2
10 -18 -29 -16 -22 1 -6 -1 -13
30 -14 -23 -12 -22 6 -4 -1 -11
60 -14 -21 -14 -18 8 -1 0 -6
90 -15 -20 -15 -15 10 1 0 -4
4.6.3 . Anion Exchange Chromatography III 
(Two-Step Elution): Summary and Conclusions
Average 90 min losses in CAPs and CMs displayed by animals perfused with the fractions 
produced by ‘Anion exchange chromatography III’ (bulked with BSA) are summarised in Table 
4.6.3.
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Table 4.6.3 : Average 90 min losses evoked by perfusion with produced by 
‘Anion exchange chromatography III’. Positive losses are bold.
Treatment Average losses (± SD) in the CAPs (dB) or CM (%) 
at 90 min post perfusion
CAP at 10 kHz CAP at 5 kHz CAP at 1kHz CM
0.2M NaCl 
Fraction (n=1)
35 40 15 -46
IMNaCI
Fraction (n=2)
-2 ±18 -9 ±15 -7 ±11 -10 ±8
Conclusions
• There was evidence of ototoxicity in the 0.2M NaCl eluted fraction and not in the IM NaCl 
eluted fraction. Statistical analysis was not carried out as data from animal 32 had been 
excluded.
• The lack of ototoxicity produced by the IM NaCl fraction meant that any ototoxicity produced 
by samples bulked with BSA could safely be attributed to ototoxicity in the Hib fraction rather 
than to BSA.
• The results indicated that the majority of the ototoxic activity was in the 0.2M eluted fraction, 
and bulking the sample with BSA enhanced maintenance of activity. Hence this fraction was 
further fractionated and samples were routinely bulked with BSA.
4.7. Anion Exchange Chromatography IV (Three-Step Elution)
A column, similar to that described in section 4.6, was loaded in an identical fashion. The first 
active desorption step was carried out using Tris.HCl buffer containing 0.1M NaCl. This was 
followed as before with a 0.2M NaCl elution step. All unadsorbed and adsorbed fractions were 
assessed for ototoxicity.
4.7.1 Unadsorbed Fraction
The unadsorbed fraction of the Hib cytoplasmic contents fraction produced no positive losses in 
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■ Animal 36
Figure 4.7 i. Losses in the CAP and CM in one animal, treated with unadsorbed 
fraction of the Hib cytoplasmic contents .
a-c) Losses in the CAP elicited with 10, 5 and 1 kHz stimuli respectively.
d) Loss in the CM elicited with a 5kHz stimuli.
Table 4.7.1 : Electrophysiological losses evoked by perfusion 
with unadsorbed fraction of crude Hib cytoplasmic contents 







10 kHz 5 kHz 1 kHz
0
(control)
Threshold CAPs (dB and Peak CM (mV)
34 24 65 0.15
Losses in CAPs (dB) and CM (% control)
1 1 -1 -10 -2
5 0 -1 -9 -5
10 0 2 -7 0
30 3 3 -7 -1
60 3 5 -6 9
90 3 6 -6 7
4.7.2 0.1M NaCI Fraction
The 0. IM NaCI fraction produced no positive losses in CAPs or CMs in either of animals 37 and 
38 within 80 min. However, at 90 min animal 37 displayed positive losses in CAPs at all 
frequencies. Neither animal displayed positive CM losses (Fig. 4.7 ii; Table 4.7.2 ).
Table 4.7.2 : Electrophysiological losses evoked by perfusion 
with the 0.1 M fraction of crude Hib cytoplasmic contents bulked 





Animal 37 Animal 38















Threshold CAPs (dB) and Peak CM (mV)
16 9 34 0.19 17 16 32 0.21
Loss in CAPs (dB) or CM (% control)
1 3 -3 1 5 -1 -4 -1 -2
5 3 -1 2 11 0 -5 -5 2
10 7 3 2 7 -1 -5 -5 2
30 7 3 2 17 -2 -2 -3 4
60 7 4 4 7 2 -1 -2 10
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■ Animal 37 •Animal 38 ▲ Animal 39 ♦ Animal 40
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Figure 4.7 ii. Losses in the CAP and CM in four animals, two treated with 0.1 M 
NaCI fraction (RED) and two treated with 0.2M NaCI fraction (BLUE) of Hib 
cytoplasmic contents all bulked with BSA .
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, 
d) Loss in the CM elicited with a 5kHz stimuli.
4.7.3 0.2M NaCl Fraction
The 0.2M NaCJ fraction produced positive losses in the 10 and 5kHz CAPs in both of two 
animals. At 90 min, 10kHz CAP losses were 38 and 48dB in animals 39 and 40 respectively. A 
positive loss in the CM was not seen in either animal (Fig. 4.7 ii; Table 4.7.3).
Table 4.7.3 : Electrophysiological losses evoked by perfusion 
with the 0.2M fraction of crude Hib cytoplasmic contents bulked with 





Animal 39 Animal 40















Threshold CAPs (dB) and Peak CM (mV)
29 28 - 0.15 19 17 43 0.20
Loss in CAPs (dB) or CM (% control)
1 0 3 18 11 2 3 6
5 3 6 • 16 19 11 7 7
10 13 12 - 14 29 21 - 7
30 32 20 • 18 46 41 - 12
60 31 18 23 49 38 • 16
90 38 26 - 18 48 34 — 12
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4.7.4. Anion Exchange Chromatography IV 
(Three-Step Elution) : Summary and Conclusions
Average 90 min losses in CAPs and CMs displayed by animals perfused with the fractions 
produced by ‘Anion exchange chromatography ПГ are summarised in Table 4.7.4.
Table 4.7.4 : Average 90 min losses evoked by perfusion with produced by 
‘Anion exchange chromatography IV. Positive losses are bold.
Treatment Average losses (± SD) in the CAPs (dB) or CM (%) 
at 90 min post perfusion (brackets represents losses 
at 80 min)
CAP at 10 
kHz
CAP at 5 kHz CAP at 3kHz CM
Unadsorbed Fraction (n=1) 3 6 -6 7








0.2M NaCl Fraction (n=2) 43±7 30 ±6 • 15±4
Conclusions
• The unadsorbed fraction of the crude Hib bacterial disruptate produced no ototoxicity in the 
guinea pig cochlea. There was some evidence for ototoxicity in the 0.1M NaCl fraction. 
However the results were inconsistent and the temporal pattern of the ototoxicity was not 
characteristic of that already seen in this work. There was evidence for ototoxicity in the 0.2M 
eluted fraction.
• Statistical analysis using ANOVA demonstrated a significant difference between the 10kHz 
CAP losses produced by the 0.1M NaCl and 0.2M NaCl fractions with time. The effect of 
treatment on the CAP at all time points was not significant (p=0.08) but the change in the CAP 
with time was significant (p=0.0003).
• These results indicated that the majority of the ototoxic activity was in the 0.2M eluted 
fraction.
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4.8. Isolation Of The Ototoxicity In Crude Hib 
Bacterial Disruptate: Summary and Conclusions
Fractionation steps and CAP losses described in this section are summarised in Fig. 4.8,
Conclusions
• The majority of the ototoxic activity of the Hib extracts was found in the supernatant fraction 
following ultracentrifugation at 500,000g, 4°C for 30 min. This suggests that the ototoxic 
factor is soluble.
• By combined ultracentrifugation and anion exchange chromatography the major part of the 
ototoxicity in crude Hib bacterial supernatant was fractionated to a sample containing 
1.3 mgmT1 of protein which is 4 % of the crude protein content (30.3 mgmT1).
• The majority of the ototoxicity of the Hib extracts was found in a fraction which adsorbed to 
DEAE sepharose at pH 7.5 and eluted by 0.2M NaCl. This suggests that the ototoxic factor is 
negatively charged at pH 7.5.
• Bulking of the samples with BSA enhanced maintenance of ototoxic activity. This may be due 
to the presence of protease/s within the extracts which fractionate with the ototoxic factor. 
The result indicates that the ototoxin is a protein. However, this is not the only explanation for 
BSA-retention of ototoxicity. For example, BSA could have increased the viscosity of the 
sample which would limit oxygen transfer. If the ototoxic factor was inactivated by oxygen 
(e.g. it was thiol-activated) the activity of the sample could have been maintained simply by 
this physical effect on oxygen diffusion.
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Figure 4.8. Fractionation steps and CAP 
losses produced during isolation of the 
ototoxin in crude Hib bacterial disruptate.
The first and second numbers beneath each 
fraction represent the 90 min mean CAP loss ± 
standard deviation at 10 and 5kHz respectively. 
Significant CAP loss is red.
Each adsorption/desorption protocol was 
carried out with a fresh batch of cytoplasmic 
contents
Crude Hib Bacterial Disruptate 
49 . 35 
±27 ±26










































The results presented in this section were carried out using one batch of crude Hib bacterial 
disruptate received from CAMR. Subsequent batches of crude Hib bacterial disruptate yielded less 
reproducible results and displayed mild ototoxicity in comparison to the data presented here. 
Therefore it appears that the toxin is either labile in preparation or produced highly varying levels 
of ototoxicity. Future experiments would involve changes in methodology and in vitro conditions 
of culture; this is discussed in the Chapter 11 (Section 11.2.3).
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CHAPTER 5
Characteristics of ‘Hib Ototoxin’
5.1. Electrophysiological Observations
In the majority of cases (1 exception), positive losses in CAPs involved an immediate large loss 
followed by a slow continued decline. 80-90% of the final loss in CAPs was achieved within 20 
min, often within 5 or 10 min. Losses in CAPs were similar at the 10 and 5 kHz frequencies, but 
not at 3/1 kHz. Mean 90 min CAP losses of all animals which displayed some ototoxicity (as 
judged by CAP loss >20dB) were 39, 38 and 22 dB at 10, 5 and 3/1 kHz respectively. Of these 
experiments, 48% had greatest CAP losses at 10kHz, 48% had greatest CAP losses at 5kHz, and 
the remainder (2%) had equal (greatest) CAP losses at 10 and 5kHz. 91% of these experiments 
displayed smallest CAP losses at 3 kHz.
A positive loss in the CM was always accompanied by a positive loss in CAP, and in 75% of these 
the CAP loss was greater than 40dB. In contrast, only 17% of animals which displayed a positive 
loss in CAP at 90 min also displayed a positive loss in the CM at 90 min. The time course of this 
CM loss was variable but in most cases a gradual decline of the CM was seen throughout the 90 
min. Losses in the CM were often preceded by an initial small increase in the CM.
An example of the characteristic effects of the Hib ototoxin was seen in animal 3 which was 
treated with crude Hib bacterial disruptate (Fig. 5). CAP losses increased with frequency, and 
exhibited an immediate large loss followed by a gradual decline. The loss in the CM was gradual 

































Figure 5. CAP and CM losses produced by perfusion of crude Hib bacterial 
disruptate in animal 3.
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a) CAP losses at 10, 5 and 1 kHz b) Peak CM losses
c) CM losses at all stimulus intensities at 0, 1, 5, 10, 30, 60 and 90 min post perfusion.
5.2. Morphological Observations
Cochleae that displayed ototoxicity in terms of electrophysiological responses were examined by 
either transmission or scanning electron microscopy.
5.2.1. Scanning Electron Microscopy
Scanning electron microscopy of cochleae treated with crude ‘Hib ototoxin’ demonstrated 
scattered areas of damage along the organ of Corti. The damage was not consistent amongst 
treated cochleae. Damage observed included cratering in the supporting cells, and splaying of the 
stereocilia of the outer and inner hair cells particularly adjacent to sites of cratering (Plates. 5 i-ii).
5.2.2. Transmission electron microscopy.
All cochleae treated with crude ‘Hib ototoxin’ displayed similar damage when examined by TEM 
(Plates 5 iii-vi). The most striking damage observed was to the mitochondria. The mitochondria 
were swollen and in some cases the whole contents were missing. In some cells mitochondria were 
swollen to more than twice their original size as compared to control (untreated) cochleae. The 
greatest degree of mitochondrial damage was observed in afferent and efferent nerve endings to 
inner and outer hair cells. However mitochondrial damage was not specific to cell type, because 
swollen and empty mitochondria were also seen in outer and inner hair cells, in supporting cells, 
and also in the basilar membrane. Treatments which produced positive CM losses appeared to be 
associated with more extensive mitochondrial damage than treatments which did not produce CM 
losses. Another common feature amongst treated cochleae was membrane damage. Both cell 
membranes and organelle membranes were often thin, broken or absent. The cytoplasmic contents 
of the inner hair cells were often thin or missing in patches and there were frequent indications of 
cellular debris. In contrast, the cytoplasmic contents of the efferent nerve endings at the outer hair 
cells were often more dense than in control material.
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Plate 5i. Low power SEM of a control cochlea showing the uniform pattern of the organ 
of Corti with 3 rows of outer hair cells and 1 row' of inner hair cells. Magnification x 1000.
Plate 5ii. Low power SEM of a cochlea treated with cytoplasniic contents of the 
Hib bacterial extract. There is splaying and detachment of stereocilia of both the outer 
and inner hair cells. The stereocihal damage is co-located with damage to the apical 
surface of supporting cells in the form of a crater (C). Magnification x 2500

Plate 5iv TEM of a row 2 outer hair cell (OHC) of the left cochlea from an animal treated 
with cytoplasmic contents of the Hib bacterial extract. There is striking swelling of the 
mitochondria (M) in the efferent nerve ending (E) at the base of the OHC. Magnification x 21750.
Plate 5v TEM of the basilar membrane of the left cochlea from an animal treated with
cytoplasmic contents of the Hib bacterial extract. Swelling of the mitochondria (M) can be
seen along with some signs of membrane damage (m). Magnification x 6300.
Plate 5vi TEM of afferent nerve endings at the base of an IHC of the left cochlea from an 
animal treated with cytoplasmic contents of the Hib bacterial extract There is striking swelling 
of the mitochondria (M) in the afferent nerve ending (A) at the base of the IHC and associated 
membranous damage (m) of the nerve terminal and organnelles within it. Magnification x 30000.
5.3 Characteristics of‘Hib Ototoxin’: Conclusions
• The ‘Hib ototoxin’ produced a consistent drop in CAPs which was sometimes accompanied by 
a fall in the CM, particularly when the fall in the CAP exceeded 40dB. This is likely to mean 
that the primary target of the ototoxic factor was either the afferent neurons, afferent synapse 
or inner hair cells (all of which affect the CAP). The inconsistency in CM loss suggests that the 
outer hair cells (main contributor to the CM) were a secondary target which were not always 
affected.
• CAP losses were similar at 10 and 5kHz, but not at 3kHz. Smaller CAP losses displayed at 
3kHz may have been due to a lack of sensitivity to reduced activity in a small number of the 
fibres because of the greater number of contributing fibres to the CAP at this frequency. In 
addition smaller CAP losses displayed at 3kHz may have been a result poor penetration of the 
extract to the apex of the cochlea.
• The morphological evidence demonstrated consistent mitochondrial damage throughout the 
organ of Corti associated with the ototoxicity produced by Hib cytoplasmic fractions. 
Therefore it appears that the major target of the Hib ototoxin was mitochondria.
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CHAPTER 6
Ototoxicity Of N.meningitidis type b Bacterial Extracts
Formal evidence for the role of pneumolysin in causation of deafness following pneumococcal 
meningitis has already been presented (Winter et al. 1997). Strongly suggestive evidence 
implicating a soluble toxin responsible for deafness associated with meningitis caused by Hib has 
also been presented here (section 4.0). In this section the question is addressed as to whether there 
are similar ototoxic proteins present in N.meningitidis functionally comparable to the ototoxic 
proteins in S. pneumoniae and H.influenzae type b. A virulent strain of N.meningitidis type b (of 
human clinical origin) was grown in bulk at CAMR, Porton Down. The culture was separated into 
culture filtrate and bacterial cells. As had been done with Hib, the organisms were disrupted at 
CAMR and all materials transported to Birmingham. To my knowledge the kind of experiments 
described in the following section have never been done before.
One large batch of meningococci was grown and worked up at CAMR. This was used for all the 
experiments described in this section. In total, 16 animals were used in the work described in this 
chapter, and the initial auditory thresholds can be seen in Fig. 6. Data from three animals were 
excluded from statistical and summary information as it was felt these animals had initial auditory 
thresholds outside the normal distribution in this group.
Aims And Objectives:
1. To test the ototoxicity of a crude meningococcal bacterial disruptate.
2. To fractionate the bacterial disruptate into a soluble fraction and pellet by ultracentrifugation.
3. To perfuse both crude and 'fractionated' meningococcal fractions into the scala tympani of 
guinea pig cochleae and monitor electrophysiological responses.
4. To examine, by electron microscopy, perfused cochleae if ototoxicity was observed in terms 
of loss of electrophysiological responses.
88
Figure 6. Threshold CAP values of all animals used in the work 
described in this chapter.
Red circles indicate thresholds either above the defined level 
(50dB at 10 and 5kHz and 65dB at 3kHz), 
or well outside the normal distribution of the group.
6.1 Crude Meningococcal Bacterial Disruptate
An initial experiment was carried out in which the crude meningococcal bacterial disruptate was 
perfused into the cochlea of one animal to give an indication of the ototoxicity of the crude extract 
(Fig. 6.1; Table 6.1), The crude bacterial disruptate produced no positive losses in CAPs or CMs. 
At 90 min, losses in the CAP were -5, -15 and 5dB at 10, 5 and 3 kHz respectively, and the loss in 
the CM was -4%.
Table 6.1: Electrophysiological losses evoked by perfusion 
of a guinea pig cochlea with meningococcal bacterial 







10 kHz 5 kHz 3 kHz
0
(control)
Threshold CAPs (c B) Peak CM mV)
35 30 40 0.46
Loss in CAPs (dB) or CM (% control)
1 0 0 0 2
5 -3 -5 0 0
10 3 3 0 -2
30 -1 -3 0 4
60 -5 * -17 3 4
90 -5 -15 5 -4
Conclusion
These initial data provided no evidence for an ototoxic factor in the crude meningococcal bacterial 
disruptate.
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Figure 6.1. Losses in the CAP and CM in animal 1 treated with crude 
meningococcal bacterial disruptate .
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 
CM elicited with a 5kHz stimuli.
6.2 Concentrated Crude Meningococcal Bacterial Disruptate.
As the initial experiment indicated no ototoxic activity in meningococcal crude bacterial 
disruptate, the extract was concentrated to UmgmT1 and further assessed for ototoxicity in three 
animals (Fig. 6.2; Table 6.2). All animals perfused with this extract displayed 10kHz CAP losses 
in excess of 15dB at 1 min post perfusion. In all animals the CAP had fully recovered by 5 min 
post perfusion, probably due to a temperature effect (as discussed in Section 3.1). Evidence of 
CAP loss beyond the 1 min recording was seen in animals 2 and 3, but not in animal 4. At 90 min, 
loss in the 10kHz CAP was 27dB and 20dB in animals 2 and 3 respectively. No animal showed 5 
or 3kHz CAP losses exceeding 20dB, or loss in CM exceeding 16%.
Table 6.2: Electrophysiological losses evoked by perfusion with concentrated 
crude meningococcal bacterial disruptate in three animals.





Animal 2 Animal 3 Animal 4



















0 Threshold CAPs (dB) and Peak CM (mV
(control) 18 37 52 0.51 21 13 33 0.27 32 45 • 0.33
Loss in CA 3s (dB) or CM (% control)
1 17 20 • 4 39 17 8 8 16 3 - 3
5 10 20 - 6 12 9 4 6 0 0 - 0
10 11 13 4 15 14 9 -10 0 0 • -2
30 21 11 • 7 24 13 10 -3 1 1 • -3
60 26 11 - 12 22 13 7 0 0 0 8
90 27 11 — 14 20 10 6 -6 1 1 • 16
Conclusions
• There was some evidence for transient ototoxic activity produced by perfusion of crude 
concentrated meningococcal bacterial disruptate into the cochlea. However this may have 
been due to imperfect temperature equilibration of the sample after removal from the ice box.
• There was some evidence for persistent ototoxicity in crude concentrated meningococcal 
bacterial disruptate, however the results were not consistent between animals.
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a b
■ Animal 2 · Animal 3 ▲ Animal 4
Figure 6.2. Losses in the CAP and CM in three animals, each treated with 
concentrated crude meningococcal disruptate.
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 
CM elicited with a 5kHz stimuli.
• Since there was some evidence that concentration of the crude meningococcal bacterial 
disruptate resulted in increased ototoxicity, all further samples were concentrated to an 
equivalent level.
6.3 Dithiothreitol (DTT) Treatment Of Concentrated Crude 
Meningococcal Bacterial Disruptate.
Since crude pneumolysin is thiol-activated, it was proposed that a similar ototoxin produced by 
meningococci may also be thiol-activated. Crude pneumolysin is inactivated by SH oxidation. 
Hence the crude concentrated disruptate was treated with DTT, a reducing agent which would 
reduce functional SH groups.
6.3.1 DTT-Treated Bovine Serum Albumin (BSA).
It was considered worthwhile to test first for any possible non-specific effects of thiol reduction 
using BSA; BSA contains numerous SH groups (Swissprot) and hence is a good protein to test 
for the non-specific effects of -S-S- reduction. DTT-treated BSA was tested for ototoxicity in 
three guinea pigs (Fig. 6.3.1; Table 6.3.1), Animal 6 displayed no positive losses in CAP or CM. 
Animals 5 and 7 exhibited an initial loss in the 10kHz CAP in excess of 30 dB at 1 min post 
perfusion. Both animals showed some recovery by 10 min, probably due to a temperature effect 
(as discussed in Section 3.1.). Animal 5 showed no further losses; animal 7 did not recover fully, 
exhibiting losses in CAP of 16dB, 22dB and 15 dB at 10, 5 and 3 kHz respectively at the 90 min 
time point. In all animals there were no positive losses in the CM.
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Figure 6.3.1. Losses in the CAP and CM in three animals, each treated with 
DTT-treated BSA.
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 
CM elicited with a 5kHz stimuli.
Table 6.3.1. Electrophysiological losses evoked by perfusion with DTT-treated 





Animal 5 Animal 6 Animal 7





















Threshold CAPS (dB) and Peak C UI (mV
23 28 48 0.33 | 41 16 38 0.25 11 3 32 0.27
Loss in CA 3s (dB) or CM (% control)
1 32 10 2 -13 12 7 6 -3. 41 37 23 -6
5 8 3 -1 -16 18 10 8 -10 20 19 12 -10
10 0 0 -3 -18. 8 2 7 -7 12 12 6 -3
30 2 2 -2 -5 3 -1 6 7 19 22 18 10
60 4 3 -2 -13 5 0 7 10 15 21 16 26
90 2 2 -3 -8 5 1 7 2 16 22 15 29
Conclusions
• There was some evidence for transient ototoxicity produced by perfusion of DTT-treated BSA 
into the cochlea, however this may have been due to incomplete equilibration of the sample 
with ambient temperature.
• There was some tentative evidence for sustained ototoxicity in DTT-treated BSA, however, 
this was seen in only one animal and was positive at only one frequency. It may be that 
sustained ototoxic activity in meningococcal samples treated with DTT can be attributed to an 
SH-activated toxin. However, the data presented here implies that such data should be 
interpreted with some caution.
6.3.2 Concentrated DTT-Treated Meningococcal Bacterial Disruptate.
DTT-treated concentrated (13 mgmT1) meningococcal bacterial disruptate was tested for 
ototoxicity in three animals (Fig. 6.3.2; Table 6.3.2), Data from animal 10 are included in Fig. 
6.3.2 and Table 6.3.2a but have been excluded from statistical calculations as the animal displayed 
initial auditory thresholds outside the defined range. In animal 8 perfusion of DTT-treated 
concentrated bacterial disruptate produced an initial fall in the 10kHz CAP of 21 dB at 1 min, but 
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Figure 6.3.2. Losses in the CAP and CM in three animals, each treated with 
concentrated DTT-treated crude meningococcal disruptate.
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 
CM elicited with a 5kHz stimuli.
or CM until 90 min, when 10 and 5kHz CAP losses reached 19dB which is just below the 
significance level. In contrast, animal 9 displayed losses in CAP in excess of 60dB at all 
frequencies, and a loss in CM of 93%. All detectable CAP was eliminated at all frequencies. 
Animal 10 had initial auditory thresholds of 33, 59 and 72 dB attenuation for the 10, 5 and 3kHz 
CAPs respectively of which only the 10kHz threshold is outside the defined range. In animal 10, 
perfusion of concentrated DTT-treated meningococcal bacterial disruptate produced no positive 
losses in the CAPs or CM. At 90 min, losses in the CAP did not exceed lOdB at any frequency, 
and the loss in the CM was 28%.
Table 6.3.2 : Electrophysiological losses evoked by perfusion with the 
concentrated and DTT-treated bacterial disruptate of meningococcus in three 





Animal 8 Animal 9 Animal 10





















Threshold CAPs (dB) and 3eak CM (mV)
-2 -7 28 0.41 18 13 37 0.38 62 31 33 0.38
Loss in CAPs (dB) or CIV (% control)
1 21 -3 -3 -25 12 43 67 26 0 15 13 19
5 -3 -3 5 -30 77 76 67 84 -2 12 17 19
10 -3 2 6 -30 77 76 67 91 -2 13 19 23
30 -2 -2 6 -25 77 76 67 93 -2 15 16 16
60 6 6 6 -17 77 76 67 93 -1 14 15 26
90 19 19 8 -9 77 76 67 93 3 10 9 28
Conclusions.
• Data from animal 9 indicated the presence of a potent ototoxic factor, however this was not 
supported by the data from animals 8 and 10.
• Overall, there was some evidence for ototoxic activity in DTT-treated crude bacterial 
meningococcal disruptate. However the data were not consistent between animals.
• DTT treatment did not consistently increase the ototoxic activity of the crude concentrated 
meningococcal bacterial disruptate. Therefore DTT treatment was not routinely carried out.
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6.4. Ultracentrifugation Of Crude Meningococcal Bacterial 
Disruptate.
The crude meningococcal bacterial disruptate contained cell wall, cell membrane and cytoplasmic 
components of meningococci. It is possible that any ototoxin in this crude extract may be 
inactivated or neutralised by the presence of other component/s in a manner that would not be the 
case in vivo. For this reason an initial ultracentrifugal step was carried out in an attempt to 
separate the soluble fraction from cell membrane and cell wall material. Both the supernatant 
fraction and resuspended pellet were assessed for ototoxicity.
6.4.1 Supernatant Fraction (Cytoplasmic Contents) Of The Concentrated 
Meningococcal Bacterial Disruptate.
The supernatant fraction was tested for ototoxicity in three animals (Fig. 6.4.1 and Table 6.4.1). 
The data from animal 11 are included in Fig. 6.4.1 and Table 6.4.1 a, but have been excluded from 
statistical analysis because the animal displayed initial auditory thresholds outside the defined range. 
In all animals perfused with the supernatant fraction no positive losses in CAP or CM were 
observed. At 90 min post perfusion losses in CAP did not exceed 5dB, and the loss in CM did not 
exceed 20%.
Table 6.4.1 : Electrophysiological losses evoked by perfusion with 





Animal 11 Animal 12 Animal 13





















Threshold CA Ps (dB) and Peak CM (mV
62 43 70 0.24 13 3 35 0.53 I 18 5 22 0.46
Loss in CA 3s (dB) or CM (% control)
1 2 -1 -1 11 1 2 2 8 4 3 1 0
5 -9 -7 -4 7 1 6 3 8 5 6 4 0
10 -6 -3 -1 11 3 10 8 17 5 6 8 -2
30 -1 1 1 15 3 10 3 13 5 8 7 -4
60 3 5 1 15 0 7 3 23 5 8 6 -4
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Figure 6.4.1. Losses in the CAP and CM in three animals, each treated with 
concentrated meningococcal cytoplasmic contents.
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 
CM elicited with a 5kHz stimuli.
6.4.2 Pellet Fraction (Cell Wall and Membrane Material) Of The Concentrated 
Crude Meningococcal Bacterial Dismptate.
The pellet fraction of the concentrated meningococcal bacterial disruptate was resuspended in 
APL and tested for ototoxicity in three animals (Fig. 6.4.2 ; Table 6.4.2). Data from animal 15 are 
included in Fig. 6.4.2 and Table 6.4.2 a, but have been excluded from statistical calculations as the 
animal displayed initial auditory thresholds above the defined level. In all animals perfused with the 
pellet fraction no positive losses in CAP or CM were observed. At 90 min post perfusion losses in 
the CAP did not exceed 6dB, and the loss in CM did not exceed 20%.
Table 6.4.2 : Electrophysiological losses evoked by perfusion with the cell wall 
and membrane material of the concentrated meningococcal bacterial disruptate.





Animal 14 Animal 15 Animal 16



















0 Threshold CAPs (dB) and Peak CM (mV
(control) 39 13 35 0.35 53 40 48 0.30 18 9 35 0.51
Loss in CA =s (dB) or CM (% control)
1 10 10 5 12 2 2 -2 -3 12 11 5 0
5 5 8 3 10 -2 -5 -2 0 6 5 4 4
10 5 8 3 10 -5 -3 -2 -6 4 4 2 -1
30 -1 2 0 5 -8 -7 -4 -3 5 5 2 2
60 0 4 2 17 -3 -5 -1 7 5 3 0 -1
90 1 6 4 20 -2 -4 -1 12 0 2 -1 -1
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Figure 6.4.2. Losses in the CAP and CM in three animals, each treated with 
concentrated meningococcal cell wall and membrane material.
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 
CM elicited with a 5kHz stimuli.
6.4.3 . Ultracentrifugation of Concentrated Crude Meningococcal 
Bacterial Disruptate : Conclusions
• There was no evidence of ototoxicity in either the cell wall and membranous material or the 
cytoplasmic material.
• Fractionation of the crude bacterial extract by ultracentrifugation did not increase the 
ototoxicity of the extract. This would suggest that there is no particulate inhibitor present in the 
crude extract which might be inhibiting the action of a soluble toxin.
• The resuspended pellet fraction would have contained considerable amounts of LOS. The data 
presented here suggests that LOS within the crude meningococcal bacterial disruptate is not 
directly ototoxic in the guinea pig.
6.5. Summary Of The Meningococcal Bacterial Disruptate Cochlear
Perfusions.
6.5.1 Statistical Analysis
A summary of the mean (± standard deviations) CAP and CM losses from all the experiments 
carried out on this meningococcal preparation is given in Fig. 6.5.1 and Table 6.5.1 a.
Table 6.5.1. a: Average losses in the CAP and CM evoked by each treatment group at 
90 min post perfusion. Positive losses are bold.
CAP CM
10kHz 5 kHz 3kHz
Bacterial Extract Average loss in CAPs (dB) or CMs (%) at 90 min
Crude (n=1) -5 -15 5 -4
Crude Concentrated (n=3) 16113 716 6 8112
DTT treated BSA (n=3) 817 812 619 8119
DTT+concentrated crude 
(n=2)
33139 35136 28134 38151
Cytoplasmic Fraction (n=2) on 115 214 12111
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A Concentrated meningococcal cytoplasmic contents
X Concentrated meningococcal cell wall and membrane material
Figure 6.5.1. Average losses (±SDs) in the CAP and CM produced by 
five different treatments.
a) Losses in the CAP elicited with a 10kHz stimulus, b) Losses in the CM 
elicited with a 5kHz stimulus.
Statistical analysis of 10kHz CAP losses by ANOVA demonstrated no statistical significance 
between all treatments groups with respect to treatment alone (Table 6.5.1 b). However, there 
were significant differences between some treatment groups with respect to the change in the CAP 
with time. There was a statistical significance between the DTT-treated BSA data and 
meningococcal cytoplasmic contents data with respect to the change in the CAP with time 
(p=0.006). However, closer inspection of the results indicates that this represents a difference in 
the 10kHz CAP losses at 1 and 5 min only which is likely to be due to differential cooling effects 
on the cochlea rather than differential ototoxicity produced by the extracts. A significant difference 
was also calculated between concentrated meningococcal extract data and pellet fraction data in 
terms of the change in the CAP with time (p=0.02). This indicates some statistical significance 
between the ototoxicity produced by concentrated meningococcal extract and the pellet fraction.
Table 6.5.1. b: Statistical results (P values) of ANOVA analysis between each 
treatment with respect to the change in the CAP with time.
Significant differences are bold.






DTT+Conc Crude 0.3 0.8
Supernatant Fraction 0.006 0.05 0.7
Pellet Fraction 0.08 0.02 0.4 0.2
The whole set of data can be seen more clearly in Fig. 6.5.2. Statistically, the data produced by 
perfusion of all bacterial extracts are not significantly different to the data from perfusion of DTT- 
treated BSA.
6.5.2. Conclusions
• The variability in animal responses to these preparations could be interpreted to mean that there 
is no meningococcal ototoxin.
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Figure 6.5.2. Losses to the auditory potentials at 90 min post perfusion, produced 
by 5 treatment groups.
a-b) CAP elicited with 10, 5kHz stimuli respectively.
Treatment groups were : Concentrated Crude Meningococcal Bacterial Extract (Cone ), 
DTT treated 'Cone' (Cone & DTT), Supernatant fraction of 'Cone' (Super), 
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Figure 6.5.2. Continued Losses to the auditory potentials at 90 min post 
perfusion, produced by 5 treatment groups.
c) CAP elicited with 3kHz stimuli d) CM elicited with 5kHz stimuli.
Treatment groups were : Concentrated Crude Meningococcal Bacterial Extract (Cone ), 
DTT treated 'Cone' (Cone & DTT ), Supernatant fraction of 'Cone' (Super), 
Pellet fraction of 'Cone' (Pellet) and DTT treated BSA (BSA & DTT ).
• Alternatively, one might conclude that there was a meningococcal ototoxin and that the 
inconsistency of the ototoxic data was an expression of the variation in sensitivity of the 
animals to low concentrations of that ototoxin. In the next section (6.6) an attempt was made 
to detect any 'pneumolysin-like' protein(s) present in the meningococcal extracts by using 
monoclonal antibodies to pneumolysin with which to probe SDS-PAGE gel analyses of the 
meningococcal extracts.
6.6 Protein Analysis
The crude meningococcal bacterial extract was analysed by SDS polyacrylamide-gel 
electrophoresis and probed with specific polyclonal anti-pneumolysin antisera to determine 
whether there were any ‘pneumolysin-like’ proteins within meningococcus (Fig. 6.6). This 
proceedure was carried out twice and produced similar results on both occasions. The major band 
within pneumococcal extracts which is recognised by the anti-pneumolysin antisera runs at around 
53kDa. There is a band (of less intensity) of comparable size present in crude Hib bacterial 
disruptate. There is also a band (of less intensity than pneumococal and Hib bands) present in the 
meningococcal extract of comparable size together with a smaller band (ca. 32kDa).
Conclusions
• Hib bacterial disruptate contains a protein with similar RF to pneumolysin, but there is far less 
of it than pneumolysin.
• There is a protein present in the meningococcal extract which has the same Rf as pneumolysin 
and the Hib protein (recognised by the anti-pneumolysin antisera) which could be a 
pneumolysin-like ototoxin. There is clearly less of this protein present than in Hib, and 
certainly much less than in pneumococcus.
• There is also a smaller protein present (ca. 32KDa) in the meningococcal extract which may be 









Figure 6.6. Western blot of the cytoplasmic extracts of S.Pneumoniae type III 
(P), Hib (H), and N.Meningitidis (M) probed with an anti-pneumolysin antisera.
• Despite the fact that this result was repeated in a second gel, it is possible that the results 
presented here were due to contamination of tracks H and M with protein from the overloaded 
P track. Therefore further confirmatory investigations are necessary.
6.7 Meningococcal Extract: Overall Conclusions
• Electrophysiological evidence revealed some ototoxic activity within the meningococcal 
extract. However, the results were not consistent between animals.
• Protein analysis revealed the presence of a ‘pneumolysin-like’ protein in the meningococcal 
extract along with a smaller polypeptide which may be a degradation product of the 
‘pneumolysin-like’ protein.
• IF the ‘pneumolysin-like’ protein revealed by protein analysis is an ototoxin, the protein 
analysis data indicated that this ototoxin was low in concentration and may have undergone 
degradation during the disruption process. This would explain the inconsistent ototoxicity 
produced by the extract in different animals.
• In summary there may be a low concentration of an ototoxin within the meningococcal extract, 
which may be a ‘pneumolysin-like’ protein, but further confirmatory investigations are needed.
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CHAPTER 7
Characteristics Of Ototoxicity In 
Crude Meningococcal Bacterial Disruptate.
Although ototoxicity was not consistently demonstrated by the crude meningococcus bacterial 
disruptate, I have nonetheless attempted below to characterise such ototoxicity as was produced 
by this extract.
7.1 Electrophysiological Observations
Extracts of the crude meningococcus bacterial disruptate produced ototoxicity in four animals. In 
three out of four animals the ototoxicity produced was very similar in both potency and timing 
(see animals 2, 3 and 7). A positive loss in the CAP was only seen at the 10kHz frequency and was 
between 20 and 27 dB. The loss in the CAP followed a gradual decline and reached a positive 
level by 30 min. There were no positive losses seen in the CM. In contrast, ototoxicity produced 
in the fourth animal (animal 9) was much more potent and fast acting. Positive loss was seen in the 
CAP at all frequencies and in the CM. All losses were achieved within 5 min of perfusion and 
continued at this level throughout. The CAP was completely eliminated, and the CM loss reached 
93%. It is possible that the data from this one animal reflects an experimental error. Since the 
result produced in this one experiment was not repeated, the data should be treated with caution.
7.2 Morphological Observations
Cochleae from animals 2, 3 and 9 which all exhibited ototoxicity in terms of electrophysiological 
responses were examined for morphological damage by scanning electron microscopy (Plates 7 i­
ii).
The treated cochlea from Animal 2 was curled in many places which meant examination of the 
organ of Corti was not possible. However, there were some areas which had not curled and these 
were examined. There was no indication damage to the surface of the organ of Corti at the base of
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Plate 71. Low power SEM of the second turn of the organ of Corti from the left 
cochlea of animal 2 treated with meningococcal extract. There is some splaying (s) 
of the stereocilia of IHCs and some OHCs of rows 2 and 3. There is also some fusing 
(f) of the sterocilia of the OHCs in row 1. Magnification x 1500
Plate 7ii. High power SEM of the left cochlea from animal 9 treated with 
meningococcal extract showing some splaying (s) of the stereocilia of IHCs and 
OHCs of row 1, and severe splaying (s) of the stereocilia of OHCs in rows 2 and 
3 with some stereocilia detached from the cell (d). Magnification x 2250
the cochlea, however there was some patchy damage in the second turn (up from the base) of the 
cochlea. Stereocilia of the inner and outer hair cells were disarrayed and fused in some cases. 
There were also some craters in the supporting cells.
There was no indication of damage to the surface of the organ of Corti of the treated cochlea from 
Animal 3. However, examination of the organ of Corti was not possible at some sites due to 
curling of the specimen.
In the cochlea from Animal 9, there was evidence of damage to the organ of Corti which involved 
splaying of the stereocilia of outer and inner hair cells, and cratering of the supporting cells. 
However, this result was from one patch of the organ of Corti in the second turn because 
examination of the organ of Corti was not possible at any other sites due to curling of the 
specimen.
Characteristics Of Ototoxicity In Crude Meningococcal 
Bacterial Disruptate: Conclusions
• There was some evidence of surface morphological damage which involved splaying of 
stereocilia of all hair cells, and cratering in supporting cells. Since the damage seen in animal 2 
was patchy, the lack of discernible damage in animal 3 may be due to the inability to see all of 
the organ of Corti rather than the absence of morphological damage.
• Curling of the specimens appeared to be at least partly due to extract treatment as control 
cochleae which had been prepared identically displayed far less curling, and the degree of 
curling was consistent with CAP losses.
• The electrophysiological data suggest that the major target of the Meningococcal “ototoxic 
factor” appears to have been to the inner hair cells, afferent synapse, or afferent neurons and 
not the outer hair cells, since in most cases the CAP was reduced without any loss to the CM. 
However, the morphological evidence suggests that the Meningococcal “ototoxic factor” also 
produced some damage to the outer hair cells and supporting cells.
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CHAPTER 8
Ototoxicity Of Streptococcus pneumoniae Type III 
Bacterial Extracts
An initial pilot study in our group suggested that there may be another ototoxic factor within the 
bacterial extract of S.pnewnoniae type III besides pneumolysin, the expression of which may be 
interrupted by the insertional mutation in ‘non-pneumolysin producing’ pneumococcal mutants 
(Comis 1992 unpublished data). In the present study similar experiments to those carried out in 
the pilot study were performed with additional protein assays in an attempt to confirm the 
existence of this potentially novel ototoxin. Identification and characterisation of ototoxicity was 
carried out by electrophysiological and morphological studies and appropriate protein assays.
Pneumococcal extracts were provided by Prof. T.J. Mitchell from Leicester (now Glasgow) 
University. Bacteria were grown and disrupted at Leicester and transported to Birmingham for 
assessment of ototoxicity. Experiments were carried out on two batches of extracts. Results from 
batches I and II are presented in sections 8A and 8B respectively. In total 30 animals were used in 
the work described in this section and the initial auditory thresholds of all these animals can be 
seen in Fig. 8. Three animals were excluded from statistical and summary information, two 
displayed initial auditory thresholds above the defined level, and a third animal displayed initial 



























Figure 8. Threshold CAP values of all animals used in the work 
described in this chapter.
a) Animals perfused with Batch I extracts b) animals perfused with Batch II extracts 
Red circles indicate thresholds either above the defined level
(50dB at 10 and 5kHz and 65dB at 3kHz), 
or well outside the normal distribution of the group.
Aims and Objectives
1. To perfuse three kinds of pneumococcal extracts derived from S.pneumoniae type III into 
scala tympani of guinea pig cochleae. These extracts were: wild type pneumococcal extract; 
wild type pneumococcal extract immunopurified to remove pneumolysin; and an extract from 
S.pneumoniae type III in which the pneumolysin gene had been inactivated.
2. To measure electrophysiological responses to test for ototoxicity in each extract.
3. To carry out morphological examinations of those treated cochleae which demonstrated 
ototoxicity in terms of electrophysiological responses.
8A Ototoxicity Of Pneumococcus Type III
Bacterial Extracts: BATCH I
All extracts from batch I are identified by (I). Each batch I extract was initially tested for 
ototoxicity in one animal. Protein analysis revealed that the protein concentrations within each 
extract were variable (Wild Type - 1.102 mgml"1, Immunopurified Wild Type - 0.3508 mgml'1 and 
Mutant - 0.5263 mgml'1). The immunopurified extract (I) contained the least amount of protein, 
therefore wild type and mutant extracts were diluted to the same concentration (0.3508 mgml'). 
Data from undiluted wild type and mutant extracts are presented, but are excluded from statistical 
and summary information as they are not strictly comparable.
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8A 1 Wild Type Pneumococcal Extract
8A 1.1 Undiluted Wild Type Pneumococcal Extract (I).
The neat (1.10 mgml') wild type extract (I) was tested for ototoxicity in animal 1 and produced 
large losses in CAPs and CMs. All recordable CAPs were eliminated, and the CM was reduced by 
80% at 90 min (Fig. 8A 1; Table 8A 1.1). Data from this animal are excluded from statistical and 
summary information as the protein concentration was not standardised, and the initial auditory 
thresholds of this animal were outside the defined range.
Table 8A 1.1 : Electrophysiological losses evoked by perfusion 








10 kHz 5 kHz 3 kHz
0 
(control)
Threshold CAPs (dB) Peak CM mV)
5 60 - 0.12
Losses in CAPs (dB) and CM (% control)
1 84 20 - 23
5 85 21 - 29
10 90 30 - 51
30 90 30 - 77
60 90 30 - 77
90 90 30 - 80
8A 1.2 Diluted Wild Type Pneumococcal Extract (I)
Diluted (0.35 mgml'1) wild type pneumococcal extract (I) was tested for ototoxicity in three 
animals (Fig. 8A 1; Table 8A 1.2) and produced positive CAP losses in animals 2 and 3 at all 
frequencies, but not in animal 4. At 90 min, 10kHz CAP losses were 26, 60 and 8 dB in animals 2, 
3 and 4 respectively. A positive CM loss of 54% was displayed by animal 3 only. However, 90 min 
CM loss in animal 10 was 37% which is just below the significance level.
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Figure 8A 1. Losses in the CAP and CM in four animals, one treated with neat 
wild type pneumococcal bacterial extract (BLUE) and three treated with diluted 
wild type pneumococcal bacterial extract (RED).
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 
CM elicited with a 5kHz stimuli.
Table 8A 1.2 : Electrophysiological losses evoked by perfusion with diluted wild type 





Animal 2 Animal 3 Animal 4





















Threshold CAPs (dB ) and Peak CM (mV)
30 24 47 0.15 35 25 53 0.12 17 8 30 0.21
Loss in CAPs (dB1 or CM (% control)
1 3 2 2 2 26 27 29 -21 3 0 1 35
5 5 3 4 19 10 15 52 9 0 2 2 7
10 5 4 4 -2 48 57 52 27 2 2 1 8
30 12 10 10 2 60 65 52 36 4 0 1 17
60 16 12 16 26 60 65 52 64 8 -3 1 35
90 26 20 22 19 60 65 52 54 8 2 5 37
8A 1.3 Wild Type Pneumococcal Extract : Conclusions
• There was evidence for potent ototoxicity (as judged by CAP losses >40dB) in neat wild type 
pneumococcal extract despite high initial auditory thresholds. However, this result was from 
just one animal.
• There was some evidence for ototoxicity in diluted wild type pneumococcal extract (I). 
However the results were not consistent between animals.
8A 2 Immunopurified Pneumococcal Wild Type Extract (I)
Wild type pneumococcal extracts contain the pneumolysin ototoxin. An immunopurified wild type 
extract from which pneumolysin had been removed was assessed for ototoxicity in order to 
establish whether or not pneumolysin is responsible for all ototoxicity produced by wild type 
pneumococcal extracts. Neat (0.35 mgml') immunopurified wild type extract (I) was tested for 
ototoxicity in animals 5, 6 and 7 and produced some positive CAP losses at all frequencies, in all 
animals. Animal 7 displayed mostly transient CAP and CM losses, however, at 90 min, a positive 
loss was seen in the 5kHz CAP. At 90 min, 10kHz CAP losses were 49, 25 and 16 dB in animals
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5, 6 and 7 respectively. In Animal 5, the CM was almost completely eliminated, whereas animal 6 
exhibited no positive CM losses. Animal 7 displayed mostly transient CM losses (Fig. 8A 2; Table 
8A2).
Table 8A 2 : Electrophysiological losses evoked by perfusion with neat immunopurified 





Animal 5 Animal 6 Animal 7





















Threshold CAPs (dE ) and Peak CM (mV)
45 38 53 0.12 19 9 32 0.21 12 -8 23 0.22
Loss in CAPs (dB or CM (% control)
1 10 2 0 -7 -8 -5 0 -11 4 -1 0 -1
5 3 11 6 29 -6 6 6 -7 0 2 2 -3
10 1 3 0 -3 1 10 9 -10 5 3 3 -1
30 4 4 0 68 18 23 19 3 4 5 2 -3
60 48 48 33 85 23 26 24 12 11 9 5 -3
90 49 52 39 97 25 27 27 18 16 21 12 29
Conclusions
• There was evidence for sustained ototoxicity in immunopurified wild type pneumococcal 
extract (I).
• In addition, there was some evidence for transient ototoxicity at 40 min in immunopurified 




















■ Animal 5 · Animal 6 ▲ Animal 7
Figure 8A 2. Losses in the CAP and CM in three animals, each treated with neat 
immunopurified wild type pneumococcal bacterial extract.
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 
CM elicited with a 5kHz stimuli.
8A 3 Mutant Pneumococcal Extract (I)
The next step was to determine whether ototoxicity was present in bacterial extract (I) of a mutant 
of pneumococcus type III which is unable to produce pneumolysin.
8A 3.1 Undiluted Mutant Pneumococcal Extract (I)
Neat (0.53 mgml mutant extract (I) was tested for ototoxicity in animal 8 and produced positive 
CAP and CM losses at 1 min (Fig. 8A 3; Table 8A 3.1). No further positive CAP or CM losses 
were displayed, indicating a temperature effect (as discussed in Section 3.1.).
Table 8A 3.1 : Electrophysiological losses evoked by perfusion 
with neat mutant pneumococcal extract (I) in one animal.







10 kHz 5 kHz 3 kHz
0 
(control)
Threshold CAPs (c B) Peak CM mV)
18 13 37 0.15
Losses in CAPs (dB) and CM (% control)
1 20 11 8 56
5 0 0 12 33
10 1 1 2 2
30 5 6 4 12
60 5 6 3 7
90 6 6 5 12
8A 3.2 Diluted Mutant Pneumococcal extract (I)
Diluted (0.35 mgmT1) mutant extract (I) was tested for ototoxicity in animals 9 and 10 and 
produced positive CAP losses in both animals. However, animal 9 displayed positive CAP losses 
at 1 min only, indicating a temperature effect (as discussed in Section 3.1.). At 90 min, 10kHz 
CAP losses were 9 and 32 dB in animals 9 and 10 respectively. A positive CM loss was displayed 


































X Animal 8 ■ Animal 9 · Animal 10
c d
Figure 8A 3. Losses in the CAP and CM in three animals, one treated with neat 
mutant pneumococcal bacterial extract (BLUE) and two treated with diluted mutant 
pneumococcal bacterial extract (RED).
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 
CM elicited with a 5kHz stimuli.
Table 8A 3.2: Electrophysiological losses evoked by perfusion 
with diluted mutant pneumococcal extract (I) in two animals. 





Animal 9 Animal 10















Threshold CAPs (dB) and Peak CM (mV)
31 26 48 0.24 24 5 22 0.18
Loss in CAPs (dB) or CM (% control)
1 32 25 - 2 2 1 11 4
5 13 18 - 0 3 1 9 10
10 7 14 - 2 4 3 9 8
30 8 14 - 21 6 6 16 8
60 10 19 - 34 10 8 17 16
90 9 17 - 54 32 36 41 14
8A 3.3 Mutant Pneumococcal Extract (I): Conclusions
• There was no evidence for authentic ototoxicity in the undiluted mutant pneumococcal 
extract (I). However this result was from one animal only.
• There was evidence for ototoxicity in the diluted mutant pneumococcal extract (I). However, 
the type of otptoxicity produced (i.e. CAP or CM loss) by this extract was not consistent 
between animals.
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8A 4 Ototoxicity Of Pneumococcal Bacterial Extracts (I) 
: Statistics
A summary of the mean (± standard deviation) losses in CAPs and CMs produced by batch I 
pneumococcal extracts can be seen in Fig. 8A 4 and Table 8A 4.
Table 8A 4 : Average 90 min CAP and CM losses evoked by perfusion with 
pneumococcal extracts (I) (standardised by protein concentration).
Positive losses are bold.
Treatment Average losses (± SD) in CAPs (dB) or CM (%) 
at 90 min post perfusion
10 kHz CAP 5 kHz CAP 3kHz CAP CM
Wild Type (n=3) 31 ±26 29 ±32 26 ±24 37 ±18
Immunopurified Wild 
Type (n=3)
30 ±17 33 ±16 26 ±14 48 ±43
Mutant (n=2) 20 ±6 26 ±13 41 34 ±29
Statistical analysis by ANOVA demonstrated no significant difference between the 10kHz CAP 
losses produced by each of the pneumococcal extracts.
Immunopurified vs. Mutant Treatment alone p-1.6
Change in the CAP with time p= 0.3
Immunopurified vs. Wild Type Treatment alone p= 0.7
Change in the CAP with time p= 0.2
Wild Type vs. Mutant Treatment alone p= 0.5
Change in the CAP with time p- 0.2
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• Diluted Wild Type Pneumococcal Extract (I)
■ Neat Immunopurified Wild Type Pneumococcal Extract (I) 
▲ Diluted Mutant Pneumococcal Extract (I)
Figure 8A 4. Average losses (± S.D.s) in the CAP and CM produced by 
three treatment groups.
a Average losses in the CAP elicited with 10 kHzstimuli. b Average losses in the
CM elicited with 5kHz stimuli.
8A 5 Ototoxicity Of Pneumococcal Bacterial Extracts (I) 
: Summary and Conclusions
CAP and CM losses produced by each extract (I) are summarised in Fig. 8A 5.
Conclusions
• There was evidence for ototoxicity in immunopurified wild type pneumococcal extract (I). 
There was some evidence for ototoxicity in wild type, and mutant pneumococcal extracts (I). 
However the results were not consistent between animals.
• The variability of the animal responses to these preparations could be interpreted to mean that 
there were no pneumococcal ototoxins. However, it is well established that pneumolysin, a 
potent ototoxin is present in wild type pneumococcal extracts. Therefore the data could 
represent a variation in the sensitivity of animals to low concentrations of ototoxin(s). 
Alternatively, since crude preparations of pneumolysin are thiol-activated, pneumolysin and 
any other thiol-activated ototoxins present in the pneumococcal extracts (I) may have been 
inactivated during preparation by oxidation of functional SH groups. Therefore, in part B of 
this section, further experiments were carried out with a second batch of pneumococcal 




Figure 8A 5. 90 min losses in CAPs and CMs produced by three pneumococcal 
extracts (I).
a-b) CAP elicited with 10 and 5kHz stimuli respectively.
• Loss at 90 min in a single animal









Red lines indicate 
“positive” loss thresholds 
defined in Chapter 3.
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Figure 8A 5. continued. 90 min losses in CAPs and CMs produced by three 
pneumococcal extracts (I).
c) CAP elicited with 3kHz stimuli, d) CM elicited with a 5kHz stimuli.
8B Ototoxicity of Pneumococcus Type III 
Bacterial Extracts: BATCH II
Initially, the neat wild type pneumococcal extract (II) was perfused into the cochlea of one ^nim^h 
to test for ototoxicity and to compare its activity with the neat wild type extract from batch I.
8B 1 Wild Type Pneumococcal Extract (II)
Wild type pneumococcal extract (II) was tested for ototoxicity in animal 1 (Fig. 8B 1; Table 8B 
1) and produced a positive loss in the 10kHz CAP of 35dB at 10 min. There were no further 
positive losses in CAPs or CM.
Table 8B 1 : Electrophysiological losses evoked by perfusion 
with neat wild type pneumococcal extract (II) in one animal. 







10 kHz 5 kHz 3 kHz
0 
(control)
Threshold CAPs (dB) and Peak CM (mV)
18 15 40 0.15
Loss in CAPs (dB) or CM (% control)
1 9 3 2 8
5 9 7 5 16
10 35 17 12 5
30 11 5 7 5
60 16 5 7 5
90 16 5 7 5
Conclusion
• There was some evidence for transient ototoxicity in the wild type pneumococcal bacterial 
extract (II).
• There was no evidence for sustained ototoxicity in wild type pneumococcal bacterial extract 











^100 —1—■—1—1—·__ l..., । ■ 












· 0 30 60 90
Time (min)
Figure 8 B 1. Losses in the CAP and CM in one animal, treated with neat wild 
type pneumococcal bacterial extract (II). .
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 
CM elicited with a 5kHz stimuli.
The transient ototoxicity displayed by this animal is reminiscent of the CAP losses 
produced by perfusion of diluted (0.5p.g) pneumolysin (Comis etai. 1993).
8B 2 DTT Treatment Of Wild Type Pneumococcal 
Bacterial extract (II)
In the following experiments wild type pneumococcal bacterial extract (II) was treated with DTT 
and reassessed for ototoxicity. DTT was added to all extracts to a final concentration of ImM.
8B 2.1 DTT-Treated BSA
The possible non-specific effects of active thiol groups on the cochleae (see Section 6.3.1.), were 
re-checked as the concentrations needed for comparison were different in this chapter. BSA was 
used at 2 mgmT1 which is the concentration to which all pneumococcal extracts were later 
concentrated (see section 8B 3). DTT-treated BSA was tested for ototoxicity in animals, 5, 6, 7 
and 8 (Fig. 8B 2.1; Table 8B 2.1). Data from animal 7 are included in Fig. 8B 2.1 and Table 8B 
2.1, but are excluded from statistical and summary information as the animal displayed initial 
auditory thresholds outside the defined range (see Fig. 8). Positive CAP losses were displayed by 
animals 6 and 8, but not by animals 5 and 7. At 90 min, animal 6 lost 20dB at 10kHz and animal 8 
lost 20dB at 5kHz. Positive CM loss of 54% was displayed by animal 5, but not by animals 6, 7 




Figure 8B 2.1. Losses in the CAP and CM in four animals, each treated with DTT- 
treated BSA.
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 
CM elicited with a 5kHz stimuli.
Table 8B 2.1 : Electrophysiological losses evoked by perfusion with 





Animal 5 Animal 6















Threshold CAPs (dE ) and Peak CM (mV)
19 14 35 0.11 3 -2 33 0.14
Loss in CAPs (dB or CM (% control)
1 3 -4 0 3 20 10 5 1
5 1 -3 0 -6 18 10 6 -5
10 2 -2 1 -3 20 13 6 3
30 8 3 -2 9 16 6 1 1
60 11 5 7 37 20 7 4 3





Animal 7 Animal 8















Threshold CAPs (dB ) and Peak CM (mV)
46 38 57 0.13 3 -10 33 0.20
Loss in CAPs (dB' or CM (% control)
1 10 3 -2 0 · 1 15 7 6
5 1 1 -3 4 23 30 12 33
10 -2 -2 -5 -8 17 20 5 20
30 5 5 2 5 18 20 5 31
60 4 3 -1 -8 19 20 5 28
90 12 10 9 16 19 20 6 36
8B 2.2 DTT-Treated Wild Type Pneumococcal Extract
DTT-treated wild type pneumococcal extract was tested for ototoxicity in animals 9 and 10 (Fig. 
8B 2.2; Table 8B 2.2) and produced positive losses in CAPs at all frequencies in both animals. 
At 90 min, 10kHz CAP losses were 53 and 36dB (higher than for DTT-treated BSA) in animals 9 
and 10 respectively. Losses in CMs were 32 and 33% in animals 9 and 10 respectively which are 
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Figure 8B 2.2. Losses in the CAP and CM in two animals, each treated with DTT- 
treated neat wild type pneumococcal bacterial extract (II)
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 
CM elicited with a 5kHz stimuli.
Table 8B 2.2 : Electrophysiological losses evoked by perfusion with 
DTT-treated neat wild type pneumococcal extract (II) in two animals.





Animal 9 Animal 10















Threshold CAPs (dE ) and Peak CM (mV)
21 20 36 0.13 16 8 37 0.22
Loss in CAPs (dB or CM (% control)
1 -3 0 3 5 13 13 15 -2
5 2 -10 1 -48 16 20 16 0
10 -7 -11 0 3 14 13 8 -5
30 43 31 30 30 37 58 68 16
60 49 38 47 22 22 17 8 32
90 53 50 69 32 36 36 45 33
8B 2.3 DTT-Treated Wild Type Pneumococcal Extract 
: Summary and Conclusions
Average 90 min losses in CAPs and CMs produced by wild type pneumococcal bacterial DTT- 
treated extracts (II), and DTT-treated BSA are summarised in Table 8B 2.3.
Table 8B 2.3: Average 90 min losses evoked by perfusion with DTT-treated 
BSA, neat wild type pneumococcal extract (II) (Neat WT PC extract) and DTT- 
treated neat wild type pneumococcal extract (II). Positive losses are bold.
Treatment Average losses (± SD) in CAPs (dB) or CM (%) 
at 90 min post perfusion_______
10 kHz CAP 5 kHz CAP 3kHz CAP CM
Neat WT PC extract (n=1) 16 5 - 5
DTT-treated Neat WT PC 
extract (n=3)
44±12 43±10 57 ±17 33 ±1
DTT-treated BSA (n=4) 17±5 12 ±7 6±2 30 ±19
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Conclusions
• There was evidence for potent ototoxicity (as judged by CAP losses >40dB) in DTT-treated 
wild type pneumococcal extract.
• DTT-treated BSA produced some variable low level ototoxicity (as judged by CAP loss) in the 
guinea pig cochlea. Therefore one may assume that ototoxicity produced by DTT-treated 
extracts (II) which is consistent between animals is not due to non-specific effects of DTT 
treatment. However the data presented here demonstrates the need for caution when 
interpreting the data of extracts treated with DTT.
• Statistical analysis by ANOVA demonstrated a significant difference between the 10kHz CAP 
losses produced by DTT-treated wild type pneumococcal extract and DTT-treated BSA. The 
effect of treatment on the CAP at all time points was just outside the significance range 
(p=0.05) but the change in the CAP with time was significant (p=0.02).
• DTT treatment considerably enhanced the ototoxicity of the wild type extract (II) (as judged 
by CAP loss), therefore DTT treatment was routinely carried out in further experiments.
8B 3: Concentrated DTT-Treated Pneumococcal Extracts (II)
Since data from part A of this chapter implied that the ototoxin(s) present in the pneumococcal 
bacterial extracts may have been low in concentration, all pneumococcal extracts were 
concentrated before further assessment of ototoxicity. All pneumococcal extracts (II) were 
concentrated and adjusted to a final protein concentration of 2mgml1 and assessed for ototoxicity.
8B 3.1 Concentrated Wild Type Pneumococcal Extract
The concentrated DTT-treated wild type pneumococcal bacterial extract (II) was tested for 
ototoxicity in animals 11, 12, 13 and 14 (Fig. 8B 3.1; Table 8B 3.1). The data from animal 14 
has been excluded from statistical calculations and summary charts as the animal displayed initial 
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Figure 8B 3.1. Losses in the CAP and CM in four animals, each treated with 
concentrated DTT-treated wild type pneumococcal bacterial extract (II).
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 
CM elicited with a 5kHz stimuli. .
perfusion of concentrated wild type pneumococcal bacterial disruptate produced positive losses in 
CAPs at two or more frequencies. Animal 13 displayed a positive 10kHz CAP loss at 1 min which 
had recovered by 5 min, indicating a temperature effect (see Chapter 3). At 90 min, 10kHz CAP 
losses were 50, 63 and 33dB in animals 11, 12 and 13 respectively. Animal 14 displayed a 10kHz 
CAP loss of 18dB at 30 min. A positive CM loss was displayed in Animal 14 of 48%, but not in 
animals 11, 12 and 13.
Table 8B 3.1 : Electrophysiological losses evoked by perfusion with 
concentrated and DTT-treated wild type pneumococcal extract (II) in 





Animal 11 Animal 12















Threshold CAPs (dE ) and Peak CM (mV)
11 -5 30 0.14 6 -10 33 0.13
Loss in CAPs (dB or CM (% control)
1 10 -5 1 -5 26 33 19 -6
5 -2 6 4 -5 26 44 22 -8
10 23 16 11 -2 26 44 22 -8
30 20 28 14 -2 35 55 26 8
60 38 52 30 3 63 63 38 -6





Animal 13 Animal 14















Threshold CAPs (dE ) and Peak CM (mV)
26 16 45 0.14 55 50 62 0.07
Loss in the CAP dB) or CM (% control
1 31 19 4 -5 9 4 10 14
5 4 2 -3 -2 1 4 11 33
10 5 8 4 3 9 5 10 48
30 14 18 7 0 18 9 13 48
60 24 29 14 3 - - - -
90 33 32 16 10 - - - -
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Conclusions
• There was evidence for sustained ototoxicity in concentrated wild type pneumococcal extract.
• In addition, there was some evidence for transient ototoxicity at Imin in concentrated wild 
type pneumococcal extract. However, this result was not consistent between animals and is 
likely to have been due to incomplete equilibration of the sample with ambient temperature.
8B 3.2 Concentrated Immunopurified DTT-Treated Wild Type Pneumococcal 
Extract.
Perfusion of concentrated and DTT-treated immunopurified wild type pneumococcal extract (II) 
produced positive CAP losses at two or more frequencies in animals 15, 16 and 18, but not in 
animal 17 (Fig. 8B 3.2; Table 8B 3.2). At 90 min, 10kHz CAP losses were 31,33, 8 and 43 dB in 
animals 15, 16, 17 and 18 respectively. Animals 15 and 16 displayed some transient CAP losses at 
1 min, but both animals displayed further losses, suggesting that the losses may not have been due 
to a temperature effect There were no positive losses seen in the CM in any animal.
Table 8B 3.2 : Electrophysiological losses evoked by perfusion with 
concentrated and DTT-treated immunopurified wild type pneumococcal 
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Threshold CAPs (dE ) and Peak CM (mV)
16 7 44 0.17 -5 0 36 0.19
Loss in CAPs (dB or CM (% control)
1 35 27 6 4 0 8 2 -2
5 17 11 1 4 10 23 6 4
10 18 12 1 4 10 18 9 4
30 11 4 -2 8 0 10 4 4
60 21 18 0 14 17 7 1 5

























Figure 8 B 3.2. Losses in the CAP and CM in four animals, each treated with 
concentrated DTT-treated immunopurified pneumococcal bacterial extract (11).
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 





Animal 17 Animal 18















Threshold CAPs (dE ) and Peak CM (mV)
23 6 26 0.17 28 8 31 0.07
Loss in CAPs (dB or CM (% control)
1 3 2 2 0 22 22 26 11
5 3 4 1 -6 16 19 20 5
10 2 6 1 -6 19 19 22 16
30 2 8 5 -6 26 24 28 11
60 1 0 5 4 39 38 38 21
90 8 1 6 6 43 43 41 16
Conclusions
• There was evidence for transient ototoxicity at 1 min, and later sustained ototoxicity in 
concentrated immunopurified wild type pneumococcal extract. However, neither of these 
results were consistent between animals.
8B 3.3 : Concentrated ‘Non-pneumolysin producing’ Mutant 
Pneumococcal Extract
The concentrated and DTT-treated mutant extract (II) was tested for ototoxicity in animals 19 and 
20 (Fig. 8B 3.3; Table 8B 3.3) and produced positive CAP losses in both animals. Animal 19 
displayed a transient CAP loss at 1 min, indicating a temperature effect (as discussed in Section 
3.1.). However, at 90 min, losses in the 10kHz CAP were 21 and 38dB in animals 19 and 20 


































• Animal 19 ■ Animal 20
Figure 8B 3.3. Losses in the CAP and CM in two animals, each treated with 
concentrated DTT-treated mutant bacterial extract (II).
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 
CM elicited with a 5kHz stimuli.
Table 8B 3.3 : Electrophysiological losses evoked by perfusion with 
concentrated and DTT-treated mutant pneumococcal extract in two 





Animal 19 Animal 20















Threshold CAPs (dE ) and Peak CM (mV)
26 22 40 0.15 25 20 45 0.21
Loss in CAPs (dB or CM (% control)
1 23 15 2 -11 8 9 8 4
5 3 6 10 7 8 9 20 6
10 8 11 20 -5 9 10 20 8
30 17 14 17 2 11 13 20 10
60 21 14 18 16 17 18 24 27
90 22 16 18 18 38 35 27 27
8B 3.4 Concentrated DTT-Treated Pneumococcal Extracts (II) 
: Statistics
Mean (± standard deviations) losses in CAPs and CMs produced by batch n pneumococcal 
extracts are summarised in Fig. 8B 3.4 and Table 8B 3.4.
Table 8B 3.4: Average losses at 90 min produced by perfusion with DTT- 
treated BSA, and three concentrated and DTT-treated pneumococcal extracts.
Positive losses are bold.
Treatment Average losses (± SD) in CAPs (dB) or CM (%) 
at 90 min post perfusion
10 kHz CAP 5 kHz CAP 3kHz CAP CM
Wild type extract (II) (n=3) 50 + 16 51 ±17 31 ±14 15±6
Immunopurified wild type 
extract (II) (n=4) 29 ±15 24 ±18 15±17 12 ±5
Mutant extract (n=2) 30 ±11 25 ±13 22 ±6 22 ±6
DTT-treated BSA (n=3) 17 ±5 12±7 6±2 30 ±19
Statistical analysis by ANOVA demonstrated no statistical significance between all treatment 




























• wild type extract
■ immunopurifired wild type extract 
▲ "non-pneumolysin producing" mutant extract 
X DTT-treated BSA
Figure 8B 3.4. Average losses (± S.D.s) in theCAP and CM produced by 
three concentrated DTT-treated pneumococcal extracts and DTT-treated BSA.
a) Average losses in the CAP elicited with 10 kHzstimuli.
b) Average losses in the CM elicited with 5kHz stimuli. 
the data of the wild type pneumococcal extract (II) and the immunopurified wild type extract with 
respect to the change in the CAP with time (p=0.03). A highly significant statistical difference was 
demonstrated between the wild type extract (II) and DTT-treated BSA with respect to the change 
in the CAP with time (p=0.0003). Therefore immunopurified wild type extract (II) produced 
significantly less ototoxicity (in terms of 10kHz CAP loss) than unpurified wild type extract. But, 
only the wild type pneumococcal extract (II) produced ototoxicity that is statistically different to 
that produced by DTT-treated BSA.
8B 3.5 Ototoxicity Of Pneumococcus Type III Extracts (II)
: Conclusions
The scattergram (Fig. 8B 3.5) shows more clearly the whole set of data from which one can 
conclude the following:
• There was evidence for ototoxicity in wild type and mutant pneumococcal bacterial extracts 
(II) which was consistent between animals. There was some evidence for ototoxicity in 
immunopurified wild type bacterial extract. However this was not produced in one out of four 
animals tested.
• Wild type bacterial extract (II) produced more potent ototoxicity (as judged by CAP loss) than 
both the mutant and immunopurified wild type pneumococcal extracts (II), the latter two 
preparations produced similar levels of ototoxicity (as judged by CAP loss).
• Therefore there appears to be another ototoxic factor within the bacterial extracts (II) of wild 
type and mutant pneumococcus type III besides pneumolysin, which may represent a novel 
ototoxin common to both bacteria.
• However, data from protein analyses, presented in section 8B 4 revealed that the 

























Red lines indicate 
"positive” loss thresholds 
defined in Chapter 3.
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Figure 8B 3.5. 90 min losses in CAPs and CMs produced by three 
pneumococcal extracts (II), and DTT treated BSA.




• Loss at 90 min in a single animal 
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Figure 8B 3.5. continued. 90 min losses in CAPs and CMs produced 
by three pneumococcal extracts (II), and DTT treated BSA.
c) CAP elicited with 3kHz stimuli, d) CM elicited with a 5kHz stimuli.
8B 4 Protein Analysis
8B 4.1 Protein Concentrations
Protein contents of each bacterial extract (II) showed:
Wild Type extract (II)





Wild type and mutant pneumococcal extracts (II) contained comparable concentrations of protein. 
However, the immunopurified wild type pneumococcal extract (II) contained more than twice as 
much protein as the wild type and mutant extracts (II). This was investigated as described below.
8B 4.2 SDS-PAGE Stained With Coomassie Brilliant Blue And Probed With 
Mab7.
The protein composition of each extract (II) was examined by electrophoresis. Pneumococcal 
extracts (II) were analysed by 1 dimensional SDS-PAGE on a 12% resolving gel stained with 
Coomassie Brilliant Blue (Fig. 8B 4.2). A large amount of peptide was present at 66.2kDa in the 
immunopurified extract (II) which was significantly greater than that seen in either the wild type or 
mutant extracts (II), and probably represents serum albumin. The immunopurified extract (II) also 







31 kDa ------------ 1
Figure 8B 4.2. SDS-PAGE of three pneumococcal extracts (II).
A) Wild Type Extract
B) Immunopurified Wild Type Extract
C) Mutant Extract
Conclusion
The immunopurified wild type bacterial extract (II) contained considerable amounts of protein not 
present in wild type and mutant extracts (II). It is suggested that two of these bands represent 
antibody fragments and serum albumin, probably leached from the column during 
immunopurification.
8B 4.3 : SDS-PAGE Probed With Monoclonal Anti-Pneumolysin Antibody 
(Mab7)
In order to determine whether pneumolysin was present in each of the extracts (II), they were 
analysed by 1 dimensional SDS-PAGE on a 12% resolving gel and probed with an anti- 
pneumolysin monoclonal antibody (Mab7) (Fig. 8B 4.3), At approximately 58kD there was a 
peptide present in both wild type extracts (II), but not in the mutant extract. This corresponded to 
pneumolysin. There was more of this peptide present in the wild type extract (II) than in the 
immunopurified wild type extract, based on staining intensity and comparable lane-loading of 
protein.
Conclusions
• Pneumolysin was present in both wild type pneumococcal extracts (II), and absent in the 
mutant extract. Considerably less pneumolysin was present in the wild type pneumococcal 
extract (II) which had been immunopurified.
• The immunopurification protocol used had removed some but not all of the pneumolysin in the 
wild type pneumococcal extract.
8B 4.4 : Native-PAGE Probed With Mab7
During immunopurification, anti-pneumolysin antibody may have successfully bound all 
pneumolysin present, but the leaching of protein from the column would have allowed some of this 
bound pneumolysin to contaminate the extract. In order to determine whether pneumolysin 
present in the immunopurified extract (II) was bound or unbound, the wild type pneumococcal
122
ABC
-<-------  66.2 kDa
Figure 8B 4.3. Western blot of three pneumococcal extracts (II), to 
analyse pneumolysin content using anti-pneumolysin monoclonal antibody.
A) Wild Type Extract
B) Immunopurified Wild Type Extract
C) Mutant Extract
extracts (II) were analysed by 1-dimensional native-PAGE on a 5% resolving gel and probed with 
Mab7 (Fig. 8B 4.4). This method separates non denatured proteins on the basis of their size and 
charge density. Despite the rather poor quality of the gel, it is possible to demonstrate that 
pneumolysin present within the immunopurified wild type extract (II) moved only a short distance 
in comparison to pneumolysin in untreated pneumococcal wild type extract.
Conclusions
Pneumolysin present in immunopurified wild type pneumococcal extract (II) had a higher 
molecular mass than that present in wild type pneumococcal extract, suggesting that it was bound 
to anti-pneumolysin antibody.
8B 4.5 Protein Analysis : Conclusions
• Wild type pneumococcal bacterial extract (II) contained free pneumolysin.
• Mutant pneumococcal bacterial extract (II) contained no pneumolysin.
• Immunopurified wild type pneumococcal extract (II) contained some pneumolysin; however it 
was bound to anti-pneumolysin antibody.
• Immunopurified wild type pneumococcal extract (II) also contained considerable amounts of 







Figure 8B 4.4. Native-PAGE gel of wild type pneumococcal extracts 
(II), to investigate the physical state of pneumolysin using anti-pneumolysin 
monoclonal antibody.
A) Wild Type Extract
B) Immunopurified Wild Type Extract
The pneumolysin in lane B travelled a short distance compared to the pneumolysin in lane 
A, suggesting that pneumolysin in lane B is part of a high molecular weight complex.
8B 5 Ototoxicity Of Pneumococcus Type III Bacterial Extracts (II) 
: Overall Conclusions
• Wild type pneumococcal bacterial extract (II) contained free pneumolysin, and as would be 
expected, produced ototoxicity within the guinea pig cochlea.
• Mutant pneumococcal bacterial extract (II) produced ototoxicity within the guinea pig cochlea 
despite the absence of pneumolysin. Therefore the ototoxicity produced by this extract was 
due to a ‘non-pneumolysin’ ototoxic factor.
• Immunopurified wild type bacterial extract (II) produced some ototoxicity in the guinea pig 
cochlea despite the absence of free pneumolysin. However, immunopurified wild type bacterial 
extract (II) contained some antibody bound pneumolysin, and some contaminants from the 
immunosorbent. Since high affinity rabbit polyclonal anti-pneumolysin serum has been 
demonstrated to be protective in the guinea pig cochlea (unpublished data; this laboratory), it 
is unlikely that the contaminants are responsible for the ototoxicity produced by the 
immunopurified extract. As all extracts were standardised with respect to protein 
concentration, the bacterial contents of the immunopurified extract would have been 
considerably diluted in comparison to the wild type and mutant extracts. Therefore, the 
variable ototoxicity produced by the immunopurified extract may represent a low 
concentration of a ‘non-pneumolysin’ ototoxic factor in this extract. This in fact enhances the 
potential significance of the immunopurified data.
• In summary, there was evidence for an ototoxic factor in the mutant extract (II) which may 
represent a novel ototoxin.
• The results presented here are not consistent with previous preliminary data which suggested 
that ototoxicity was produced by wild type and immunopurified wild type S.pneumoniae type 
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Ill extracts, but not by ‘non-pneumolysin producing’ S.pneumoniae type III extracts 
(unpublished data Comis 1992). The lack of DTT treatment in previous experiments, could 
have been responsible for the lack of activity of the mutant extract. If this were the case it 
would imply that the novel ototoxic factor is thiol-activated. Alternatively, since the protein 
concentration of the pneumococcal extracts was not reported in the previous study, the 
concentration of an ototoxic factor in that extract may have been insufficient to produce 
ototoxicity. Either explanation is supported by the data from perfiisions of ‘non-pneumolysin 
producing’ mutant extract from batch I which was neither concentrated nor DTT-treated and 
was less consistent at producing ototoxicity than the concentrated and DTT-treated extract.
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CHAPTER 9
Characteristics Of Ototoxicity In Pneumococcus Type III
9.1 Electrophysiological Observations
A summary of the ototoxicity produced by batch II pneumococcal extracts is described below.
9.1.1 Wild Type Pneumococcal Extract
Perfusion of wild type pneumococcal bacterial extract (II) produced mean losses at 90 min of 50, 
51 and 31 dB in the 10, 5 and 3 kHz CAP respectively, and 15% in the CM. CAP losses occurred 
throughout the 90 min, however the rate of decline was greatest between 20 and 60 min. Greatest 
CM loss occurred between 60 and 90 min however losses in the CM did not reach significance in 
any animal. Similar CAP losses were seen at 10 and 5 kHz, however the 3kHz CAP losses were 
considerably smaller.
9.1.2 Immunopurified Wild Type Pneumococcal Extract
Perfusion of immunopurified wild type pneumococcal extract (II) produced mean losses at 90 min 
of 29, 24 and 15 dB in the 10, 5 and 3 kHz CAP respectively, and 12% in the CM. The rate of 
decline in the CAP was greatest between 40 and 90 min. Greatest CM loss occurred between 30 
and 50 min, however the losses did not reach positive levels in any animal. Similar CAP losses 
were seen at 10 and 5kHz, however the 3 kHz CAP losses were considerably smaller.
9.1.3 Mutant Pneumococcal Extract
Perfusion of mutant pneumococcal extract (II) produced mean losses at 90 min of 30, 25 and 22 
dB in the 10, 5 and 3 kHz CAP respectively, and 22% in the CM. The rate of decline in the CAP 
varied between animals and between frequencies. Animal 19 achieved most of its CAP loss within 
the first 20 min. Animal 20 showed similar timing in CAP loss at 3kHz, but a more gradual loss in 
the 10 and 5 kHz CAPs in which greatest losses were between 60 and 90 min. Greatest CM losses 
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were seen between 30 and 60 min, however the losses did not reach positive levels in either 
animal. Similar CAP losses were seen at all frequencies.
9.1.4 Electrophysiological Observations: Conclusions
• Ototoxicity produced by all pneumococcal extracts (II) involved CAP losses despite no loss in 
the CM. Therefore the ototoxicity was due to an effect on either the inner hair cells, afferent 
synapses and/or afferent neurons, whilst the outer hair cells were relatively unaffected.
• · All extracts (II) produced some positive CAP loss at all frequencies tested, therefore the 
ototoxicity produced by each extract (II) affected a considerable portion of the cochlea. In 
some extracts (II), loss in the 3kHz CAP was considerably less than seen in the 10 and 5kHz 
CAP, this may be due to the greater number of contributing fibres to the CAP at this frequency 
and hence loss of activity in a small number of fibres would have little affect on the CAP. . In 
addition smaller CAP losses displayed at 3 kHz may have been a result poor penetration of the 
extract to the apex of the cochlea.
• The ototoxicity produced by extracts (II) which did not contain free pneumolysin more often 
involved greatest losses in the CAP in the later half of the experiment, whereas wild type 
extract (II) containing free pneumolysin produced greatest losses in the first half of the 
experiment. This may represent a difference in the rate of intoxication of the two ototoxins. 
Pneumolysin produces greatest losses in the first 10 min following perfusion (Comis et al. 
1993). The potential ‘novel pneumococcal ototoxin’ may produce ototoxicity which is slower 
in action and therefore responsible for later CAP losses as displayed in animals treated with 
extracts (II) with free pneumolysin absent.
• The results presented here are not consistent with previous preliminary studies in which the 
ototoxicity produced by both unpurified (pneumolysin containing) and purified wild type 
pneumococcal extracts was similar (as judged by CAP losses) and was relatively slow in onset 
(majority of the CAP loss after 20-3 Omin). This difference is unlikely to due to concentration 
differences, because even at low concentrations pneumolysin-mediated effects are fast (Comis 
et al. 1993). However, it could have been because the wild type extracts used previously were 
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not DTT-treated and so pneumolysin present in the unpurified extract may have been 
inactivated by oxidation.
9.2 Morphological Observations
9.2.1 Wild Type Pneumococcal Extract
Scanning Electron Microscopy (SEM) examination of the cochleae treated with wild type 
pneumococcal extracts (II) (animals 9-13) was very difficult to achieve because the cochleae were 
damaged during the preparation for examination. Treated cochleae were more readily damaged 
than control (right) cochleae which had undergone identical preparation. Therefore it could be 
argued that the pneumococcal extract contributed to this damage. In an attempt to lessen the 
damage to the cochlea by this extract, and thus enable examination by SEM, animal 7 was killed at 
30 min. Examination of this cochlea by SEM was achieved and revealed several types of damage. 
Animal 7 displayed high initial auditory thresholds, which may indicate some pre-existing cochlear 
damage. However, the right cochlea displayed no damage, and the damage seen was characteristic 
of that associated with pneumolysin-mediated ototoxicity. Therefore it is likely that the damage 
seen is representative of damage evoked by perfusion of the extract (II) rather than pre-existing 
damage. Large craters were present in the supporting cells between outer hair cells of all rows 
(Plate 9i). Large swellings were also seen in these supporting cells which may well represent a 
prerequisite to crater formation (Plate 9ii). Similar swelling was seen in some inner hair cells. 
There was evidence of damage to stereocilia of inner hair cells and outer hair cells in all three 
rows. Stereocilial damage included breakage of linkages between stereocilia and collapse of 
stereocilia (Plates 9iii & iv).
Transmission Electron Microscopy (TEM) examination of cochleae from animals treated with 
neat wild type pneumococcal bacterial extract (II) revealed a specific pattern of damage. The most 
striking and consistent damage was seen to the mitochondria of the nerve terminals at the base of 
the inner hair cells and in the base of the outer hair cells. Mitochondria were swollen, empty or 
ruptured. In addition, membranes of the nerve terminals at the base of the inner hair cells were 
damaged, and the cytoplasmic contents of the outer hair cells were thin or absent in patches.
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Plate 9i. High power SEM of the OHCs and supporting cells of the left cochlea 
from animal 7 treated with neat wild type pneumococcal extract (II). Large craters 
are seen in the supporting cells between outer hair cells (C). Magnification x 4500.
Plate 9ii. High power SEM of the OHCs and supporting cells of the left cochlea from 
animal 7 treatea with neat wild type pneumococcal extract (II). Large swellings are 
seen in the supporting cells between outer hair cells (S), as well as cratering between 
adjacent outer hair cells (C). Magnification x 6000.
Plate 9111. Low power SEM of the left cochlea from animal 7 treated with neat 
wild type pneumococcal extract (II) showing some splaying (s) of the stereocilia of 
IHCs and some OHCs of all 3 rows. Magnification x 1200.
Plate 9iv. High power SEM of an OHC from the left cochlea of animal 7 treated with 
neat wild type pneumococcal extract (II). Some stereocilia have lost their rigidity and 
collapsed, and there is a tear (T) in the apical surface of the adjacent supporting cell. 
Magnification x 12000.
9.2.2 Immunopurified Wild Type Pneumococcal Extract
SEM examination of cochleae treated with immunopurified wild type pneumococcal bacterial 
extract (II) revealed some damage to the organ of Corti, however this damage was neither 
consistent between animals, nor consistent with CAP losses. In animal 11 there was some damage 
to the inner hair cells at the base of the cochlea. The stereocilia of these inner hair cells were often 
splayed or detached and in some cases showed a thinning in diameter at their base (Plate 9v). In 
addition many of the adjacent supporting cells contained craters. There was also some evidence of 
damage to the outer hair cells at the apical end of the organ of Corti which involved splaying of 
the stereocilia and tearing of the adjacent supporting cell surface. Cochleae from animals 12 and 
13 revealed no morphological damage.
9.2.3 ‘Non-pneumolysin producing’ Mutant Pneumococcal Extract
SEM examination of cochleae treated with mutant bacterial extract (II) revealed some damage in 
animal 16, but not in animal 15. In animal 16, there was some patchy damage to the stereocilia of 
inner hair cells and outer hair cells of all three rows. Stereocilia were often splayed, fused 
together, and/or detached (Plate 9vi).
9.2.4 DTT-treated BSA
SEM examination of cochleae treated with DTT-treated BSA revealed no damage to the organ of 
Corti.
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Plate 9v. High power SEM of IHCs from the left cochlea of animal 11 treated with 
immunopurified pneumococcal extract (II). Stereocilia of the IHCs are splayed (S) 
and are thinner at their base, and there are craters in the supporting cells (C).
Magnification x 6000
Plate 9vi. Low power SEM of the left cochlea from animal 16 treated with 
mutant pneumococcal extract (II) showing splaying (s) of the stereociha of 
IHCs and OHCs of rows 2 and 3. Magnification x 2250
9.2.5 Morphological Data: Conclusions
From the limited data tentative conclusions can be drawn concerning the morphological damage 
produced by each extract.
• Wild type pneumococcal bacterial extract (II) produced some swelling and cratering in the 
supporting cells of the organ of Corti along with splaying and detachment of stereocilia of 
inner and outer hair cells. However this result is from one animal.
• Immunopurified wild type pneumococcal bacterial extract (II) produced some cratering to 
supporting cells and splaying or detachment of stereocilia similar to that seen in cochleae 
treated with the unpurified wild type extract. However the results were not consistent between 
animals.
• Mutant bacterial extract (II) produced some patchy damage which was limited to stereocilia. 
Splaying, detachment and fusing of stereocilia of outer and inner hair cells was observed. 
However the results were not consistent between animals.
• In summary, the wild type extract (II) may have produced severe damage to the organ of Corti 
which prevented examination by SEM. The kind of damage that this extract (II) produced 
probably involved cratering of supporting cells which led to the widespread damage during 
SEM preparation. Immunopurified extract (II) produced moderate damage to the organ of 
Corti similar to that seen in wild type extract (II) treated cochlea after 30 min. Mutant extract 
(II) produced some damage to the organ of Corti, but considerably less severe than that 
observed in both purified and non purified wild type extracts (II) .
• TEM examination of cochleae treated with wild type pneumococcal extract revealed striking 
damage to the mitochondria of the nerve endings to the inner hair cells, and in the base of the 
outer hair cells. Therefore, cochleae treated with immunopurified and mutant extracts which 
revealed no morphological damage by SEM, despite positive CAP losses, may have similar 
underlying mitochondrial damage which cannot be seen using the SEM technique.
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CHAPTER 10
Excitotoxicity Within The Cochlea
Excitatory amino acids, nitric oxide (NO) and reactive oxygen species (ROSs) are all ototoxic in 
the cochlea (Eybalin 1993; Amaee et al. 1997 and Clerici and Yang 1996), and have been 
implicated in the deleterious outcomes that are associated with bacterial meningitis (reviewed in 
Pfister et al. 1994 and Miltstien, Sakai, Brew et al. 1994). Therefore they may be involved in 
meningogenic hearing losses. The relationship between the ototoxicity produced by all three is not 
clear. We have recently reported that either inhibition of nitric oxide synthase (NOS), or 
scavenging for superoxide considerably attenuates the excitotoxicity evoked by perfusion of N- 
methyl-D-aspartate (NMDA) into cochleae (Amaee et al. 1997). Therefore it seems likely that 
excitotoxicity mediated by NMDA receptors within the cochlea is at least in part mediated by NO 
and superoxide (a ROS). Despite reports of NO and ROSs as mediators of excitotoxicity 
produced by non-NMDA receptors in brain and retinal cells (Dutrait et al. 1995 and Schulz, 
Matthews, Jenkins et al. 1995), and the predominant role played by non-NMDA receptors in the 
evolution of excitatory damage, there is at present no experimental data to support or reject a 
similar relationship between NO or ROSs and non-NMDA mediated excitotoxicity in the cochlea. 
Therefore, the present study was carried out in order to investigate the potential role of NO and 
ROSs in the excitotoxicity mediated by non-NMDA receptors within the cochlea. Excitotoxicity 
was assessed by electrophysiological recordings and morphological examinations. To my 
knowledge this is the first work of this kind.
A total of 46 animals were used in the work described in this chapter; the initial auditory 
thresholds of these animals can be seen in Fig. 10. Five animals were excluded from statistical and 
summary data as they displayed initial auditory thresholds above the defined level. Animals were 
killed at several different time points in order to examine cochleae at various stages of 
excitotoxicity. However, for the purpose of statistical comparisons, all electrophysiological losses 








Figure 10. Threshold CAP values of all animals used in the work 
described in this chapter.
Red circles indicate thresholds above the defined level 
(50dB at 10 and 5kHz and 65dB at 3kHz), 
or well outside the normal distribution of the group.
Aims and objectives
1. To perfuse non-NMDA agonists quisqualate and kainate into scala tympani of guinea pig 
cochleae.
2. To pre-treat cochleae with nitric oxide inhibitors, or free radical scavengers prior to perfusion 
of quisqualate or kainate.
3. To measure electrophysiological recordings of the CAP and CM.
4. To carry out morphological investigations of treated cochleae.
10.1 Excitotoxicity Produced By Kainate and Quisqualate Alone
In order to establish the degree of excitotoxicity produced by excessive stimulation of the non- 
NMDA receptors, kainate (a selective agonist for kainate receptors) and quisqualate (a selective 
agonist for a-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) and metabotropic 
receptors) were tested for excitotoxicity in cochleae which had not been pre-treated. Although 
quisqualate does not discriminate between AMPA and metabotropic receptors, it was felt that the 
most rapid and least costly approach would be to investigate excitotoxicity produced by 
quisqualate first, and then to proceed to more selective agonists (e.g. AMPA) if the results were 
found to be positive. Previous reports of electrophysiological responses in guinea pig cochleae to 
cumulative doses of these agonists demonstrate a steep slope in the electrophysiological responses 
to increasing doses of kainate and quisqualate (Bledsoe, Bobbin and Chihal 1981; Jenison, 
Winbery and Bobbin 1986). Since these reports were from cumulative doses of both agonists, the 
electrophysiological responses may have been enhanced, particularly in the case of kainate because 
of its inability to produce desensitisation in other cells (Kiskin, Krishtal and Tsyndrenko 1986). 
Therefore supra maximal doses were used initially in order to achieve positive CAP losses (as 
defined in Chapter 3) from single perfusions.
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10.1.1 lOmM Kainate 
lOmM kainate was perfused into cochleae of animals 1 and 2 (Table 10.1.1; Fig.10.1.1) and 
produced large CAP losses at all frequencies in both animals. At 30 min, 10kHz CAP losses were 
68 and 89 dB in animals 1 and 2 respectively. Positive CM losses were not displayed by either 
animal.
Table 10.1.1 : Electrophysiological losses evoked by perfusion 





Animal 1 Animal 2















Threshold CAPs (dB) and Peak CM (mV)
20 13 41 0.13 -4 -10 36 0.23
Loss in CAPS (dB' or CM (% control)
1 72 72 64 17 83 93 - -9
5 70 71 64 17 89 94 - -6
10 70 71 64 19 89 93 - -6
30 68 68 64 17 89 93 - -6
10.1.2 100p,M Kainate
In an attempt to produce a less potent degree of kainate mediated excitotoxicity, 100pM kainate 
was perfused into cochleae of animals 3, 4, 5 and 6 (Table 10.1.2; Fig.10.1.2), Data from animal 
6 are included in Table 10.1.2 and Fig.10.1.2, but have been excluded from statistical and 
summary data as the animal displayed initial auditory thresholds above the defined level. Positive 
CAP losses were displayed by animals 4, 5, and 6, but not by animal 3. At 30 min, 10kHz CAP 
losses were 14, 22, 21 and 27 dB in animals 3, 4, 5 and 6 respectively. Positive CM losses were 






















■ Animal 1 · Animal 2
Figure 10.1.1. Losses in the CAP and CM in two animals treated with 
10mM kainate.
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss 
in the CM elicited with a 5kHz stimuli.
■ Animal 3 · Animal 4 ▲ Animal 5 ♦ Animal 6
Figure 10.1.2. Losses in the CAP and CM in four animals perfused with 
100gM kainate.
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, 
d) Loss in the CM elicited with a 5kHz stimuli.
Table 10.1.2 : Electrophysiological losses evoked by perfusion with 





Animal 3 Animal 4















Threshold CAPs (dB) and Peak CM (mV)
18 0 29 0.12 34 20 43 0.17
Loss in CAPs (dB) or CM (% control)
1 5 1 1 2 21 21 - 0
5 9 8 1 0 31 62 - 0
10 14 11 1 0 23 40 - 0





Animal 5 Animal 6















Threshold CAPs (dB) and Peak CM (mV)
22 2 37 0.1 54 25 47 0.23
Loss in CAPs (dB) or CM (% control)
1 0 -2 -7 14 11 65 - 1
5 18 17 7 17 41 65 - 1
10 20 20 9 21 32 62 - 1
30 21 23 17 21 27 59 - 2
10.1.3 Quisqualate
lOmM quisqualate was tested for excitotoxicity in animals 7, 8, 9 and 10 (Table 10.1.3; 
Fig.10.1.3), Data from animal 7 is included in Table 10.1.3 and Fig. 10.1.3, but has been excluded 
from statistical and summary data as the animal displayed initial auditory thresholds outside the 
defined range. Positive CAP losses were displayed by all 4 animals, at all frequencies recorded. At 
30 min, 10kHz CAP losses were 22, 26, 55 and 45 dB in animals 7, 8, 9 and 10 respectively. 
Positive CM losses were not displayed by any animal.
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0 30 0 30
Time (min) Time (min)
♦ Animal 7 ■ Animal 8 ▲ Animal 9 · Animal 10
Figure 10.1.3. Losses in the CAP and CM in four animals perfused with 
10mM quisqualate.
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, 
d) Loss in the CM elicited with a 5kHz stimuli.
Table 10.1.3 : Electrophysiological losses evoked by perfusion 





Animal 7 Animal 8















Threshold CAPs (dB) and Peak CM (mV)
73 68 84 0.06 6 15 30 0.18
Loss in CAPs (dB) or CM (% control)
1 22 22 21 23 57 46 - 0
5 22 22 21 59 44 66 - -12
10 22 22 21 18 44 67 - -8





Animal 9 Animal 10















Loss in CAPs (dB) or CM (% control)
15 -10 28 0.22 27 19 44 0.12
Loss in CAPs (dB or CM (% control)
1 28 69 - 5 42 35 39 3
5 35 69 • 5 21 24 23 3
10 50 95 - 6 21 24 18 -3
30 55 98 - 7 45 38 47 6
10.1.4 Excitotoxicity Produced by Kainate and Quisqualate Alone: 
Summary and Conclusions
Average losses in CAPs and CMs produced by perfusions of kainate and quisqualate are 
summarised in Table 10.1.4.
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Table 10.1.4 : Average 30 min losses in CAPs and CMs produced by lOmM and 
100pM kainate (KA), and 10mM quisqualate (QA).
Positive losses are bold.
Treatment Average losses (± SD) in CAPs (dB) or CM (%) 
______ at 30 min post perfusion
10 kHz CAP 5 kHz CAP 3kHz CAP CM
10mMKA(n=2) 78 ±15 80 ±18 64 5±16
100pMKA(n=3) 19±4 20 ±8 16±5 6±13
10mM QA (n=3) 42 ±15 58 ± 35 42 ±6 3±6
Conclusions
• lOmM kainate produced potent excitotoxicity (as judged by CAP losses >40dB) in the guinea 
pig cochlea. There was evidence for moderate excitotoxicity (as judged by CAP losses >20dB) 
produced by 100pM kainate, however this was not seen in one animal. lOmM quisqualate 
produced excitotoxicity in the guinea pig cochlea which was either moderate or potent (as 
judged by CAP losses of20-40 or >40dB respectively).
• lOmM kainate often reduced the CAP to an extent that a threshold response (i.e. 2mV on the 
screen) could not be produced by the maximum stimulus intensity (95-105dB dependent on 
frequency see Chapter 2 for details). Therefore the calculated CAP loss was highly dependent 
on the initial threshold values. lOmM quisqualate and 100pM kainate did not reduce the CAP 
to this extent and so produced excitotoxicity which was less dependent on the size of the initial 
threshold values. For this reason, 100pM, rather than lOmM concentration was used to assess 
the degree of excitotoxicity produced by kainate in all further experiments. However, lOmM 
kainate was perfused on some occasions when this was deemed relevant.
• The results presented here appear to be consistent with previous studies. Jenison et al. (1986) 
reported maximal responses of 67 and 100% suppression of the CAP reached at approximately 
25 and 110 pM concentrations of quisqualate and kainate respectively. This would imply that 
lOmM doses are supramaximal doses and should produce similar suppression. Jenison et al. 
(1986) measured suppression as the average reduced size of the CAP over a range of 
intensities. This cannot be compared with my data which is presented as losses in dB.
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However, Bledsoe et al. (1981) reported a complete elimination of the 10kHz CAP at all 
intensities (20-100dB) by kainate at 250pM and ImM, loss of between 50 and 60dB at 
lOOpM, and no loss in the CAP at 1, 25 and 50gM. These results are comparable with mine in 
which lOmM kainate either eliminated or nearly eliminated (within 5dB) all CAPs at all 
intensities (-5-105dB), and lOOpM kainate produced a maximum of 31dB hearing loss. The 
CAP losses from my data appear to be smaller, but this is likely to be because Bledsoe et al. 
(1981) used cumulative doses. Since responses to kainate in brain tissues show no 
desensitisation (Kiskin et al. 1986), this may be the case in the cochlea too which would 
explain greater CAP losses as a result of cumulative doses of kainate. I have found no other 
reports of CAP losses in response to quisqualate which are directly comparable.
10.1.5 Morphological Examinations
10.1.5.1 lOmM Kainate
Cochleae treated with lOmM kainate revealed widespread damage to the base of the inner hair cell 
and surrounding structures. Nerve terminals at the base of the inner hair cells were absent, as was 
the base of the inner hair cells themselves. Outer hair cells showed very little damage, although the 
contents of the efferent terminals at the base of the outer hair cells were more dense than in 
control cochleae, and there was some membrane damage in these efferent nerve endings. There 
was little or no sign of mitochondrial damage (Plates lOi & ii).
10.1.5.2 100pM Kainate
Cochleae treated with lOOpM kainate revealed very little sign of morphological damage. There 
was some evidence of mitochondrial damage within afferent nerve terminals at the base of the 
inner hair cells, and some evidence of membrane damage at the afferent neuron-inner hair cell 
synapse. However, the damage was not widespread (Plate lOiii).
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Plate lOi. Inner hair cell of the left cochlea from animal 2 treated with 
lOmM kainate. Extensive damage to the inner hair cell (IHC) and surrounding 
Structures. Magnification x 4100
Plate lOii. Outer hair cells of the left cochlea from animal 2 treated with 
lOmM kainate. Outer hair cells (OHCs) are mostly unaffected. The efferents 
at the base of the outer hair cells appeal' to be slightly more dense than in control 
cochleae. Magnification x 3000
IHC
Plate lOiii. Afferent nerve endings at the base of an inner hair cell of the left 
cochlea from animal 4 treated with lOOuM kainate. A small amount of 
mitochondrial (M) damage can be seen to the afferent nerve endings (NEs) at the 
base of the inner hair cell (IHC). Magnification x 17400
10.1.5.3 lOmM Quisqualate
Cochleae treated with lOmM quisqualate revealed widespread damage to the afferent nerve 
terminals at the base of the inner hair cells with some associated damage to surrounding 
structures. The contents of the nerve terminals at the base of the inner hair cells were often absent, 
as was the base of the inner hair cells and supporting cells. Many mitochondria of surrounding 
nerve terminals were empty or swollen. Outer hair cells showed very little damage, although the 
contents of the efferent terminals at the base of the outer hair cells were more dense than in 
control cochleae and showed some indications of membrane damage (Plates lOiv-vi).
10.1.5.4 Morphological Examinations : Conclusions
• 10mM kainate and lOmM quisqualate produced qualitatively similar morphological damage 
which was specific to the afferent nerve terminals of the inner hair cells. However, kainate 
produced more extensive damage than quisqualate. 100pM kainate produced veiy little 
morphological damage which was limited to mitochondrial and membrane damage at the base 
of the inner hair cells. The degree of morphological damage was consistent with the extent of 
CAP losses.
• Therefore, it appears that the primary target of excitotoxicity produced by both these agonists 
is the afferent nerve terminals of the inner hair cells, which then extends to surrounding 
structures, most likely by release of their contents. Since 100p.M kainate revealed only 
mitochondrial and membrane damage, this may represent the early stages in afferent nerve 
terminal damage.
• These results are consistent with previous data concerning kainate excitotoxicity. 
Morphological examinations by Pujol, Lenow, Roberts et al. (1985) following perfusion of 
500pM kainate revealed swelling of most afferent nerve terminals at the base of the inner hair 
cells without any damage to the hair cells themselves. Their dose response was consistent with 
my data since morphological damage was less extensive than that produced by lOmM kainate 




Plate 101V. Inner hair cell of the left cochlea from animal 10 treated with 
lOmM quisqualate. Striking swelling to the nerve endings (NEs) at the base 
of the inner hair cell (IHC). Magnification x 4100
Plate lOv. Inner hair cell of the left cochlea from animal 9 treated with 
lOmM quisqualate. Swelling of the nerve endings (NEs) at the base of the inner 
hair cell (IHC) and associated damage to the IHC, supporting cell (SC) and 
reticular lamina (RL). Magnification x 4100
Plate lOvi. A row 3 outer hair cell of the left cochlea from animal 9 treated 
with lOmM quisqualate. Efferent nerve endings (Es) at the base of the outer hair 
cell appear to be more dense than in control cochleae, and there is some damage to 
the mitochondria (M) and membrane (m). Magnification x 22000
• To my knowledge there are no reports of morphological damage produced by quisqualate in 
cochleae in vivo. There have been reports from in vitro studies of the effect of quisqualate on 
cultures of spiral ganglion neurons of the cochlea. Lefebvre, Weber, Leprince et al. (1991) 
reported no neuronal loss within 24h; but their results were not conclusive. Experiments using 
50 and lOOpM AMP A produced afferent swelling in cochleae with no accompanying damage 
to the hair cells themselves at both concentrations. At lOOpM concentration, AMP A 
eliminated the CAP, whereas 40 and 80 pM concentrations produced approximately 30 and 50 
dB losses (Puel, Pujol, Ladrech et al. 1991). Hence, 40-80 pM AMP A produced similar CAP 
losses to that seen here with lOmM quisqualate and produced a similar extent of 
morphological damage. Therefore although the two agonists cannot be directly compared, the 
data appear to be consistent.
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10.2 Effect Of Pre-treatment Of Cochleae With Nitric Oxide 
Synthase (NOS) Inhibitors On The Degree Of Excitotoxicity 
Produced By Quisqualate And Kainate.
10.2.1 Pre-treatment with Nitro-L-arginine methyl ester (L-NAME) 
50mM L-NAME was perfused into cochleae prior to perfusion of kainate and quisqualate in order 
to determine whether inhibition of NOS protects cochleae against excitotoxicity produced by these 
non-NMDA agonists. L-NAME was used as hitherto it has been the most commonly used 
research NOS inhibitor; its effects have been established in many tissues including the cochlea. 
Previously round window application of 37 and 370 mM L-NAME had been shown to produce 
effects which are associated with NOS inhibition (e.g. increase in cochlear blood flow) without 
any losses to the auditory thresholds (Brechtelsbauer, Nuttal and Miller 1994). Since this method 
depends upon diffusion across the round window membrane, a concentration of 50mM (which is 
within the 37-371mM range, but towards the lower end) was used to pre-treat cochleae.
10.2.1.1 L-NAME control
50 mM L-NAME was perfused into cochleae of 8 animals (Table 10.2.1.1; Fig. 10.2.1.1) in order 
to determine whether L-NAME itself produced any affects on cochlear potentials. Positive CAP 
losses were displayed by animals 12, 13, 14, 15, 16 and 17, but not by animals 11 and 18. There 























• Animal 12 A Animal 13 ♦ Animal 14
►Animal 16 •¡•Animal 17
Figure 10.2.1.1. Losses in the CAP and CM in five of the eight animals 
treated with 50mM L-NAME (data is only presented from animals which 
had positive losses at 90 min).
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss 
in the CM elicited with a 5kHz stimuli.
Table 10.2.1.1 : Electrophysiological losses evoked by perfusion with 50mM L-NAME in 





Animal 11 Animal 12 Animal 13





















Threshold CAPs (dE!) and Peak CM (mV)
17 9 39 0.14 18 7 27 0.14 7 -10 22 0.13
Loss in CAPs (dB' or CM (% control)
1 19 18 14 -3 7 -3 3 5 63 68 51 9
5 14 7 4 0 9 -3 3 5 41 45 30 16
10 3 3 4 0 9 -3 1 -3 39 38 53 12
30 5 4 2 15 13 5 2 12 28 30 26 19
60 9 2 2 20 18 14 - 17 26 31 30 19





Animal 14 Animal 15 Animal 16





















Threshold CAPs(dEI) and Peak CM (mV)
24 5 37 0.14 15 -10 58 0.09 9 -6 28 0.10
Loss in CAPs (dB or CM (% control)
1 14 - 12 - 40 62 13 - 21 -4 -2 5
5 4 28 6 - - - - - 1 -4 2 2
10 - - - 15 46 62 3 -20 4 -4 2 9
30 24 27 10 10 19 8 -3 16 16 -4 1 19
60 22 27 10 10 18 8 7 -36 - - - -





Animal 17 Animal 18













0 Threshold CAPs (dB) and Peak CM (mV) __
(control) 36 12 32 0.12 40 43 - 0.19
Loss in CAPs (dB' or CM (% control)
1 -4 -11 -2 6 27 7 - -6
5 • • - - 0 5 - -2
10 9 7 5 - -7 -2 - -2
30 18 12 7 0 -10 -5 - 6
60 21 21 6 • -8 -5 - 11
90 27 28 13 -18 -7 -3 - 18
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Conclusions
L-NAME produced some ototoxicity in the guinea pig cochlea. However the results were not 
consistent between animals. Therefore, in all subsequent pre-treatment experiments using L- 
NAME, perfusions of quisqualate and kainate were not carried out until CAPs had reached a 
steady level (as judged by more than 2 recordings within 5dB of each other). This method was 
adopted since it allowed more accurate judgement of the significance of losses produced by 
kainate and quisqualate. The approach is justified since the in vivo effects of L-NAME in the brain 
have been reported to remain maximal up to 6 h post administration if introduced directly into the 
CNS (Salter, Duffy, Garthwaite, and Strijbos 1995). Therefore inhibition of NOS should be 
effective throughout the experiments described hereafter.
10.2.1.2 lOOpM Kainate following L-NAME Pre-treatment
lOOpM kainate was perfused into cochleae of animals 15, 19 and 20 which had been pre-treated 
with L-NAME (Table 10.2.1.2; Fig. 10.2.1.2), Data from animal 20 are included in Table 
10.2.1.2 and Fig. 10.2.1.2, but are excluded from statistical and summary information as the pre­
perfusion thresholds (post L-NAME) were below the defined range for initial auditory thresholds. 
Positive CAP losses were displayed by animals 19 and 20, but not by animal 15. CAP losses in 
animal 20 were transient. At 30 min, 10kHz CAP losses were 2, 33 and 10 dB in animals 15, 19 
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- O 80 -
-------------------------------------- ------- 2100 ----------------------------------------------
0 Time (min) 30 0 Time (min) 30
■ Animal 3 ▲ Animal 4 · Animal 5 
♦ Animal 15 X Animal 19 ▼ Animal 20
Figure 10.2.1.2. Losses in the CAP and CM in six animals treated with 100|iM 
kainate, three pretreated with 50mM L-NAME (BLUE), and three not pretreated 
(RED).
a-c) Losses in the CAP elicited with 10. 5 and 3kHz stimuli respectively, d) Loss in the
CM elicited with a 5kHz stimuli.
Table 10.2.1.2 : Electrophysiological losses evoked by perfusion with 100pM kainate in 





Animal 15 Animal 19 Animal 20





















Pre-perfusion CAPs (dB) and Peak CM (mV) (i.e. post L-M AME)
25 -10 43 0.08 32 -5 52 0.10 56 32 52 0.21
Loss in CAPs (dB or CM (% control)
1 -3 0 -3 22 13 35 6 0 5 43 - 6
5 0 0 3 25 39 70 - -6 25 46 - 6
10 0 0 -3 20 39 70 - -6 24 43 - 6
30 2 0 2 14 33 61 - 9 10 12 19 2
10.2.1.3 . lOmM Kainate following L-NAME Pre-treatment
Since it appeared that L-NAME may have afforded some protection on cochleae from lOOpM 
kainate, its ability to protect cochleae from the action of lOmM kainate was investigated. lOmM 
kainate was perfused into cochleae of animals 21 and 22 which had be pre-treated with L-NAME 
(Table 10.2.1.3; Fig. 10.2.1.3) and produced large CAP losses at all frequencies in all animals. At 
30 min, 10kHz CAP losses were 71, and 44 dB respectively. Positive CM losses of 84% were 
displayed by animal 21 but not by animal 22.
Table 10.2.1.3 : Electrophysiological losses evoked by perfusion 
with 10mM kainate in two animals which had been pre-treated with 





Animal 21 Animal 22



















Peak CM (mV) 
E)
19 12 36 0.13 25 22 43 0.12
Loss in CAPs (dB) or CM (% control)_______
1 59 56 52 78 44 52 62 12
5 61 56 64 73 45 55 60 9
10 58 54 69 62 45 56 62 12





















■ Animal 1 •Animal 2 < Animal 21 ▲ Animal 22
d
Figure 10.2.1.3. Losses in the CAP and CM in four animals treated with 10mM 
kainate, two pretreated with 50mM L-NAME (BLUE), and two not pretreated (RED).
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the
CM elicited with a 5kHz stimuli.
10.2.1.4 lOmM Quisqualate following L-NAME Pre-treatment
lOmM quisqualate was perfused into cochleae of animals 23 and 24 which had been pre-treated 
with L-NAME (Table 10.2.1.4; Fig. 10.2.1.4) and produced positive CAP losses in both animals. 
At 30 min, animal 23 lost 64dB at 10 and 5kHz, and animal 24 lost 65 dB at 5kHz. There were no 
positive CM losses.
Table 10.2.1.4 I Electrophysiological losses evoked by perfusion 
with 10mM quisqualate in two animals which had been pre-treated 





Animal 23 Animal 24













0 Pre-perfusion T 
(m'
ireshold CAPs (dB) and Pea 
/) (i.e. post L-NAME)
kCM
(control) 16 9 35 0.10 23 25 48 0.22
Loss in CAPs (dB’ or CM (% control)
1 14 -2 0 -16 52 65 - -17
5 29 11 8 -21 50 65 - -13
10 67 36 18 -14 33 65 - -13
30 64 64 18 -14 17 65 - -7
10.2.1.5 Pre-treatment with L-NAME ¡Summary and Conclusions
30 min CAP and CM losses produced by perfusion of quisqualate and kainate into cochleae with 












0 Time (min) 30
■ Animal 8 ▲ Animal 9 · Animal 10
d
♦ Animal 23 X Animal 24
Figure 10.2.1.4. Losses in the CAP and CM in five animals treated with 10mM 
quisqualate, two pretreated with 50mM L-NAME (BLUE), and three not pretreated 
(RED).
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the
CM elicited with a 5kHz stimuli.
Time (min)
Figure 10.2.1.5. Average (± S.D) 10kHz CAP losses produced by perfusion of 
kainate and quisqualate with (■) and without(·) pretreament with 50mM L-NAME.











Figure 10.2.1.5. Continued. Average (± S.D) 10kHz CAP losses produced 
by perfusion of kainate and quisqualate with (■) and without(·) pretreament 
with 50mM L-NAME.
a) 100iiM kainate b) 10mM kainate c) 10mM quisqualate
Table 10.2.1.5 . Average 30 min losses in CAPs and CMs produced by perfusion 
with 10mM and 100pM kainate (KA) and 10mM quisqualate (QA) with or without prior 
perfusion of L-NAME (+/- respectively). Positive losses are bold.
Treatment Average losses (± SD) in CAPs (dB) or CM (%) 
__ at 30 min post perfusion
10 kHz CAP 5 kHz CAP 3kHz CAP CM
10mMKA - L-NAME (n=2) 78 ±15 80 ±18 64 5 ±16
WmMKA + L-NAME (n=2) 58 ±19 65 ±18 65 ±6 51 ±47
100pM KA-L-NAME (n=3) 19±4 20 ±8 16±5 6±13
100pM KA + L-NAME (n=2) 18 ±22 30 ±43 2 12±3
10mM QA - L-NAME (n=3) 42 ±15 58 ±35 42 ±6 3±6
10mM QA + L-NAME (n=2) 40 ±33 64±1 18 -11 ±5
Conclusions
• There was evidence of excitotoxicity produced by lOmM kainate and lOmM quisqualate 
despite pre-treatment of cochleae with L-NAME. There was some evidence of excitotoxicity 
produced by lOOpM kainate despite pre-treatment with L-NAME, however the results were 
not consistent between animals.
• Statistical analysis of the 10kHz CAP results indicates that were no significant differences 
between the data from pre-treated and non-pre-treated cochleae perfused with lOmM kainate, 
lOOpM kainate and lOmM quisqualate with respect to treatment alone (p= 0.2, 0.95 and 0.6 
respectively), or the change in the CAP with time (p= 0.7,0.98 and 0.1 respectively).
• Therefore L-NAME provided no protection on cochleae from the effects of kainate and 
quisqualate at the concentrations used.
10.2.2 Pre-treatment with L-Methyl arginine (L-MA)
Since L-MA had previously been reported to protect cochleae from several ototoxic insults 
(Amaee et al. 1997), the hypothesis that NOS inhibition may protect cochleae against the action 
of quisqualate and kainate was further examined by pre-treatment of cochleae with L-MA. L-MA 
is an inhibitor of NOS but is less potent at inhibiting nNOS than L-NAME (Korytko and Boje 
1996). 50mM concentration was used because this was the concentration at which the compound
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afforded protection to cochleae against the action of NMDA and pneumolysin (Amaee et al. 
1997).
10.2.2.1 L-MA control
In order to assess whether L-MA itself produced similar ototoxicity to L-NAME, 50 mM L-MA 
was tested for ototoxicity in 9 animals (Table 10.2.2.1; Fig. 10.2.2.1), Data from animals 25 and 
26 are included in Table 10.2.2.1 and Fig. 10.2.2.1, but have been excluded from statistical and 
summary information as the animals displayed initial auditory thresholds outside the defined range. 
Positive CAP losses were displayed by animals 25, 27, 28, 30, 31, 32 and 33, but not by animals 
26 and 29. The CAP losses were transient in animals 25, 30 and 32 with no positive CAP losses at 
60 min. Positive CM loss was displayed by animal 25 only, although animal 27 displayed positive 
increases in the size of the CM.
Conclusions
• L-MA produced some excitotoxicity in the guinea pig cochlea. However the results were not 
consistent between animals. Therefore, in all pre-treatment experiments using L-MA, 
perfusions of quisqualate and kainate were not carried out until CAPs had reached a steady 
level (as judged by more than 2 recordings within 5dB of each other). This method was 
adopted since it allowed more accurate judgement of the significance of losses produced by 
kainate and quisqualate and was justifiable since the in vivo effects of L-MA have been 
reported to be irreversible (Korytko and Boje 1996). Therefore it is highly likely that inhibition 
































♦ Animal 27 ►Animal 28 
▼ Animal 31 ▲ Animal 33
Figure 10.2.2.1. Losses in the CAP and CM in four out of nine animals 
treated with 50mM L-MA (data is only presented from animals which 
displayed positive losses at 60 min).
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss 
in the CM elicited with a 5kHz stimuli.
Table 10.2.2.1 : Electrophysiological losses evoked by perfusion with 50mM 





Animal 25 Animal 26 Animal 27





















Threshold CAPs (dB) and Peak CM (mV)
56 48 53 0.18 53 40 51 0.14 30 22 45 0.08
Loss in CAPs (dB' or CM (% control)
1 22 21 37 35 12 11 - -5 37 42 60 -21
5 19 21 35 30 12 13 - -8 33 42 60 -25
10 19 20 37 41 7 8 14 -10 36 43 60 -25
30 10 10 12 33 2 1 4 -5 37 46 60 -46
60 11 9 11 37 -2 -2 -2 -5 27 43 60 -63





Animal 28 Animal 29 Animal 30





















Threshold CAPs (dEI) and Peak CM (mV)
29 19 43 0.06 37 22 45 0.05 25 -10 45 0.04
Loss in CAPs (dB' or CM (% control)
1 36 39 27 31 13 8 10 7 30 52 7 -18
5 14 21 15 19 -2 -2 3 7 10 30 0 -18
10 12 18 15 19 -2 1 3 14 8 18 -2 -18
30 21 23 18 12 1 -2 2 7 5 7 -2 -18
60 23 27 21 6 - - - - 5 10 0 0





Animal 31 Animal 32 Animal 33





















Threshold CAPs (dEI) and Peak CM (mV)
-5 -10 5 0.21 10 -10 5 0.09 20 -10 15 0.11
Loss in CAPs (dBJ or CM (% control)
1 75 83 - 8 47 60 65 15 35 63 53 16
5 48 60 - 5 36 53 44 15 24 36 21 16
10 30 45 - 5 27 46 40 0 20 28 24 19
30 46 58 • 10 15 22 20 7 - - - •
60 43 63 « 13 15 6 6 0 11 0 23 23
90 - - - - - - - - - - - -
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10.2.2.2 100 p.M Kainate following L-MA Pre-treatment
lOOgM kainate was perfused into cochleae of animals 25, 26, 27 and 28 which had been pre­
treated with L-MA (Table 10.2.2.2; Fig. 10.2.2.2), All animals tested displayed pre-perfusion 
(post L-MA) CAP thresholds outside the defined range for initial auditory thresholds, therefore 
data from this treatment group are interpreted with caution and will be bracketed when presented 
in statistical and summary information. Positive CAP losses were displayed by animal 27, but not 
by animals 25, 26 and 28. At 30 min, 10kHz CAP losses were 12, 15, 38 and 0 dB in animals 25, 
26, 27 and 28 respectively. There were no positive CM losses seen in any animal.
Table 10.2.2.2 : Electrophysiological losses evoked by perfusion 
with 100pM kainate in two animals which had been pre-treated with 





Animal 25 Animal 26



















:dB) and Pea 
MA)
kCM
(control) 67 57 64 0.10 51 38 49 0.15
Loss in CAPs (dB or CM (% control)
1 2 4 6 33 0 -2 0 -3
5 - 8 9 30 16 11 - -2
10 13 9 9 23 16 13 - -3





Animal 27 Animal 28





















(dB) and Pea 
MA)
kCM
57 67 - 0.14 52 46 64 0.06
Loss in CAPs (dB or CM (% control)
1 11 -1 - 9 -2 -1 -1 -14
5 38 23 - 15 0 -1 -2 -14
10 33 22 - 17 0 -1 -2 -14
30 38 23 - 17 0 4 1 -2
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10.2.2.3 lOmM Kainate following L-MA Pre-treatment
Since it appeared that L-MA may have afforded some protection on cochleae from 100pM 
kainate, experiments were repeated with lOmM kainate. lOmM kainate was perfused into cochleae 
of animals 29 and 30 which had been pre-treated with 50mM L-MA (Table 10.2.2.3; Fig. 10.2.3) 
and eliminated all CAPs in all animals. At 30 min, 10kHz CAP losses were 57 and 65 dB in 
animals 29 and 30 respectively. Positive CM losses were not seen in either animal
Table 10.2.2.3 : Electrophysiological losses evoked by perfusion 
with 10mM kainate in two animals which had been pre-treated with 





Animal 29 Animal 30


















nV) (i.e. post L-
(dB) and Pea 
MA)
kCM
38 20 47 0.05 I 30 0 45 0.04
Loss in CAPs (dB’ or CM (% control)
1 57 70 58 -31 65 90 60 3
5 57 70 58 -34 65 90 60 9
10 57 70 58 -31 65 90 60 16
30 57 70 58 -17 65 90 60 16
10.2.2.4 lOmM Quisqualate following L-MA Pre-treatment
lOmM quisqualate was perfused into cochleae of animals 31 and 32 which had been pre-treated 
with L-MA (Table 10.2.2.4; Fig. 10.2.2.4), Data from animal 32 are included in Table 10.2.2.4 
and Fig. 10.2.2.4, but have been excluded from statistical and summary information as the animal 
displayed pre-perfusion (i.e. post L-MA) auditory thresholds above the defined level. Positive 
CAP losses were displayed in both animals. At 30 min, 10kHz CAP losses were 24 and 27dB in 




















■ Animal 1 · Animal 2 ▲ Animal 29 ♦ Animal 30
Figure 10.2.2.3. Losses in the CAP and CM in four animals perfused with 10mM 
kainate, two pretreated with 50mM L-MA (BLUE), and two not pretreated (RED).
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, 



















0 Time (min) 30
■ Animal 8 ▲ Animal 9 · Animal 10
d
♦ Animal 31 X Animal 32
Figure 10.2.2.4. Losses in the CAP and CM in five animals treated with 10mM 
quisqualate, two pretreated with 50mM L-MA (BLUE), and three not pretreated 
(RED).
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 
CM elicited with a 5kHz stimuli.
Table 10.2.2.4 : Electrophysiological losses evoked by perfusion with 
10mM quisqualate in two animals which had been pre-treated with 50mM 





Animal 31 Animal 32


















nV) (i.e. post L-
¡dB) and Pea 
MA)
kCM
38 53 - 0.19 I 25 -4 11 0.09
Loss in CAPs (dB) or CM (% control)
1 52 37 - *4 20 19 9 11
5 40 36 - -2 23 19 8 15
10 37 27 - 0 23 24 12 10
30 24 9 - 2 27 28 13 19
10.2.2.5 Pre-treatment with L-MA ¡Summary and Conclusions
30 min CAP and CM losses produced by perfusion of kainate and quisqualate in cochleae with and 
without L-MA pre-treatment are summarised in Fig. 10.2.2.5 and Table 10.2.2.5.
Table 10.2.2.5 : Average 30 min losses in CAPs and CMs produced by perfusion 
with 10mM and 100pM kainate (KA) and 10mM quisqualate (QA) with or without prior 
perfusion of L-MA (+/- respectively). Positive losses are bold.
Treatment Average losses (± SD) in CAPs (dB) or CM (%) 
at 30 min post perfusion
Bracketed results are from animals with pre-perfusion 
thresholds above the defined level
10 kHz CAP 5 kHz CAP 3kHz CAP CM
10mMKA-L-MA (n=2) 78 ±15 80 ± 18 64 5±16
10mMKA+ L- MA (n=2) 61 ±6 80 ±14 59 ±1 -1 ±23
100pM KA - L-MA (n=3) 19±4 20 ±8 16±5 6±13
10OpM KA + L-MA (n=4) (16 ±16) (12 ±8) (7 ±8) (10 ±12)
10mM QA-L-MA(n=3) 42 ±15 58 ±35 42 ±6 3±6
10mM QA+L-MA(n=1) 27 28 13 19
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Figure 10.2.2.5. Average (± S.D) 10kHz CAP losses produced by perfusion of 
kainate and quisqualate with (■) and without(·) pretreament with 50mM L-MA.











Figure 10.2.2.5. Continued. Average (± S.D) 10kHz CAP losses produced 
by perfusion of kainate and quisqualate with (■) and without(·) pretreament 
with 50mM L-MA.
a) (WOuM kainate) b) 10mM kainate c) 10mM quisqualate
Conclusions
• There was evidence of excitotoxicity produced by lOmM kainate and quisqualate despite pre- 
treatment of cochleae with L-MA. There was some evidence of excitotoxicity produced by 
lOOpM kainate despite pre-treatment with L-MA, however the results were not consistent 
between animals, and all animals presented pre-perfüsion thresholds outside the defined range 
(i.e. all animals had positive existing hearing losses due to L-MA perfusions).
• Statistical analysis of 10kHz CAP losses by ANOVA demonstrated no significant differences 
between L-MA pre-treated and non pre-treated data from cochleae perfused with either lOmM 
kainate, lOOpM kainate or lOmM quisqualate with respect to treatment alone (p= 0.2, 0.8 and 
0.5 respectively), or the change in the CAP with time (p= 0.95,0.94 and 0.89 respectively).
• Therefore L-MA provided no protection on cochleae from the effects of kainate and 
quisqualate at the concentrations used.
10.2.3 Morphological Examinations
10.2.3.1. lOmM Kainate following L-NAME pre-treatment
Cochleae pre-treated with L-NAME and perfused with lOmM kainate revealed widespread 
damage to the base of the inner hair cell and surrounding structures similar to that seen in non-pre- 
treated cochleae.
10.2.3.2. lOmM Quisqualate following L-NAME pre-treatment
Cochleae pre-treated with L-NAME and perfused with lOmM quisqualate revealed widespread 
damage to the afferent nerve terminals at the base of the inner hair cell with some associated 
damage to surrounding structures, very similar to that seen in non-pre-treated cochleae.
Conclusion
There was no morphological evidence that L-NAME afforded any protection on cochleae from the 
excitotoxic action of either quisqualate or kainate at the concentrations used.
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10.2.4 Effect Of Pre-treatment With NOS Inhibitors On The Degree 
Of Excitotoxicity Produced By Kainate And Quisqualate
: Summary And Conclusions
30 min 10kHz CAP losses produced by perfusion of quisqualate or kainate in cochleae with and 
without pre-treatment with NOS inhibitors are summarised in Fig. 10.2.4,
Conclusions
• At the concentrations used, neither L-NAME nor L-MA pre-treatment afforded any protection 
on cochleae from the excitotoxic action of either kainate or quisqualate as judged by 
electrophysiological and morphological criteria.
• The data could be interpreted in two ways.
(i) Both inhibitors did not inhibit NOS production. However, perfusion of both 
inhibitors produced some changes in the size of the CAP, which suggests that per 
se they did have some effect on cochlear function. In the case of L-MA it had 
previously been shown to be active within cochleae at these concentrations in 
inhibiting the effects of NMD A and pneumolysin (Amaee et al. 1997 and 
Brechtelsbauer et al. 1994).
(u) Alternatively, the data could mean that production of NO by NOS is not 
involved in the excitotoxicity produced by kainate and quisqualate at the 
concentrations used.
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alone +lname +lma 
b
Figure 10.2.4. 30 min 10kHz CAP losses produced by perfusion 
of kainate and quisqualate with and without pretreament with NOS 
inhibitors L-NAME/L-MA (Iname/lma).
a) 10mM kainate perfusions b) 100 M kainate perfusions
Bracketed data are from animals with pre-perfusion (post L-MA) 
thresholds above the defined level.
9 Loss at 30 min in a single animal 
- mean loss at 30 min
c
100-1
OH------------- t------------- ------------- 1—
QA QA QA
alone +lname +lma
Figure 10.2.4. continued. 30 min 10kHz CAP losses produced by 
perfusion of kainate and quisqualate with and without pretreament with 
NOS inhibitors L-NAME/L-MA (Iname/lma).
c) 10mM quisqualate perfusions
10.3 Effect Of Pre-treatment Of Cochleae With Free Radical 
Scavengers On The Degree Of Excitotoxicity Produced By 
Quisqualate And Kainate.
10.3.1 Pre-treatment with Superoxide Dismutase (SOD)
SOD was perfused into cochleae prior to perfusion of kainate and quisqualate in order to 
determine whether scavenging for superoxide protects cochleae against excitotoxicity produced by 
these non-NMDA agonists. SOD is a scavenger of the superoxide radical and has been 
demonstrated to protect successfully cochleae from the ototoxic effects of excessive exposure to 
superoxide at 0.05 unitspl1 (Clerici and Yang 1996). It has also been demonstrated to afford 
protection on cochleae from the excitotoxic action of NMDA at 1560 unitspl'1 (Amaee et al. 
1997). Therefore SOD was used at a concentration of 0.1 unitspT1 in this study.
10.3.1.1 SOD control
100 umf1 SOD was perfused into cochleae of animals 34, 35, 36 and 37 (Table 10.3.1.1) in order 
to determine whether SOD itself produced any affects on cochlear potentials. No animal displayed 
positive losses in CAPs or CMs within 30 min.
Table 10.3.1.1 : Electrophysiological losses evoked by perfusion with 





Animal 34 Animal 35















Threshold CAPs (dB) and Peak CM (mV)
18 13 39 0.19 25 18 46 0.20
Loss in CAPs (dB) or CM (% control)
1 -8 -3 - -8 -5 2 4 3
5 • - -1 - -5 6 4 3
10 0 -3 2 -2 -5 4 - 3






Animal 36 Animal 37















Threshold CAPs (dB) and Peak CM (mV)
15 -10 26 0.14 18 15 39 0.15
Loss in CAPs (dB) or CM (% control)
1 18 15 7 -5 2 0 -3 -12
5 8 9 9 0 0 -1 -1 -7
10 10 13 14 5 0 -2 -3 -12
30 10 10 10 2 - - - -
Conclusions
There was no evidence from the electrophysiological data of ototoxicity produced by SOD, 
therefore kainate and quisqualate were perfused into cochleae of these animals without any pre­
existing damage having been caused by perfusion of SOD.
10.3.1.2 lOOptM Kainate following SOD Pre-treatment
100pM kainate was perfused into cochleae of animals 34 and 35 which had been pre-treated with 
100 uml’1 SOD (Table 10.3.1.2; Fig. 10.3.1.2) and produced positive CAP losses at all 
frequencies in both animals. At 30 min, 10kHz CAP losses were 53 and 58 dB in animals 34 and 
35 respectively. There were no positive CM losses.
Table 10.3.1.2 : Electrophysiological losses evoked by perfusion 
with 10OpM kainate in two animals which had been pre-treated with 





Animal 34 Animal 35



















CAPs (dB) and Pea 
post SOD)
kCM
20 15 41 0.20 20 22 - 0.19
Loss in CAPs (dB) or CM (% control) _____
1 -2 3 4 -12 58 61 - 9
5 -2 - 4 -12 58 63 - 13
10 65 75 64 -12 59 63 - 16




















0 Time (min) 0 Time (min) 30
■ Animal3 · Animal 4 ▲ Animal 5
▼ Animal 34 ♦ Animal 35
Figure 10.3.1.2. Losses in the CAP and CM in five animals perfused with 100pM 
kainate, two pretreated with SOD (BLUE), and three not pretreated (RED).
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively.
d) Loss in the CM elicited with a 5kHz stimuli.
10.3.1.3 lOmM Quisqualate With SOD Pre-treatment
lOmM quisqualate was perfused into cochleae of animals 36 and 37 which had been pre-treated 
with 100 uml SOD (Table 10.3.1.3; Fig. 10.3.1.3) and produced positive CAP losses at all 
frequencies in both animals. At 30 min, 10kHz CAP losses were 53 and 30dB in animals 36 and 37 
respectively. There were no positive CM losses.
Table 10.3.1.3 : Electrophysiological losses evoked by perfusion 
with 10mM quisqualate in two animals which had been pre-treated 





Animal 36 Animal 37

















ireshold CAPs (dB) and Pea 
nV) (i.e. post SOD)
kCM
25 0 36 0.14 | 18 13 36 0.17
Loss in CAPS (dB) or CM (% control)
1 48 71 - -2 27 20 - 4
5 51 71 69 0 27 21 - 1
10 53 73 69 0 30 22 - 3
30 53 72 69 -2 30 21 - 1
10.3.1.4 Pre-treatment with SOD ¡Summary and Conclusions
30 min CAP and CM losses produced by perfusion of kainate and quisqualate in cochleae with and 
without pre-treatment with SOD are summarised in Fig. 10.3.1.4 and Table 10.3.1.4.
Table 10.3.1.4 : Average 30 min losses in CAPS and CMs produced by 
perfusion with 100pM kainate (KA) and 10mM quisqualate (QA) with or without 
prior perfusion of SOD (+/- respectively). Positive losses are bold.
Treatment Average losses (± SD) in CAPs (dB) or CM (%) 
at 30 min post perfusion
10 kHz CAP 5 kHz CAP 3kHz CAP CM
100nMKA-SOD (n=3) 19±4 20 ±8 16±5 6±13
100pMKA + SOD (n=2) 56 ±4 67 ±11 64 -2 ±21
10mM QA-SOD(n=3) 42 ±15 58 ±35 42 ±6 3±6






























▲ Animal 9 •Animal 10
d
X Animal 36 ♦ Animal 37
Figure 10.3.1.3. Losses in the CAP and CM in five animals treated with 10mM 
quisqualate, two pretreated with SOD (BLUE), and three not pretreated (RED).
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 
CM elicited with a 5kHz stimuli.
Figure 10.3.1.4. Average (± S.D) 10kHz CAP losses produced by perfusion of 
kainate and quisqualate with (■) and without(·) pretreament with SOD.
a) 100uM kainate b) 10mM quisqualate
Conclusions
• There was evidence of excitotoxicity produced by lOOpM kainate and lOmM quisqualate 
despite pre-treatment of cochleae with SOD.
• Following perfusion with 100pM kainate, cochleae which had been pre-treated with SOD 
produced greater 10kHz CAP losses than non-pre-treated cochleae. Statistical analysis of the 
10kHz CAP results by ANOVA demonstrated almost a significant difference between the data 
from SOD pre-treated and non-pre-treated cochleae perfused with lOOpM kainate but not 
with lOmM quisqualate with respect to the effect of treatment on the CAP at all time points 
(p= 0.05 and 0.5 respectively). Neither set of data was significantly different with respect to 
the effect of treatment with time (p= 0.3 and 0.7 respectively).
• Therefore SOD did not protect cochleae from the excitotoxic effects of kainate and 
quisqualate at the concentrations used; pre-treatment with SOD actually worsened the 
excitotoxicity produced by IOOjjM kainate.
10.3.2 Pre-treatment with Deferoxamine (DEF)
ImM DEF was perfused into cochleae prior to perfusion of kainate and quisqualate in order to 
determine whether scavenging of the hydroxyl radical (OH*) protects cochleae against 
excitotoxicity produced by these non-NMDA agonists. DEF is a scavenger of the hydroxyl radical 
and has been shown to successfully protect the guinea pig cochlea from the ototoxic effect of 
excessive exposure to hydroxyl radicals at ImM (Brechtelsbauer et al. 1994). Therefore ImM 
DEF was used in this study.
10.3.2.1 DEF control
ImM DEF was perfused into cochleae of animals 38, 39, 40, 41, 42 and 43 (Table 10.3.2.1) in 
order to determine whether DEF itself produced any effects on cochleae potentials. No positive 
CAP or CM losses were displayed by any animal. At 10 min, 10kHz CAP losses were -9, 5, 5, -1, 
-20, and 6 dB in animals in animals 38-43 respectively. Animal 42 displayed increases in all CAPs 
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and CMs following perfusion which is indicative of poor initial coupling (as discussed in Section 
3.1.). Nonetheless, there were no positive losses in CAPs or CMs when recalculated using the 1 
min recordings as the control values.
Table 10.3.2.1 : Electrophysiological losses evoked by perfusion with 1mM 





Animal 38 Animal 39 Animal 40





















Threshold CAPs (dE!) and Peak CM (mV)
10 15 31 0.18 20 0 35 0.18 35 25 41 0.17
Loss in CAPs (dB1 or CM (% control)
1 -1 1 -1 -2 1 0 0 -4 1 3 2 0
5 -8 2 -1 2 1 11 5 -8 6 10 7 6
10 -9 2 2 2 5 17 7 2 5 11 5 17





Animal 41 Animal 42 Animal 43





















Threshold CAPs (dEI) and Peak CM (mV)
37 39 50 0.17 24 29 43 0.15 38 21 42 0.11
Loss in CAPs (dB or CM (% control)
1 1 1 1 2 -16 -24 -17 -19 6 7 4 -3
5 0 1 2 4 -21 -38 -23 -19 8 7 6 0
10 -1 1 0 2 -20 -39 -18 -28 6 7 5 -3
30 - - - - - - - - - - - -
Conclusion
• There was no evidence of ototoxicity produced by ImM DEF, therefore kainate and 
quisqualate were perfused into cochleae of these animals without any pre-existing 
electrophysiological damage having been caused by perfusion of DEF.
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10.3.2.2 100|lM Kainate following DEF Pre-treatment
IOOjiM kainate was perfused into cochleae of animals 38 and 39 which had been pre-treated with 
DEF (Table 10.3.2.2; Fig. 10.3.2.2) and produced positive CAP losses in both animals. At 30 
min, 10kHz CAP losses were 59 and 34 dB in animals 38 and 39 respectively. There were no 
positive CM losses.
Table 10.3.2.2 : Electrophysiological losses evoked by 
perfusion with 100pM kainate in two animals which had been 





Animal 38 Animal 39



















£B) and Pea 
EF)
kCM
(control) 1 17 33 0.17 21 17 41 0.16
Loss in CAPs (dB or CM (% control)
1 27 7 -4 8 24 2 2 19
5 58 18 4 8 47 16 7 21
10 58 20 6 10 47 19 7 15
30 59 22 9 19 34 21 5 19
10.3.2.3 lOmM Quisqualate following DEF Pre-treatment
lOmM quisqualate was perfused into cochleae of animals 40, 41, 42 and 43 which had been pre­
treated with DEF (Table 10.3.2.3; Fig. 10.3.2.3) and produced positive CAP losses in all animals. 
At 30 min, 10kHz CAP losses were 38, 59,29 and 36 dB in animals 40-43 respectively. A positive 





















0 Time (min) 30 0 Time (min) 30
■ Animal 3 · Animal 4 ▲ Animal 5
X Animal 38 ♦ Animal 39
Figure 10.3.2.2. Losses in the CAP and CM in five animals treated with 100pM 
kainate, two pretreated with 1mM DEF (BLUE), and three not pretreated (RED).
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 



















■ Animal 8 ▲ Animal 9 · Animal 10
♦ Animal 40 X Animal 41 ▼ Animal 42 ► Animal 43
Figure 10.3.2.3. Losses in the CAP and CM in seven animals treated with 10mM 
quisqualate, four pretreated with DEF (BLUE), and three not pretreated (RED).
a-c) Losses in the CAP elicited with 10, 5 and 3kHz stimuli respectively, d) Loss in the 
CM elicited with a 5kHz stimuli.
Table 10.3.2.3 : Electrophysiological losses evoked by perfusion 
with 10mM quisqualate in four animals which had been pre-treated 





Animal 40 Animal 41


















nV) (i.e. post D
;dB) and Pea 
EF)
kCM
40 36 46 0.14 I 36 40 50 0.17
Loss in CAPs (dB) or CM (% control)
1 15 24 24 -20 49 37 32 25
5 19 23 26 -23 40 38 55 29
10 25 23 25 -20 42 47 52 86





Animal 42 Animal 43






















14 -10 25 0.19 I 44 28 47 0.12
Loss in CAPs (dB' or CM (% control)
1 16 5 -10 11 31 35 18 39
5 24 15 -2 9 33 32 18 -4
10 26 23 3 9 31 29 18 3
30 29 26 6 2 36 30 16 11
10.3.2.4 Pre-treatment with DEF :Summary and Conclusions
30 min CAP and CM losses produce by kainate and quisqualate in cochleae with and without pre­
treatment with DEF are summarised in Fig. 10.3.2.4 and Table 10.3.2.4.
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Figure 10.3.2.4. Average (± S.D) 10kHz CAP losses produced by perfusion of 
kainate and quisqualate with (■) and without(·) pretreament with 1mM DEF.
a) 100pM kainate b) 10mM quisqualate
Table 10.3.2.4 : Average 30 min losses in CAPs and CMs produced by 
perfusion with 100pM kainate (KA) and 10mM quisqualate (QA) with or without 
prior perfusion of 1mM DEF (+/- respectively). Positive losses are bold.
Treatment Average losses (± SD) in CAPs (dB) or CM (%) 
at 30 min post perfusion
10 kHz CAP 5 kHz CAP 3kHz CAP CM
100pMKA-DEF (n=3) 19±4 20 ±8 16±5 6±13
100pM KA + DEF (n=2) 46 ±18 22 ±1 7±3 19±0
10mM QA-DEF (n=3) 42 ±15 58 ±35 42 ±6 3±6
10mM QA+DEF (n=4) 42 ±16 46 ±36 69 -1 ±3
Conclusions
• There was evidence of excitotoxicity produced by lOOpM kainate and lOmM quisqualate 
despite pre-treatment of cochleae with DEF.
• Statistical analysis of the 10kHz CAP results by ANO VA demonstrated a significant difference 
between the data from DEF pre-treated and non-pre-treated cochleae perfused with lOOpM 
kainate (0.0231, 0.1149), but not those perfused with lOmM quisqualate with respect to 
treatment alone (p= 0.02 and 0.8 respectively). Neither set of data was significantly different 
with respect to the change in the CAP with time (p= 0.1 and 0.9 respectively). Following 
perfusion with lOOpM kainate, cochleae which had been pre-treated with DEF produced 
statistically greater 10kHz CAP losses than non-pre-treated cochleae.
• Pre-treatment with DEF provided no protection on cochleae from the effects of kainate and 
quisqualate at the concentrations used. However, pre-treatment with DEF actually worsened 
the excitotoxicity produced by IOOjiM kainate.
10.3.3. Morphological Examinations
10.3.3.1.100pM Kainate following SOD or DEF pre-treatment
Cochleae pre-treated with SOD or DEF and perfused with 100pM kainate revealed more 
extensive afferent nerve terminal damage than seen in cochleae that had not been pre-treated. In 
addition to mitochondrial and membrane damage of the type I afferents (seen in non-pre-treated 
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cochleae), some afferent nerve terminals beneath the inner hair cells were swollen and denuded of 
cellular contents.
10.3.3.2. lOmM Quisqualate following SOD or DEF pre-treatment
Cochleae pre-treated with SOD or DEF and perfused with lOmM quisqualate revealed widespread 
damage to the afferent nerve terminals at the base of the inner hair cell with some associated 
damage to surrounding structures, very similar to that seen in non-pre-treated cochleae.
Conclusion
There was no morphological evidence that SOD or DEF afforded any protection on cochleae from 
the excitotoxic action of either quisqualate or kainate at the concentrations used. Moreover, SOD 
and DEF actually worsened the afferent nerve terminal damage of inner hair cells produced by 
100pM kainate.
10.3.4. Effect Of Pre-treatment With Free Radical Scavengers On 
The Degree Of Excitotoxicity Produced By Kainate And 
Quisqualate : Summary And Conclusions
30 min 10kHz CAP losses produced by perfusion of kainate and quisqualate in cochleae with and 
without pre-treatment with free radical scavengers are summarised in Fig. 10.3.4 a.
Conclusions
• At the concentrations used, neither SOD nor DEF afforded any protection on cochleae from 
the excitotoxic action of either kainate or quisqualate as judged by electrophysiological and 
morphological criteria. Both SOD and DEF apparently enhanced the excitotoxic action of 
lOOpM kainate.
• The results could be interpreted in several ways.
(i) Neither SOD nor DEF were active in cochleae in terms of scavenging for superoxide 
and hydroxyl radicals. However, the data from pre-treated cochleae were statistically
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alone +SOD +DEF
Figure 10.3.4.a 30 min 10kHz CAP losses produced by 
perfusion of kainate (KA) and quisqualate (QA) with and without 
pretreament with SOD and DEF.
a) 10mM kainate perfusions b) 100^M kainate perfusions
different than the data from non-pre-treated controls, therefore it appears that the 
inhibitors were having some effect within cochleae. In addition, SOD and DEF had 
previously been shown to be active within cochleae in inhibiting the effects of O2* and OH* 
generation systems.
(ii) SOD and DEF may have produced some ototoxicity themselves beyond the 10-30 min 
recordings that were taken in control experiments. However, SOD (SOunitsml1) and DEF 
(ImM) had been previously shown to produce no CAP losses up to 120 min post perfusion 
when they were perfused into cochleae in combination with SOD and DEF generating 
systems (Clerici and Yang 1996). Also cochleae perfused with NMD A which had been 
pre-treated with SOD (1560unitsp.r1) produced no CAP losses up to 90 min post perfusion 
(Amaee et al. 1997). Moreover, the timing of the losses in this chapter and morphological 
evidence is characteristic of losses associated with kainate and quisqualate.
(iii) Another consideration to be made is that the protective action of these scavengers 
reported by Clerici and Yang (1996) was seen in CAPs measured at frequencies between 9 
and 30kHz. Therefore any protective action of SOD and DEF on the action of kainate and 
quisqualate in my study might have been evident at higher frequencies. However, partial 
data from incomplete experiments carried out for this thesis concerning CAP at losses at 
20kHz (Fig. 10.3.4 b) did not support this. Perfusion with kainate and quisqualate in 
animals pre-treated with SOD or DEF produced CAP losses at 20kHz which were greater 
than or equal to the losses in animals untreated or treated with L-MA; the latter showed no 
protection at other frequencies. However, further data are needed to draw firm 
conclusions.
(iv) The most likely interpretation of the data concerning ROSs is that superoxide and the 
hydroxyl radical are not involved in mediating the excitotoxic action of kainate and 
quisqualate. However, since scavenging these radicals worsened the excitotoxicity 
produced by kainate and quisqualate, it is just possible that superoxide and hydroxyl 
radicals may play a protective role in the excitotoxicity mediated by these non-NMDA 
agonists in cochleae. This was not further examined.
162
Figure 10.3.4.b. 30 min CAP losses at 20kHz produced by 
perfusion of kainate (KA) and quisqualate (QA) with and without 
pretreament with L-MA (Ima), SOD or DEF.
a) 100^iM kainate perfusions b) 10mM quisqualate perfusions
CHAPTER 11 
Discussion
In this concluding chapter I shall discuss the results in Chapters 3-10, the validity of the techniques 
used, and further confirmatory experiments which should be carried out. Finally I shall discuss the 
most likely causes of meningitis-induced deafness, the most likely preventative measures and the 
direction in which I feel future work should be directed.
11.1. Summary of the Results
1. The evidence presented confirmed the presence of a potent ototoxic protein(s) in cytoplasmic 
extracts of a clinical isolate of H. influenzae type b.
2. The evidence presented also suggests that there may be present in low concentration an 
ototoxin in cytoplasmic extracts of a clinical isolate of N. meningitidis, further confirmatory 
investigations are clearly needed.
3. There was evidence for an ototoxic factor in the cytoplasmic extracts of a pneumolysin- 
deficient mutant of 5. pneumoniae type III which may represent a novel ototoxin. A similar 
ototoxin in the bacterial extract of wild type S. pneumoniae type III may have been responsible 
for the ototoxicity produced by this extract after immunochemical removal of pneumolysin. 
However the presence of some contaminants in the immunopurified extract, makes this 
conclusion tentative.
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4. There was evidence of pneumolysin-like’ proteins in the bacterial extracts of N. meningitidis 
and H. influenzae type b similar to that present in extracts of wild type S. pneumoniae type III. 
The relative concentration of these proteins was greatest in pneumococcal extracts, and less in 
H. influenzae type b extracts and considerably less in a meningococcal extract. However, 
further confirmatory experiments are necessary in order to eliminate the role of cross-track 
contamination in these findings.
5. Pre-treatment of guinea pig cochleae with L-NAME, L-MA, SOD or DEF provided no 
protection against the excitotoxicity produced by kainate and quisqualate at the concentrations 
used.
11.2. Novel ototoxins/o to toxic factors in H. influenzae type b, N. meningitidis 
and 5. pneumoniae type III bacterial extracts
In this thesis evidence is adduced for the existence of novel ototoxins/ototoxic factors in bacterial 
extracts of N. meningitidis, H. influenzae type b, and S. pneumoniae type III. However further 
investigations are necessary, particularly with regards to N. meningitidis. This is the first time to 
my knowledge that evidence has been produced for the existence of directly acting ototoxic 
factors in bacterial extracts of H. influenzae type b, N. meningitidis and pneumolysin-deficient S. 
pneumoniae type III. The ototoxicity produced by these bacterial extracts is most likely to have 
been due to the presence of hitherto undescribed ototoxic proteins for the following reasons. First, 
low molecular ototoxic species (e.g. NO, glutamate and hydrogen peroxide) would have been 
eliminated by dialysis. Second the time course of CAP losses was in general consistent with 
hearing losses being produced by direct ototoxicity and not by secondary ototoxic events mediated 
by the inflammatory response. Third, those fractions of H. influenzae type b and meningococcal 
bacterial extracts which were likely to have contained large amounts of endotoxin were either not 
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as ototoxic as other fractions, or, not ototoxic at all. Fourth, some bacterial extracts were not 
ototoxic as for example pneumococcal extracts when not DTT-treated. Therefore, ototoxicity was 
not due to non-specific effects of perfusing a crude bacterial extract into the cochlea such as the 
increased viscosity of the perilymphatic fluid. Finally, ototoxicity produced by those bacterial 
extracts examined was specific as judged by electrophysiological measurements and morphological 
examinations.
The degree of ototoxicity produced by each bacterial extract reflected the relative concentrations 
of ‘pneumolysin-like’ proteins in each extract, i.e. CAP losses produced were greatest with 
pneumococcal extracts, less with H. influenzae type b extracts, and least with meningococcal 
extracts. Therefore it is conceivable that these ‘pneumolysin-like’ proteins were responsible for the 
ototoxicity produced in guinea pig cochleae. However, further studies will be necessary to confirm 
or weaken these conclusions. If they were confirmed, it would be the first time to my knowledge 
that, SH-activated ototoxins had been demonstrated in the two gram negative bacteria H. 
influenzae type b and N. meningitidis. If these ‘pneumolysin-like’ proteins in meningococci and H. 
influenzae type b are ototoxins which are thiol-activated and released by autolysis similar to 
pneumolysin, this would explain the lack of ototoxicity of culture filtrates and increased activity 
of the crude extracts after DTT treatment.
The ototoxicity produced by the bacterial extracts was comparable with that produced by live 
bacteria in the cochlea following direct perfusion or experimental meningitis (see next section). 
Therefore the ototoxic factors in the crude extracts of these bacteria may be responsible for the 
hearing losses associated with these pathogens. In fact, both the relative ototoxic potency (as 
judged by CAP losses at 90 min) and the relative concentration of ‘pneumolysin-like’ proteins in 
these bacterial extracts seem to correlate with the incidence of meningitis-induced deafness 
associated with these pathogens (see Section 1.2.), Moreover, the incidence of hearing loss 
associated with N. meningitidis type b may be less than that reported for N meningitidis (of all 
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serotypes) because it has been reported that the type b serotype causes considerably fewer cases of 
deafness than other serotypes (Mayatepek, Grauer, Hansch et al. 1993).
Although the main aim of this study was to identify and isolate ototoxins in the bacterial extracts 
of the three main pathogens responsible for bacterial meningitis, attention was diverted to 
characterisation of the mode of ototoxic action by establishing the type of electrophysiological 
losses produced and ultrastructural changes by examination of the cochlea.
11.2.1. Characterisation of Novel “Ototoxins”
Electrophysiological recordings revealed that ototoxicity produced by H. influenzae type b, 
meningococcal and pneumococcal bacterial extracts consistently included a fall in the CAP but not 
the CM. Any CM losses produced were mostly associated with losses in the CAP of >40dB. 
Losses in CAP were apparent across several frequencies. Two types of time course of ototoxicity 
were produced by the bacterial extracts described here. Ototoxicity produced by H. influenzae 
type b extracts and pneumococcal extracts containing pneumolysin were usually rapid, the 
majority of the CAP loss being achieved within 10 min. Meningococcal extracts and 
pneumococcal extracts which did not contain free pneumolysin produced ototoxicity whose onset 
was a little slower, the majority of the loss occurring after 20 or 30 min.
The electrophysiological evidence implied that the major target of all bacterial ototoxic factors 
described here was the afferent neuron, afferent synapse or inner hair cell, and these factors were 
uniformly active along the length of the cochlea. In contrast, outer hair cells were mostly 
unaffected. The time courses of all hearing losses described here were sufficiently rapid to imply 
that these bacterial extracts were directly toxic to the cochlea and did not produce ototoxicity by 
evoking an inflammatory response.
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SEM examination of treated cochleae was often difficult due to curling of the specimens which 
appeared to be affected by perfusion of the extract, because it was not apparent in similarly treated 
control cochleae. Nevertheless, the ototoxicity produced by all bacterial extracts was associated 
with some evidence of structural damage to the surface of the organ of Corti. There was some 
damage to the stereocilia of inner and outer hair cells (splaying, detachment and fusing), and some 
swelling and cratering of supporting cells, particularly the border cells. Stereocilial damage was 
commonly co-located with craters in supporting cells and more often affected inner hair cells. 
However, with the possible exception of wild type S. pneumoniae extract the surface structural 
damage produced by all extracts was very patchy, inconsistent between animals, and was not 
always correlated with electrophysiological losses. SEM examination of cochleae treated with wild 
type pneumococcal extract containing free pneumolysin revealed stereocilial damage and cratering 
in the border cells which was less patchy than seen in cochleae treated with other bacterial 
extracts. In addition there was striking swellings of the supporting cells between outer hair cells. 
However, examination was only possible in one cochlea due to curling. The apparent discrepancy 
between electrophysiological losses and morphological damage was resolved by ТЕМ examination 
which revealed consistent morphological damage, the degree of which correlated with 
electrophysiological losses in all cochleae examined in this way. Ultrastructural examination by 
ТЕМ revealed consistent and striking damage to the mitochondria of nerve endings at the base of 
the hair cells, particularly the inner hair cells. In cochleae which had displayed large CM losses, 
severe mitochondrial damage was apparent in all cells including the inner and outer hair cells. 
Cochleae treated with meningococcal extracts, and pneumococcal extracts which did not contain 
free pneumolysin were not examined by ТЕМ due to either lack of specimens, or lack of time (see 
Section 2.2.5.). Since the surface structural damage produced by these extracts was not consistent 
with electrophysiological losses, it is most likely that ultrastructural damage was responsible for 
the electrophysiological losses which cannot be seen by SEM and would have been seen by ТЕМ.
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Thus, all cochleae which showed electrophysiological losses, consistently revealed ultrastructural 
damage observed following examination by ТЕМ but not by SEM. Therefore it seems likely that 
the primary action of the bacterial extracts was most likely to have been to the under side of the 
organ of Corti, in particular the mitochondria of the nerve endings. Surface structural damage was 
most likely secondary to this ultrastructural damage to the nerve endings and hair cells and so was 
less consistently produced.
11.2.2. Comparisons with Previous Studies
The electrophysiological and morphological data were in general consistent with previous 
preliminary studies (as discussed previously in Chapters 4 and 8). However, there were some 
discrepancies with respect to pneumococcal extracts, but these probably arose from differences in 
protein concentrations and DTT treatment. Apart from these preliminary studies, there have been 
no other studies which involved investigating the ototoxicity of crude bacterial extracts. There has 
however, been some previous investigations carried out into the effects of purified toxins and live 
bacteria in the cochlea which can be compared with the data described here. Several groups have 
evaluated hearing losses and carried out morphological examinations of the cochlea following 
experimental meningitis. However, since the only electron microscopic examinations and direct 
cochlear recordings have been carried out in our laboratories I shall limit this discussion to data 
from previous experiments within our laboratories as they are most comparable to the data 
presented here.
H. influenzae type b “ototoxin”
The ultrastructural damage to the organ of Corti described here following perfusion of H. 
influenzae type b bacterial extracts was also reported following SEM and ТЕМ examination of 
cochleae following experimental meningitis in rabbits induced by H. influenzae type b (Osborne 
et al. 1995). However, experimental meningitis produced some additional structural damage such 
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as pyknosis of hair cell nuclei, swollen or empty nerve endings, vacuolation of cells within stria 
vascularis and some evidence of intracochlear bleeding. The hearing losses produced by 
experimental H. influenzae type b meningitis were measured by click evoked ABERs and so are 
not directly comparable with the CAP data reported here. Since loss of sensitivity to click stimuli 
represents more profound hearing losses than equivalent losses to tone pip stimuli, the 9-50dB 
losses detected by ABERs (over 9-20h) are probably similar if not greater than the losses 
produced by H. influenzae type b “ototoxin” described here. There are no reports of direct 
cochlear recordings during experimental H. influenzae type b meningitis.
Wild type pneumococcal ‘ototoxins’
The ototoxicity produced by wild type pneumococcal extract containing free pneumolysin is 
almost identical to that produced by live pneumococci (type II) perfused directly into the cochlea 
in terms of morphological damage examined by SEM, and CAP and CM losses. However, the 
onset of CAP losses produced by live pneumococci was delayed in comparison to bacterial 
extracts. Experimental pneumococcal (type II) meningitis in guinea pigs produced more extensive 
cochlear damage (as judged by both electrophysiological recordings and TEM and SEM 
examinations) than cochlear perfusion with bacterial extracts or live pneumococci. Following 
experimental pneumococcal meningitis, cochleae revealed all the structural damage sustained by 
perfusion of wild type pneumococcal extract, or live wild type pneumococci. However additional 
damage was seen including severe outer hair cell and supporting cell damage (swollen and 
vacuolated, breaks in basal and apical membranes and mitochondrial vacuolation), and disruption 
of intercellular tight junctions (Winter et al. 1997). In addition, experimental pneumococcal 
meningitis often produced large CM losses, whereas perfusion of pneumococcal extracts and live 
pneumococci did not. The effects of perfusing purified pneumolysin into the cochlea were earlier 
described as very similar to those described following experimental pneumococcal meningitis (as 
judged by CAP and CM losses and SEM examinations). Similar but more extensive surface 
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structural damage was revealed than that produced by perfusion of wild type S. pneumoniae 
extract (containing free pneumolysin), or live wild type pneumococci. Additional pitting, swelling 
and cratering of the hair cells was seen, and large CM losses were produced in addition to CAP 
losses (Comis et al. 1993).
New (?) pneumococcal ototoxin
Cochleae treated with pneumococcal extracts which did not contain free pneumolysin revealed 
very similar surface structural damage to that described following experimental meningitis 
induced by pneumolysin-deficient pneumococci (type II) (as judged by CAP and CM losses and 
SEM examinations). Some CAP losses were observed, but smaller than those produced by 
experimental wild type pneumococcal meningitis. CM losses and surface structural damage were 
not consistently produced by the pneumolysin-deficient mutants. TEM examination following 
experimental meningitis induced by pneumolysin-deficient pneumococci revealed consistent 
vacuolation of mitochondria in the nerve endings (Winter et al. 1997). Similar ultrastructural 
damage may have been responsible for the CAP losses produced by pneumococcal extract which 
did not contain pneumolysin, since surface structural damage was not consistent.
The greater extent of cochlear damage produced by pneumolysin in comparison to pneumococcal 
extracts and live pneumococci following cochlear perfusion is most likely to have been due to a 
difference in the concentration of pneumolysin present. 1-1 Opg of pneumolysin produces large 
CAP and CM losses, whereas 0.5pg pneumolysin produces only transient and cumulative CAP 
losses with no CM loss within 90 min (Comis et al. 1993). Therefore, either an additional ototoxin 
(perhaps similar to that responsible for ototoxicity in both the pneumococcal extracts which did 
not contain free pneumolysin) combined with a small concentration of pneumolysin produced the 
CAP losses observed. Or alternatively, since the effects of pneumolysin have only been examined 
over 90 min previously, a small concentration of pneumolysin may lead to permanent CAP but not
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CM losses if present in the cochlea for greater than 90 min. The delay of onset of CAP losses 
produced by live bacteria in comparison to bacterial extracts is likely to represent the time that it 
took pneumococci to release a sufficient amount of pneumolysin (and any other ototoxins) by 
multiplication and autolysis to cause ototoxicity.
Cochlear damage produced by experimental meningitis compared with cochlear perfusion
It is of interest to ask whether the damage seen in experimental meningitis is comparable to that 
seen in cochlear perfusion. As far as the work of this group is concerned, the most direct 
comparison that could be made of the nature and extent of damage caused by these two routes 
involved experiments with the relatively non-pathogenic E. coli K12. A greater degree of cochlear 
damage was produced by experimental meningitis than by cochlear perfusion. E. coli KI 2 
produced no significant electrophysiolgical losses or ultrastructural damage to the cochlea when 
perfused directly into the cochlea (Winter 1997), yet produced considerable hearing losses (as 
judged by ABERs) and ultrastructural damage in an experimental meningitis model (Osborne et al. 
1995); there are several explanations for these differences. First, the time course of experimental 
meningitis is longer and so may provide a longer exposure of the cochlea to bacterial 
components/toxins and inflammatory mediators. Second, the higher total number of bacteria 
arising from a longer experimental time, could result in the generation/release of a greater amount 
of bacterial components and inflammatory mediators. Third, complications of the inflammatory 
response in the CSF such as oedema may have caused some ototoxicity (e.g. ototoxicity induced 
by ischaemia). Finally, perforated cochleae may be less sensitive to ototoxic agents than intact 
cochleae.
11.2.3. Use of the Cochlear Perfusion Model in Identifying and Isolating 
Bacterial Ototoxins
171
The data presented here suggest that electrophysiological and morphological examination of 
cochlea following perfusion of bacterial extracts can provide valuable insight into the type of 
ototoxicity produced by bacterial pathogens. This method may not be able to detect hearing losses 
that are the cumulative result of inflammatory responses in the CSF, but is able to identify bacterial 
components which are directly ototoxic as opposed to those which only produce ototoxicity 
through the inflammatory responses. My results suggest that identification and isolation of 
ototoxins from meningogenic pathogens is possible using the cochlear perfusion model as a 
screening/detection system. However, the cost and inter-animal variation associated with the use 
of guinea pigs makes isolation of ototoxins a time consuming and expensive task, especially if the 
ototoxic potency of the crude extract is low. For example, the results presented in section 4 were 
carried out using one batch of crude H. influenzae type b bacterial disruptate received from 
CAMAR. Subsequent batches of crude H. influenzae type b bacterial disruptate yielded less 
reproducible results and displayed mild ototoxicity in comparison to the data presented here. It is 
thus possible that the toxin may be labile in preparation or under-expressed under certain growth 
conditions. Expression of ototoxin by this strain of H. influenzae type b may have been lost or 
reduced by repeated in vitro growth of the organism. If the ototoxin is a virulence factor, passage 
of the bacterium through an animal could restore its production. Alternatively, new clinical isolates 
could be used, in particular strains that were responsible for causing deafness. However, the 
incidence of hearing loss in experimental meningitis induced by H. influenzae type b was not 
greater in animals which had been infected with strains which had caused clinical deafness (Kaplan 
et al. 1989). The efficiency of the disruption process could be monitored in terms of protein 
concentrations to ensure comparable concentration of proteins in each batch. The degree of 
disruption could also be monitored by assaying the concentration of succinate dehydrogenase (a 
membrane bound enzyme found on the inner surface of plasma membranes). DTT treatment 
(and/or using degassed APL) should be considered for all extracts because the ototoxicities of 
bacterial extracts of £ pneumoniae and H. influenzae type b (including later batches of H.
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influenzae type b extract not described in this thesis) were enhanced by DTT treatment of the 
sample. Therefore, by monitoring the growth and disruption, and preparation of the extracts, 
methods could be optimised to produce maximally potent bacterial extracts.
Future experiments should focus on production of high activity bacterial extracts, and 
developing better methods for fractionating the ototoxic factors in these bacterial extracts. In 
addition, the culture filtrate of meningococcus should be tested for ototoxicity to see if any 
secreted ototoxins were present. Once ototoxins have been isolated, amino acid sequence could be 
determined, the gene/s responsible for their production identified which would permit all kinds of 
sophisticated molecular biological experiments to be considered.
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11.3. Excitotoxicity produced by quisqualate and kainate in the 
cochlea
11.3.1. Excitotoxicity produced by quisqualate and kainate in the cochlea
Perfusion of lOmM quisqualate or lOmM kainate into the cochlea produced large losses in CAPs, 
but not CMs. Transmission electron microscopy revealed widespread swelling of the afferent 
nerve endings of the inner hair cells with some associated damage to the base of the inner hair cells 
and supporting cells, particularly in cochleae treated with kainate. There was no evidence of 
damage to the outer hair cells, although the cytoplasmic contents of the efferent nerve endings at 
the base of the outer hair cells appeared to be more dense than in controls. lOOpM kainate 
produced small CAP losses which were associated with a small degree of mitochondrial and 
membrane damage in the afferent neurons at the base of the inner hair cell. In addition there was 
some fragmentation of the plasma membrane at the base of the inner hair cell.
11.3.1.1. Comparisons with previous data
As previously discussed (Chapter 10), the results presented here are consistent with the previous 
data concerning the action of quisqualate and kainate in the cochlea (Jenison et al. 1986; Bledsoe 
et al. 1981; Pujol et al. 1985). The CAP losses are likely to be a consequence of an initial increase 
in the spontaneous activity (excitation) followed by a post excitatory depression (excitotoxicity) of 
the type I afferents which is produced by perfusion of quisqualate and kainate into guinea pig 
cochleae (Bledsoe et al. 1981; Jenison and Bobbin 1985). The slight structural damage produced 
by lOOpM kainate and the increase in density of the efferent neurons beneath the outer hair cells 
has not been previously reported. In addition, there have been no previous reports of 
ultrastructural examinations following quisqualate mediated excitotoxicity in the cochlea.
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The function of the medial efferents is thought to be to modulate the motile response of outer hair 
cells. Therefore medial efferents could alter the stimulus for the inner hair cells by modifying the 
amplification of the basilar membrane movement produced by outer hair cell motility. The increase 
in the density of the medial efferents beneath the outer hair cells could represent a change in the 
activity of the efferent neurone in response to either the initial excess activation, or the post- 
excitatory depression of activity of the type I aflferents. However, there was no detectable change 
in the CM during excitotoxicity produced by kainate, quisqualate or AMP A (Bledsoe et al. 1981; 
Jenison et al. 1986; Puel et al. 1991), nor in OAEs during excitotoxicity produced by kainate 
(Zheng, Wang, Salvi et al. 1996). Therefore, either efferents can produce changes in the motility 
of OHCs without affecting CMs and OAEs, or there was some change in the cytoplasm of the 
medial efferent dendrites which did not affect the function of the outer hair cells.
The slight structural damage produced by lOOpM kainate may represent the initial effect of 
kainate on the type I afferent nerve endings before swelling. Perfusion of 50mM NMD A into 
guinea pig cochleae produces very similar ultrastructural damage to that seen in cochleae treated 
with lOOpM kainate. However since the electrophysiological losses and surface structural damage 
produced by NMD A but not lOOpM kainate can be attenuated by NOS inhibition and scavenging 
for superoxide, it seems likely that this similar ultrastructural damage is produced by different 
routes of toxicity.
11.3.2. Attenuation of excitotoxicity mediated by quisqualate and kainate by pre-treatment 
of the cochlea.
At all concentrations used, pre-treatment of guinea pig cochleae with L-NAME, L-MA, SOD or 
DEF did not afford any protection on cochleae from the excitotoxic action of either kainate or 
quisqualate as judged by electrophysiological and morphological criteria. Electrophysiological data 
alone cannot exclude the possibility that excitotoxicity had been reduced, because even if post- 
175
excitatory depression of type I afferents (excitotoxicity) were attenuated/blocked, CAP loss could 
still occur if excitation of the type I afferents continued. Nevertheless, morphological examination 
revealed that there was no reduction in the degree of afferent nerve ending swelling, therefore it is 
unlikely that excitotoxicity was attenuated.
11.3.3. Comparisons with Previous Data
11.3.3.1. Involvement of NO in Excitotoxicity mediated by non-NMDA receptors
The results presented here imply that production of NO by NOS is not involved in the acute 
excitotoxicity produced by kainate and quisqualate. There are no comparative data concerning the 
role of NO in the excitotoxic action of non-NMDA receptors in the cochlea. There is some 
evidence that inhibition of NOS is neuroprotective against the action of kainate in retinal cultures 
(Dutrait et al. 1995). However, selective inhibition of neuronal NOS was unable to provide 
protection against striatal lesions produced by kainate and AMPA in vivo (Schulz et al. 1995b). In 
addition, cortical cultures from mice deficient in neuronal NOS were not resistant to kainate and 
quisqualate toxicity despite being resistant to NMDA toxicity (Dawson, Kizushi, Huang et al. 
1996). The inconsistency of these data could be due to the use of different NOS inhibitors. 
However, since all inhibitors were capable of inhibiting neuronal NOS which is the predominant 
isoform of NOS in neuronal cells, this is unlikely. Therefore the current evidence suggests that 
non-NMDA receptors may mediate some toxicity through production of NO by NOS in some but 
not all neuronal cells. The ability of neuronal cells to produce NO in response to non-NMDA 
receptor activation may be related to the subunit composition of the receptors. Neuronal NOS 
(and endothelial NOS) is activated by an increase in the concentration of intracellular Ca++. 
Activation of non-NMDA receptors can evoke an increase in intracellular Ca++ by voltage 
dependent Ga** channels. In addition, certain subunits of the non-NMDA receptors can confer the 
ability to passage Ca^. Therefore, cell types containing non-NMDA receptors which are 
permeable to Ca*4 may produce greater increases in intracellular Ca , and therefore greater 
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production of NO by NOS. Alternatively, some neuronal cells may produce NO by other routes, 
for example, AMPA and metabotropic (type AP-3) glutamate receptors in the rat cerebellum 
produce NO via a NOS independent pathway (Yamada and Nabeshima 1997). In conclusion, 
several types of non-NMDA receptors may be able to produce NO by various different 
mechanisms. Therefore, although non-NMDA receptors do not appear to mediate excitotoxicity in 
the cochlea by NOS, an involvement of NOS independent production of NO has yet to be 
investigated.
11.3.3.2. Involvement of Superoxide and Hydroxyl radicals in Excitotoxicity mediated by 
non-NMDA receptors
The results presented here imply that neither superoxide nor hydroxyl radical are involved in the 
acute excitotoxicity produced by kainate and quisqualate. There are no comparative data 
concerning the involvement of ROSs in the excitotoxicity mediated by non-NMDA receptors in 
the cochlea. Ototoxicity following acoustic trauma and ischaemia/reperfusion is believed to be 
mediated predominantly by non-NMDA activation (Pujol et al. 1992; Pujol et al. 1993), and can 
be attenuated by treatment with SOD or allopurinol (an inhibitor of xanthinine oxidase which is a 
cellular source of superoxide) (Seidman, Shivapuja and Quirk 1993; Seidman, Quirk, Nuttal et al. 
1991). However, morphological examinations were not carried out, and ischaemia/reperfusion and 
acoustic trauma involve additional mechanisms of ototoxicity besides those mediated by non- 
NMDA receptors. Therefore the protective effects of SOD and allopurinol may not have involved 
attenuation of toxicity which was mediated by non-NMDA receptors. The role of ROSs in non- 
NMDA mediated excitotoxicity is more clear in non cochlear tissue. A neuroprotective action of 
superoxide and hydroxyl radical scavengers or inhibitors of OH- production has been reported 
against kainate mediated excitotoxicity mediated in cortical, cerebellar and retinal cell cultures 
(Patel, Day, Crapo et al. 1996; Dugan, Gabrielson, Lin et al. 1996; Giusti, Gusella, Lipartiti et al. 
1995; Dykens, Stem and Trenkner 1987; Dutrait et al. 1995). Until recently there was no evidence 
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of a similar protection against the excitotoxicity mediated by the AMP A receptor. However, 
Schulz et al. (1995a) reported that pre-treatment with a free radical spin trap (N-tert-butyl- 
alpha(2-sulfophenyl)-nitrone) significantly attenuated excitotoxic striatal lesions produced by 
kainate and AMP A in vivo. Therefore ROSs appear to be involved in mediating neurotoxicity 
produced by kainate and AMPA receptors in the CNS. Since both in vivo and in vitro 
neuroprotection conferred by antioxidants in the CNS often required a minimum of two treatments 
(one before and one after the excitotoxic event) (Schulz et al. 1995a; Giusti et al. 1995), single 
treatments given to the cochlea may not have been sufficient to provide protection. In addition, the 
in vivo protection in the CNS was determined 1 week post excitotoxicity whereas the experiments 
described here were acute (excitotoxicity was assessed 30 min post perfusion of quisqualate or 
kainate). Therefore the data presented here do not exclude an involvement of superoxide or 
hydroxyl radical in the excitotoxicity produced by kainate and quisqualate.
During this study, an unexpected finding was that scavenging for SOD and DEF appeared to have 
worsened the excitotoxicity produced by 100pM kainate in the cochlea. SOD and DEF appeared 
to enhance the ability of kainate to produce swelling of the type I afferent dendrites and CAP 
losses. Since ROSs have only been associated with toxicity and not protection in the cochlea, and 
SOD and DEF do not appear to produce ototoxicity on their own, this finding is difficult to 
interpret. I/the scavengers selectively entered afferent neurons, they may have altered the osmotic 
gradient between the afferent neurone synapse and the extracellular space, which would produce 
greater swelling of the neurons. Alternatively, if superoxide and/or hydroxyl anions could 
antagonise kainate receptors, scavenging for these radicals could have lead to greater activation of 
kainate receptors by removal of these antagonists. However, this is pure speculation because there 
is no evidence to support either theory. An alternative explanation is that the difference in the 
responses to 100pM kainate between pre-treated and non pre-treated cochleae was simply due to 
inter-animal variation. According to Jenison et al. (1985) a lOOpM dose of kainate is on the steep 
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slope of the dose response curve, therefore slight alterations in the concentration of kainate in the 
cochlea would have lead to large changes in the CAP losses produced. Data from cochlear 
perfusions is particularly variable with agents which produce CAP losses of the magnitude that 
100pM kainate produced. Therefore although it is statistically very unlikely, the differences may 
have been purely down to chance. Clearly, further experiments are necessary.
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11.3.4. Summary and Future Studies
In summary, although the results presented here do not provide any evidence for a putative role of 
NO, superoxide and hydroxyl radicals in the genesis of excitotoxicity produced by kainate and 
quisqualate, they do not preclude the possibility. Future experiments should involve administration 
of ROSs scavengers and NOS inhibitors both before and after perfusion of non-NMDA agonists, 
and excitotoxicity should be assessed several hours or days after perfusion. This may require use 
of the round window technique rather than the cochlear perfusion method because the 
physiological condition of the cochlea tends to deteriorate after 2-3 hours if the cochlear wall is 
fenestrated. With respect to the possible role of NO, an important step would be to determine 
whether activation of non-NMDA receptors in the cochlea results in production of NO by assaying 
the cochlear fluids or cochlear tissue for the presence of nitrites, nitrates (products of NO 
breakdown) and L-arginine (precursor of NO).
Non-NMDA receptor activation can evoke cell death through two main routes: osmotic swelling 
and lysis following the passive influx of СГ, and/or increased intracellular Ca++ which can cause 
cell death by several routes (including production of NO and ROSs). The contribution of either 
route varies between cell type (Monaghan, Bridges and Cotman 1989). The ultrastructural damage 
produced by ЮОцМ kainate implies that osmotic swelling is not the only type of excitotoxicity 
produced by non-NMDA receptors in the cochlea because there was mitochondrial and membrane 
damage despite no apparent swelling of the nerve ending itself. However, higher concentrations of 
non-NMDA agonists produce striking swelling of the afferent nerve endings which suggests that 
the predominant form of toxicity is mediated by osmotic swelling. If non-NMDA mediated 
excitotoxicity in the cochlea is produced predominantly by osmotic swelling and lysis, it would be 
unlikely that inhibition and scavenging of NOS and ROSs respectively could attenuate this 
excitotoxicity. This could be tested experimentally by adjusting the Ca and Cl concentrations in 
180
the extracellular medium of cultured type I afferent neurons and the Cl concentration in the 
perilymph in vivo.
Another approach to reduce excitotoxicity in the cochlea would be to utilise neurotransmitters 
acting on the lateral efferents. There are at least 6 neurotransmitters at the lateral efferent synapse 
including Ach, GABA and dopamine (Pujol et al. 1995). Dopamine depresses the increased 
activity in type I afferents produced by glutamate, NMDA, kainate or AMP A (Oestreicher, 
Arnold, Ehrenberger et al. 1997). ImM Piribedil (a dopamine D2/D3 agonist) has been shown to 
attenuate swelling of afferent neurons induced by ischaemia (Pujol et al. 1993) or acoustic trauma 
(d’Aldin, Puel, Leducq et al. 1995), and significantly attenuated the CAP threshold shifts 
produced by acoustic trauma. In addition, enkephalins inhibit presynaptic release of Ach in the 
cochlea. Therefore it is likely that dopamine (and possibly enkephalins) may be capable of 
attenuating the excitotoxicity produced by non-NMDA agonists by reducing the induced increase 
in activity in the type I afferents.
Since AMPA and kainate mediated excitotoxicity, and ototoxicity following mild ischaemia and 
mild acoustic trauma is reversible within 5-10 days (Puel, d’Aldin, Ruel et al. 1997; Zheng, 
Henderson, Hu et al. 1997), an alternative approach would be to investigate the factors which 
inhibit or enhance re-innervation following non-NMDA mediated excitotoxicity. Recent data 
suggests that NMDA and metabotropic receptors are upregulated in primary auditory neurons 
during re-innervation of the inner hair cells following AMPA induced excitotoxicity (Puel, 
Saffiedine, d’Aldin et al. 1995), and NMDA antagonists lengthen the repair time (Puel et al. 
1997). Yet, if given after an excitotoxic insult NMDA antagonists can reduce excitotoxicity 
(presumably by inhibiting the action of excitotoxicity mediated glutamate release). Therefore it is 
essential to understand these processes in order to enhance repair as well as reduce excitotoxicity.
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11.3.5. Use of the Cochlear Perfusion Model in studies involving possible 
protection against the action of ototoxic agents.
The results presented here demonstrate that in order to determine whether pre-treatment of the 
cochlea with appropriate substances provides any protection against the action of ototoxic agents, 
it is essential to establish a concentration of the ototoxic agent that produces a reliable level of 
ototoxicity, and to pre-treat the cochlea with agents that are not themselves ototoxic. If the 
substance used to pre-treat the cochlea is itself ototoxic, the significance of further losses 
produced by other agents becomes unclear. If the ototoxic agent is too potent (CAP loss>60dB), 
the hearing loss is difficult to measure because the threshold CAP amplitude cannot be produced 
by maximum intensity stimulation, and is therefore highly dependent on the initial threshold. In 
addition, a small degree of attenuation may not be detected. Equally, if the ototoxic agent is not 
potent enough (15-25dB CAP loss) the inter-animal variation in susceptibility to such ototoxic 
agents is greater, and cochlear damage is less detectable in terms of ultrastructural damage. For 
optimum results, the concentration of the ototoxic agent should be adjusted to produce CAP 
losses of around 30-50dB.
If pre-treatment substances are not ototoxic, and ototoxic agents produce CAP losses of around 
30-50dB, the cochlear perfusion model is a suitable method to investigate the effect of pre-treating 
the cochlea on the ototoxicity produced by various agents. However, morphological examinations 
are an essential part of the investigations in order to verify whether the degree or type of 
ototoxicity has changed. An alternative method may be to administer potentially protective drugs 
systemically (or i.c.), particularly as this is the most likely route by which protective agents would 
be administered clinically.
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11.4. Role of excitotoxicity and ototoxins in meningitis-induced 
deafness
The main lines of evidence for an involvement of ototoxins in meningitis-induced deafness, 
discussed in chapter one, were: i) cochlear damage/infection is always associated with hearing 
losses ii) the early onset of meningitis-induced deafness precludes the involvement of 
complications of the inflammatory response; iii) data from isogenic mutant pneumococci implies 
that pneumolysin is the major cause of hearing loss in experimental pneumococcal meningitis; and 
iv) there is a similarity between cochlear damage produced by purified pneumolysin and 
experimental pneumococcal meningitis. The data presented here provides further support for the 
role of ototoxins in meningitis-induced deafness. There was some evidence that ototoxins exist in 
the bacterial extracts of all three major meningogenic pathogens, and the relative ototoxicity of 
each extract (as judged by CAP losses) was proportional to both the relative concentration of 
“pneumolysin-like” proteins in each extract, and the incidence of hearing loss in clinical meningitis 
produced by each pathogen.
However, other lines of evidence do not support the view that ototoxins are the sole contributor 
to meningitis-induced deafness. First, inflammation undoubtedly contributes, probably by 
exacerbating rather than initiating deafness because there is some evidence that adjunctive anti­
inflammatory treatment is effective in reducing experimental and clinical meningitis-induced 
deafness (reviewed in Townsend and Scheid 1996). Second, almost all of the direct evidence to 
indicate ototoxins in the genesis of meningitis-induced deafness comes from experimental 
meningitis induced by i.c. inoculation without antibiotic treatment. These experiments produce a 
far higher incidence of hearing loss than seen clinically. Although factors such as the size and 
structure of the cochlear aqueduct, the route of meningeal infection, and concentration of bacteria 
used to inoculate the CSF may be responsible for the greater incidence of hearing loss in 
experimental meningitis, omission of antibiotic treatment during experimental meningitis is the 
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most likely cause. Losses in the size of the CAP produced by S. pneumoniae type II perfused 
directly into the cochlea were significantly reduced by pre-treatment with cefotaxime or 
amoxycillin (Winter, Comis, Osborne et al. 1998). In addition, Bhatt et al. (1995) treated rabbits 
with antibiotics during experimental pneumococcal meningitis, and found that although all animals 
suffered initial hearing losses, several animals regained their hearing by 2 weeks. The reversible 
hearing losses produced by experimental pneumococcal meningitis suggest that either the hearing 
losses produced by pneumococcal ototoxin/s were reversible, or ototoxin/s ‘like pneumolysin’ 
were not responsible for the hearing losses in these animals.
In conclusion, although the ototoxin pneumolysin appears to be a major factor in the onset of 
meningitis-induced deafness in untreated experimental pneumococcal meningitis, definitive 
investigations are necessary to implicate ototoxins such as those suggested in this thesis as being 
responsible for hearing losses produced by pathogens such as H. influenzae and N. meningitidis. 
In addition more experiments involving antibiotic treatment and long term assessments of hearing 
(several days) are necessary to determine whether ototoxins are involved in transient and 
permanent meningitis-induced hearing losses produced in animals treated with antibiotics.
The main lines of evidence for an involvement of excitotoxicity in meningitis-induced 
deafness, discussed in Chapter one, were: i) there is an increase in the concentration of excitatory 
amino acids in the CSF during experimental and clinical meningitis: ii) high concentrations of 
excitatory amino acids are ototoxic; ii) glutamate antagonists are neuroprotective in experimental 
meningitis; and iv) ototoxicity produced by pneumolysin can be attenuated by antagonists of the 
NMDA receptor. There is now additional supportive evidence. The ultrastructural damage 
produced by bacterial extracts and live pneumococci (inoculated in the CSF or cochlea) often 
involves selective damage to the afferent neurons which is similar to that produced by 50mM 
NMDA (unpublished data from our laboratories) or a low concentration (100pM) of the non-
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NMD A agonist kainate (this thesis). Moreover, swelling of the afferent neurones very similar to 
that produced by non-NMDA agonists (this thesis) has been seen following experimental 
pneumococcal meningitis (Winter, unpublished findings). There is also a similarity in the time 
course of recovery in reversible hearing losses following non-NMDA mediated excitotoxicity and 
clinical or experimental meningitis. CAP losses produced by the non-NMDA agonists AMPA and 
kainate recover within 5-10 days (Zheng et al. 1997; Puel et al. 1997), ABERs were seen to 
return to control levels between 5 days and 2 weeks after inoculation in experimental 
pneumococcal meningitis (Bhatt et al. 1991), and clinically, reversible hearing losses return to 
normal 18 h to 5 days after diagnosis (Richardson 1997).
However, other lines of evidence do not support excitotoxicity as the sole factor responsible for 
meningitis-induced deafness. First, OAEs are not affected by kainate (Zheng et al. 1996) but were 
affected in all children with transient or permanent meningitis-induced hearing losses (Richardson 
1997). Second, the early onset of all meningitis-induced hearing losses precludes the involvement 
of ischaemia which is the most likely source of excess glutamate release. However, it must be 
pointed out that bacteria contain glutamic acid in peptidoglycan and cytoplasm, therefore bacterial 
sources of excitatory amino acids could be responsible for early excitotoxic damage in the cochlea.
In conclusion, despite a lack of direct evidence, it is conceivable that excitotoxicity in the cochlea 
during meningitis may be, responsible for, or contribute to, some (particularly transient) hearing 
losses. If this were the case, it is likely that both non-NMDA and NMD A receptors are involved.
11.5. Antibiotic Treatment
In experimental meningitis, the most important treatment in order to reduce the incidence and 
degree of hearing loss appears to be early antibiotic treatment because antibiotics significantly 
reduced the incidence and degree of labyrinthitis and hearing loss in experimental H. influenzae 
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type b and S. pneumoniae meningitis (Kaplan et al. 1989, Bhatt et al. 1995) and in cochlear 
perfusion of pneumococci (Winter, Comis, Osborne et al. 1998). In these studies, antibiotics were 
given early in the course of the infection, and so are likely to have reduced the cochlear damage by 
reducing the total amount of toxins released by hindering multiplication of bacteria. Clinically there 
have been several reports which indicate that there is a correlation between meningitis-induced 
hearing loss and length of time the patient was unwell before admission. This would imply that late 
antibiotic treatment is associated with a greater incidence of hearing loss. Other reports have not 
shown this, but this may be because of the difficulty in determining the exact onset of the infection 
clinically. Since the onset of meningitis-induced deafness occurs early in the course of meningitis, 
the way in which late antibiotic treatment could lead to a higher incidence of meningitis-induced 
deafness is most likely to have been by making existing hearing losses permanent rather than 
inducing them.
11.6. A proposal for the site of damage responsible for transient and 
permanent meningitis-induced hearing losses
The morphological and electrophysiological data from experimental meningitis, and cochlear 
perfusion of bacterial extracts/toxins suggests that the primary site of cochlear damage is often the 
nerve endings, whereas hair cell damage only occurs if cochlear damage progresses. Since auditory 
nerves, but not hair cells can regenerate, it is conceivable that nerve endings alone are the site of 
initial cochlear damage produced during meningitis which is responsible for either transient hearing 
losses, or the onset of permanent hearing losses, whereas hair cell damage is a later event 
responsible for making initial hearing losses permanent. However, OAEs are altered in patients 
with transient (as well as permanent) hearing losses. Nevertheless, a change in the OAEs could 
represent a change in the motile response of the hair cells in response to the nerve ending damage, 
and does not necessarily represent hair cell damage. Alternatively, initial cochlear damage could 
also involve cratering of supporting cells which would produce some loss of hair cell function by 
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the resultant drop in the endocochlear potential due to endolymph and perilymph mixing. This type 
of cochlear damage could be reversible by re-growth of the supporting cells.
Ototoxins are the most likely candidates for the initial nerve ending damage because they can be 
released early in the course of meningitis. Additional bacterial components such as glutamate (a 
constituent of some bacterial cell walls) and NO (which some bacterial can release) may also 
contribute to early cochlear damage. Later hair cell damage could involve several factors such as 
ototoxins, excitatory amino acids, NO, ROSs, other inflammatory mediators, and consequences of 
the inflammation such as ischaemia. It is most likely that a combination of these factors is 
responsible for the progression of cochlear damage to include hair cell damage, although those 
factors which can induce CM losses in cochlea are the most likely candidates (e.g. NO, ischaemia, 
certain ototoxins, and NMDA receptor activation).
The major determinant of whether cochlear damage progresses to include hair cell damage (i.e. 
hearing losses become permanent) is likely to be the timing of antibiotic treatment because if given 
early the antibiotics could prevent cochlear damage progressing beyond nerve ending damage by 
limiting the concentration of ototoxins and inflammatory mediators.
11.7. Meningitis-induced Deafness : Final Overview and 
Conclusions
In order to reduce the incidence and degree of meningitis-induced deafness, the most important 
treatment appears to be prompt antimicrobial therapy. However, adjunctive therapy may also be of 
use, particularly in patients which receive antibiotic treatment late in the course of the infection. 
The most likely effect of anti-inflammatory agents is to prevent hearing losses becoming 
permanent by eliminating the role which inflammation plays in cochlear damage. Additional agents 
which block later stages of toxicity such as NOS inhibitors and glutamate receptor antagonists 
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should also be considered because a considerable inflammatory response may have already been 
produced in patients which present late. Therefore, in terms of future research, I believe that apart 
from vaccination which is the most important preventative method, investigations into how initial 
hearing losses become permanent rather than how initial losses occur is most important because it 
is unlikely that the patient will present before some hearing losses occur, whereas the period of 
time in which reversible hearing losses become permanent is when treatment can be given.
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1.35g KH2PO4 in 50ml distilled H2O
0.31g NaOH in 39ml distilled H2O
Glutaradehyde Fixative (0.05M 2.5% Osmolarity = 350 mmolkg'1)
25ml 0.2M Phosphate Buffer
10ml 25% glutaraldehyde
1.71g sucrose
Distilled H2O to make a final volume of 100ml








4.2 ml Dodecenylsuccinic anhydride
0.15ml Dibutylphthalate
0.25ml 2,4,6-tri(dimethylaminomethyl) phenol
Artificial Perilymph (Osmolarity = 300 mmolkg1)
8g NaCl (final concentration = 137mM)
0.37g KC1 (final concentration = 5mM)
2ml ImM CaCl2 (final concentration = 137mM)
0.156 NaH2PO42H2O (final concentration = ImM)
0.202g MgCl2 6H2O (final concentration = ImM)
1.01 mg NaHCO3 (final concentration = ImM)
1.982g Glucose (final concentration = 1 ImM)
Appendix II 
Construction of the non-pneumolysin producing mutant of 
S. pneumoniae type III
Extracts from S. pneumoniae type III batería were generously provided by Prof Tim Mitchell, 
Glasgow University (formerly University of Leicester).
The pneumolysin deficient S. pneumoniae type III from which the bacterial extract was 
derived was constructed by insertion-duplication mutagenesis (Berry, Paton and Hansman 
1992). This process is briefly outlined below (Schematic representation in Figure All).
A 690 fragment of the pneumolysin gene was excised from pJCP20 (a plasmid which carries 
the complete S. pneumoniae pneumolysin gene) and purified. This fragment of the 
pneumolysin gene was then ligated into the vector pVA891 (a plasmid which carries a 
streptococcal gene encoding erythromycin resistance), and transformed into E.coli DHL The 
recombinant plasmid was then purified from its E.coli host. Since this plasmid could not be 
directly transformed with encapsulated S. pneumoniae, the recombinant was transformed with 
a non-encapsulated S. pneumoniae first (Rxl). Recombination between the plasmid inserts 
and the homologous regions of the Rxl chromosonal DNA the chromosomal coding sequence 
for pneumolysin was interrupted. This was confirmed with Southern blot hybridisation. DNA 
from this organism was finally transformed into encapsulated S. pneumoniae type III and the 





Figure All. Schematic representation of the insertion-duplication 
mutagenesis of the S. pneumoniae pneumolysin gene (pin).
Erythromycin resistance marker (erm)
Restriction enzyme sites EcoRi, BamHl and Sau3 Al (E, B and S respectively).
